"ID","Study.ID","Reference","Grouping","Victim","Perpetrator","Route.Victim","Route.Perpetrator","Mechanism","Compartment","AUCR.Avg","AUCR.AvgType","AUCR.Var","AUCR.VarType","CmaxR.Avg","CmaxR.AvgType","CmaxR.Var","CmaxR.VarType","t_placebo_0","t_placebo_end","t_treatment_0","t_treatment_end","t.Unit","R.Dose.correction.factor","Comment","Dose","Dose.free.API","Dose.Unit","Route","Times.of.Administration","Times.Unit","Description","Comment.Regimen","Administered.form","Formulation.type","Infusion.duration.[min]","Water.volume.ingested.for.drug.intake.[mL]","Comment.on.administration/formulation","Fasted/Fed.state","Duration.of.fasting.before.drug.administration.[h]","Duration.of.fasting.after.drug.administration.[h]","Comment.on.food.intake"
50,"Ahonen 1995","http://www.ncbi.nlm.nih.gov/pubmed/8527290","with Perpetrator (Itraconazole)","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",5.74509803921569,"Approx. Avg",NA,NA,2.55882352941176,"Approx. Avg",NA,NA,"0","inf","74","inf","h",NA,NA,"100",NA,"mg","PO","(S-0,T-24,R-4)","h","MD OD (4 days)","OD",NA,"Sporanox",NA,NA,"Sporanox Janssen",NA,NA,NA,NA
54,"Backman 1996","https://www.ncbi.nlm.nih.gov/pubmed/8549036","with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.041,"Arith.mean",NA,NA,0.0618181818181818,"Approx. CmaxR",NA,NA,"0","inf","113","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)",NA,NA,"300 mg capsules, Rimapen Orion",NA,NA,NA,NA,NA,NA,NA
56,"Backman 1998","https://www.ncbi.nlm.nih.gov/pubmed/9591931","Phase IV (during Perpetrator (Rifampicin))","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.023,"arith. mean","6.0000000000000001E-3","Arith. SEM",0.054,"Arith. Mean","1.2E-2","Arith. SEM","0","inf","113","185","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)",NA,NA,"300 mg capsules, Rimapen Orion",NA,NA,NA,"Fasted",NA,NA,NA
57,"Backman 1998","https://www.ncbi.nlm.nih.gov/pubmed/9591931","Phase V (4 days after Perpetrator (Rifampicin))","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.132,"arith. mean","2.8000000000000001E-2","Arith. SEM",0.202,"Arith. Mean","4.2000000000000003E-2","Arith. SEM","0","inf","185","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)",NA,NA,"300 mg capsules, Rimapen Orion",NA,NA,NA,"Fasted",NA,NA,NA
58,"Backman 1998","https://www.ncbi.nlm.nih.gov/pubmed/9591931","Phase II (during Perpetrator (Itraconazole))","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",7.97,"arith. mean","1.1399999999999999","Arith. SEM",3.12,"Arith. Mean","0.37","Arith. SEM","0","inf","74","170","h",1,"Cave! Different dose treatment vs control. Ratios are dose-corrected.","200",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)",NA,NA,"Sporanox 100-mg capsule",NA,NA,NA,"Fasted",NA,NA,NA
59,"Backman 1998","https://www.ncbi.nlm.nih.gov/pubmed/9591931","Phase III (4 days after Perpetrator (Itraconazole))","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",2.63,"arith. mean","0.4","Arith. SEM",1.92,"Arith. Mean","0.31","Arith. SEM","0","inf","170","inf","h",1,"Cave! Different dose treatment vs control. Ratios are dose-corrected.","200",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)",NA,NA,"Sporanox 100-mg capsule",NA,NA,NA,"Fasted",NA,NA,NA
113,"Chung 2006","https://www.ncbi.nlm.nih.gov/pubmed/16580903","with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.124489795918367,"Approx. Avg",NA,NA,0.169565217391304,"Approx. CmaxR",NA,NA,"0","inf","166","inf","h",1,NA,"600",NA,"mg","PO","S0-T24-R9","h","MD OD (9 days)",NA,"300-mg capsules (UDL)",NA,NA,NA,"2x 300 mg capsules",NA,NA,NA,NA
114,"Chung 2006","https://www.ncbi.nlm.nih.gov/pubmed/16580903","with Perpetrator (Ketoconazole)","Midazolam","Ketoconazole","PO","PO","Reversible_Inhibition","Plasma",9.51020408163265,"Approx. Avg",NA,NA,2.39130434782609,"Approx. CmaxR",NA,NA,"0","inf","118","inf","h",NA,NA,"400",NA,"mg","PO","(S-0,T-24,R-10)","h","MD OD (10 days)",NA,"200-mg tablets (Taro)",NA,NA,NA,"2x 200 mg tablets",NA,NA,NA,NA
116,"Chung 2006","https://www.ncbi.nlm.nih.gov/pubmed/16580903","with Perpetrator (Rifampicin)","Simvastatin","Rifampicin","PO","PO","Induction","Plasma",0.0896551724137931,"Approx. Avg",NA,NA,0.148648648648649,"Approx. CmaxR",NA,NA,"0","inf","190","inf","h",1,NA,"600",NA,"mg","PO","S0-T24-R9","h","MD OD (9 days)",NA,"300-mg capsules (UDL)",NA,NA,NA,"2x 300 mg capsules",NA,NA,NA,NA
117,"Chung 2006","https://www.ncbi.nlm.nih.gov/pubmed/16580903","with Perpetrator (Ketoconazole)","Simvastatin","Ketoconazole","PO","PO","Reversible_Inhibition","Plasma",12.551724137931,"Approx. Avg",NA,NA,7.43243243243243,"Approx. CmaxR",NA,NA,"0","inf","190","inf","h",NA,NA,"400",NA,"mg","PO","(S-0,T-24,R-10)","h","MD OD (10 days)",NA,"200-mg tablets (Taro)",NA,NA,NA,"2x 200 mg tablets",NA,NA,NA,NA
129,"Eap 2004","https://www.ncbi.nlm.nih.gov/pubmed/15114429","0.075 mg with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.441176470588235,"Approx. Avg",NA,NA,0.225806451612903,"Approx. Avg",NA,NA,"0","inf","90","114","h",1,NA,"450",NA,"mg","PO","S0-T24-R5","h","MD OD (5 days)","QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
130,"Eap 2004","https://www.ncbi.nlm.nih.gov/pubmed/15114429","0.075 mg with Perpetrator (Ketoconazole)","Midazolam","Ketoconazole","PO","PO","Reversible_Inhibition","Plasma",6.47058823529412,"Approx. Avg",NA,NA,3.74193548387097,"Approx. Avg",NA,NA,"0","inf","48","inf","h",NA,NA,"200",NA,"mg","PO","0-12-24-36","h","MD BID (2 days)","BID",NA,NA,NA,NA,NA,NA,NA,NA,NA
132,"Eap 2004","https://www.ncbi.nlm.nih.gov/pubmed/15114429","7.5 mg with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.0522388059701493,"Approx. Avg",NA,NA,0.111538461538462,"Approx. Avg",NA,NA,"0","inf","114","inf","h",1,NA,"450",NA,"mg","PO","S0-T24-R5","h","MD OD (5 days)","QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
173,"Gorski 1998","https://www.ncbi.nlm.nih.gov/pubmed/9728893","po with Perpetrator (Clarithromycin)","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Whole Blood",7.14285714285714,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","146","inf","h",NA,"from CL (L/hr/kg)","500",NA,"mg","PO","0-(S12-T12-R13)","h","MD BID (7 days)","MD",NA,"pill",NA,NA,NA,NA,NA,NA,NA
175,"Gorski 1998","https://www.ncbi.nlm.nih.gov/pubmed/9728893","iv with Perpetrator (Clarithromycin)","Midazolam","Clarithromycin","IV","PO","Mechanism_based_Inactivation","Whole Blood",2.66666666666667,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","146","inf","h",NA,"from CL (L/hr/kg)","500",NA,"mg","PO","0-(S12-T12-R13)","h","MD BID (7 days)","MD",NA,"pill",NA,NA,NA,NA,NA,NA,NA
177,"Gorski 2003","https://www.ncbi.nlm.nih.gov/pubmed/12966371","po with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Whole Blood",0.103351955307263,"Approx. Avg",NA,NA,0.100558659217877,"arith. Mean",NA,NA,"0","inf","132","inf","h",1.5,"Cave! Different dose treatment vs control.","600",NA,"mg","PO","S0-T24-R7","h","MD OD (7 days)","MD",NA,"pill, INN, rifampicin",NA,NA,NA,NA,NA,NA,NA
179,"Gorski 2003","https://www.ncbi.nlm.nih.gov/pubmed/12966371","iv with Perpetrator (Rifampicin)","Midazolam","Rifampicin","IV","PO","Induction","Whole Blood",0.448979591836735,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","132","inf","h",1,NA,"600",NA,"mg","PO","S0-T24-R7","h","MD OD (7 days)","MD",NA,"pill, INN, rifampicin",NA,NA,NA,NA,NA,NA,NA
191,"Greiner 1999","https://www.ncbi.nlm.nih.gov/pubmed/10411543","po with Perpetrator (Rifampicin)","Digoxin","Rifampicin","PO","PO","Induction","Plasma",0.697080291970803,"Approx. Avg",NA,NA,0.481481481481481,"Approx. Avg",NA,NA,"0","144","240","384","h",1,NA,"600",NA,"mg","PO","S0-T24-R16","h","MD OD (16 days)","MD","rifampin","RIFA Grünenthal GmbH",NA,NA,NA,NA,NA,NA,NA
193,"Greiner 1999","https://www.ncbi.nlm.nih.gov/pubmed/10411543","iv with Perpetrator (Rifampicin)","Digoxin","Rifampicin","IV","PO","Induction","Plasma",0.853379152348225,"Approx. Avg",NA,NA,0.834008097165992,"Approx. Avg",NA,NA,"0","144","240","384","h",1,NA,"600",NA,"mg","PO","S0-T24-R16","h","MD OD (16 days)","MD","rifampin","RIFA Grünenthal GmbH",NA,NA,NA,NA,NA,NA,NA
215,"Gurley 2006","https://www.ncbi.nlm.nih.gov/pubmed/16432272","with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.057160804,"Approx. Avg",NA,NA,0.1209150326797,"arith. Mean",NA,NA,"0","inf","146","inf","h",1,NA,"300",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD","Rifampin","300mg, Rifadin®, Aventis Pharmaceuticals",NA,NA,"twice daily",NA,NA,NA,NA
217,"Gurley 2006","https://www.ncbi.nlm.nih.gov/pubmed/16432272","with Perpetrator (Clarithomycin)","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Plasma",8.39285714,"Approx. Avg",NA,NA,3.795597484,"arith. Mean",NA,NA,"0","inf","146","inf","h",NA,NA,"500",NA,"mg","PO","(S-0,T-12,R-14)","h","MD BID (7 days)","MD","clarithromycin","500 mg, Biaxin®, Abbott Laboratories",NA,NA,"twice daily",NA,NA,NA,NA
221,"Gurley 2008a","https://www.ncbi.nlm.nih.gov/pubmed/17495878","with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.060317460317,"Approx. Avg",NA,NA,0.107623318,"arith. Mean",NA,NA,"0","inf","146","inf","h",1,NA,"300",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD","Rifampin","300mg, Rifadin®, Aventis Pharmaceuticals",NA,NA,"twice daily",NA,NA,NA,NA
223,"Gurley 2008a","https://www.ncbi.nlm.nih.gov/pubmed/17495878","with Perpetrator (Clarithomycin)","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Plasma",5.4833984,"Approx. Avg",NA,NA,2.1743295019,"arith. Mean",NA,NA,"0","inf","146","inf","h",NA,NA,"500",NA,"mg","PO","(S-0,T-12,R-14)","h","MD BID (7 days)","MD","clarithromycin","500 mg, Biaxin®, Abbott Laboratories",NA,NA,"twice daily",NA,NA,NA,NA
227,"Gurley 2008b","https://www.ncbi.nlm.nih.gov/pubmed/18214850","with Perpetrator (Rifampicin)","Digoxin","Rifampicin","PO","PO","Induction","Serum",0.753086419753086,"Approx. Avg",NA,NA,0.615384615384615,"Approx. Avg",NA,NA,"0","24","146","170","h",1,NA,"300",NA,"mg","PO","S0-T12-R12","h","MD BID (7 days)","MD","Rifampin","Rifadin®, Aventis Pharmaceuticals",NA,NA,"twice daily",NA,NA,NA,NA
229,"Gurley 2008b","https://www.ncbi.nlm.nih.gov/pubmed/18214850","with Perpetrator (Clarithomycin)","Digoxin","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Serum",1.46575342465753,"Approx. Avg",NA,NA,1.75,"Approx. Avg",NA,NA,"0","24","146","170","h",1,NA,"500",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD","clarithromycin","Biaxin®, Abbott Laboratories",NA,NA,"twice daily",NA,NA,NA,NA
271,"Jalava 1997","https://www.ncbi.nlm.nih.gov/pubmed/9421099","po with Perpetrator (Itraconazole)","Digoxin","Itraconazole","PO","PO","Reversible_Inhibition","Serum",1.68,"arith. Mean",NA,NA,1.34,"arith. Mean",NA,NA,"0","inf","49","inf","h",1,NA,"200",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)",NA,NA,"Sporanox 100-mg caps, Janssen Pharmaceuticals, Beerse, Belgium",NA,120,NA,NA,NA,NA,NA
276,"Kharasch 1997","https://www.ncbi.nlm.nih.gov/pubmed/9232132","with Perpetrator (Rifampicin)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.379310344827586,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","120","inf","h",1,"AUCR estimated from CL ratio","600",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA
278,"Kharasch 1997","https://www.ncbi.nlm.nih.gov/pubmed/9232132","with Perpetrator (Rifampicin)","Alfentanil","Rifampicin","IV","PO","Induction","Plasma",0.363013698630137,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","120.5","inf","h",1,"AUCR estimated from CL ratio","600",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA
280,"Kharasch 2004","https://www.ncbi.nlm.nih.gov/pubmed/15536460","iv with Perpetrator (Rifampicin)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.52112676056338,"Approx. Avg",NA,NA,1.00996015936255,"Approx. CmaxR",NA,NA,"0","inf","104","128","h",1,NA,"600",NA,"mg","PO","S0-T24-R6","h","MD OD (6 days)","MD OD",NA,NA,NA,NA,NA,NA,NA,NA,NA
283,"Kharasch 2004","https://www.ncbi.nlm.nih.gov/pubmed/15536460","iv with Perpetrator (Rifampicin)","Alfentanil","Rifampicin","IV","PO","Induction","Plasma",0.375,"Approx. Avg",NA,NA,1.00332594235033,"Approx. CmaxR",NA,NA,"0","inf","105","129","h",1,NA,"600",NA,"mg","PO","S0-T24-R6","h","MD OD (6 days)","MD OD",NA,NA,NA,NA,NA,NA,NA,NA,NA
286,"Kharasch 2004","https://www.ncbi.nlm.nih.gov/pubmed/15536460","po #1 with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.0526315789473684,"Approx. Avg",NA,NA,0.10989010989011,"Approx. CmaxR",NA,NA,"0","inf","128","inf","h",1,NA,"600",NA,"mg","PO","S0-T24-R6","h","MD OD (6 days)","MD OD",NA,NA,NA,NA,NA,NA,NA,NA,NA
288,"Kharasch 2004","https://www.ncbi.nlm.nih.gov/pubmed/15536460","po #1 (60 µg/kg) with Perpetrator (Rifampicin)","Alfentanil","Rifampicin","PO","PO","Induction","Plasma",0.045631067961165,"Approx. Avg",NA,NA,0.111111111111111,"Approx. CmaxR",NA,NA,"0","inf","129","inf","h",1,NA,"600",NA,"mg","PO","S0-T24-R6","h","MD OD (6 days)","MD OD",NA,NA,NA,NA,NA,NA,NA,NA,NA
294,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","iv with Perpetrator (Rifampicin @ 5 mg)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.84,"geo. Mean","0.13","+/- 90%CI",1.03225806,"arith. Mean",NA,NA,"0","inf","108","132","h",1,NA,"5",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
295,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","iv with Perpetrator (Rifampicin @ 10 mg)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.77,"geo. Mean","0.12","+/- 90%CI",1.064516129,"arith. Mean",NA,NA,"0","inf","108","132","h",1,NA,"10",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
296,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","iv with Perpetrator (Rifampicin @ 25 mg)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.63,"geo. Mean","0.11","+/- 90%CI",0.838709677,"arith. Mean",NA,NA,"0","inf","108","132","h",1,NA,"25",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
297,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","iv with Perpetrator (Rifampicin @ 75 mg)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.6,"geo. Mean","0.12","+/- 90%CI",1.322580645,"arith. Mean",NA,NA,"0","inf","108","132","h",1,NA,"75",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
299,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","iv with Perpetrator (Rifampicin @ 5 mg)","Alfentanil","Rifampicin","IV","PO","Induction","Plasma",0.83,"geo. Mean","0.16","+/- 90%CI",1.039215686,"arith. Mean",NA,NA,"0","inf","109","133","h",1,NA,"5",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
300,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","iv with Perpetrator (Rifampicin @ 10 mg)","Alfentanil","Rifampicin","IV","PO","Induction","Plasma",0.75,"geo. Mean","0.15","+/- 90%CI",1.0490196078,"arith. Mean",NA,NA,"0","inf","109","133","h",1,NA,"10",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
301,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","iv with Perpetrator (Rifampicin @ 25 mg)","Alfentanil","Rifampicin","IV","PO","Induction","Plasma",0.59,"geo. Mean","0.12","+/- 90%CI",1,"arith. Mean",NA,NA,"0","inf","109","133","h",1,NA,"25",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
302,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","iv with Perpetrator (Rifampicin @ 75 mg)","Alfentanil","Rifampicin","IV","PO","Induction","Plasma",0.51,"geo. Mean","0.12","+/- 90%CI",1.0294117647,"arith. Mean",NA,NA,"0","inf","109","133","h",1,NA,"75",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
304,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","po with Perpetrator (Rifampicin @ 5 mg)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.8,"geo. Mean","0.19","+/- 90%CI",0.8,"arith. Mean",NA,NA,"0","inf","132","inf","h",1,NA,"5",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
305,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","po with Perpetrator (Rifampicin @ 10 mg)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.68,"geo. Mean","0.17","+/- 90%CI",0.93333333,"arith. Mean",NA,NA,"0","inf","132","inf","h",1,NA,"10",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
306,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","po with Perpetrator (Rifampicin @ 25 mg)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.4,"geo. Mean","0.1","+/- 90%CI",0.5066666666,"arith. Mean",NA,NA,"0","inf","132","inf","h",1,NA,"25",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
307,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","po with Perpetrator (Rifampicin @ 75 mg)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.25,"geo. Mean","0.09","+/- 90%CI",0.34,"arith. Mean",NA,NA,"0","inf","132","inf","h",1,NA,"75",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
309,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","po with Perpetrator (Rifampicin @ 5 mg)","Alfentanil","Rifampicin","PO","PO","Induction","Plasma",0.74,"geo. Mean","0.16","+/- 90%CI",0.862745098,"arith. Mean",NA,NA,"0","inf","133","inf","h",1,NA,"5",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
310,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","po with Perpetrator (Rifampicin @ 10 mg)","Alfentanil","Rifampicin","PO","PO","Induction","Plasma",0.61,"geo. Mean","0.23","+/- 90%CI",0.862745098,"arith. Mean",NA,NA,"0","inf","133","inf","h",1,NA,"10",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
311,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","po with Perpetrator (Rifampicin @ 25 mg)","Alfentanil","Rifampicin","PO","PO","Induction","Plasma",0.3,"geo. Mean","0.1","+/- 90%CI",0.4901960784,"arith. Mean",NA,NA,"0","inf","133","inf","h",1,NA,"25",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
312,"Kharasch 2011","https://www.ncbi.nlm.nih.gov/pubmed/21562488","po with Perpetrator (Rifampicin @ 75 mg)","Alfentanil","Rifampicin","PO","PO","Induction","Plasma",0.13,"geo. Mean","0.06","+/- 90%CI",0.254901960784,"arith. Mean",NA,NA,"0","inf","133","inf","h",1,NA,"75",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampin","capsules",NA,NA,"at bedtime",NA,NA,NA,NA
314,"Kirby 2012","https://www.ncbi.nlm.nih.gov/pubmed/22190694","Study 1 - Staggered Administration with RIF","Digoxin","Rifampicin","PO","PO","Induction","Plasma",0.943396226415094,"geo. Mean",NA,NA,NA,NA,NA,NA,"0","inf","324","inf","h",1,"1/CLR ratio","600",NA,"mg","PO","S0-T24-R14","h","MD OD (14 days)","QD","rifampin","300-mg capsules Novartis",NA,NA,NA,NA,NA,NA,NA
316,"Kirby 2012","https://www.ncbi.nlm.nih.gov/pubmed/22190694","Study 2 - Simultaneous Administration with RIF","Digoxin","Rifampicin","PO","PO","Induction","Plasma",1.14942528735632,"geo. Mean",NA,NA,NA,NA,NA,NA,"0","inf","360","inf","h",1,"1/CLR ratio","600",NA,"mg","PO","S0-T24-R14","h","MD OD (14 days)","QD","rifampin","300-mg capsules Novartis",NA,NA,NA,NA,NA,NA,NA
318,"Kivistö 1997","https://www.ncbi.nlm.nih.gov/pubmed/9333111","with Perpetrator (Erythromycin)","Buspirone","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",5.9,NA,NA,NA,5,NA,NA,NA,"0","inf","79","inf","h",NA,NA,"500",NA,"mg","PO","0-6-14-24-30-38-48-54-62-72-78","h","MD TID (3 days)","MD","erythromycin base","Ery-Max 250 mg enterocapsule",NA,150,NA,"Fasted","2","3","wrt. administration of buspirone"
320,"Kivistö 1997","https://www.ncbi.nlm.nih.gov/pubmed/9333111","with Perpetrator (Itraconazole)","Buspirone","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",19.2,NA,NA,NA,13.4,NA,NA,NA,"0","inf","79","inf","h",NA,NA,"100",NA,"mg","PO","0-6-24-30-48-54-72-78","h","MD BID (3 days)","MD",NA,"Sporanox",NA,150,NA,"Fasted","2","3","wrt. administration of buspirone"
327,"Lamberg 1998a","https://www.ncbi.nlm.nih.gov/pubmed/9923581","with Perpetrator (Fluvoxamine)","Buspirone","Fluvoxamine","PO","PO","Reversible_Inhibition","Plasma",2.35,NA,"0.75-4.69","Range",2.01,NA,"0.69-3.96","Range","0","inf","114","inf","h",NA,NA,"100",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)","SD",NA,"Fevarin",NA,150,NA,"Fasted","2","3","wrt. administration of buspirone"
329,"Lamberg 1998b","https://www.ncbi.nlm.nih.gov/pubmed/9578186","with Perpetrator (Rifampicin)","Buspirone","Rifampicin","PO","PO","Induction","Plasma",0.104,NA,"0.063-0.145","95% CI",0.163,NA,"0.101-0.226","95% CI","0","inf","113","inf","h",1,NA,"30",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)","SD",NA,"Rimapen Orion",NA,150,NA,"Fasted","2","3","wrt. administration of buspirone"
331,"Lamberg 1998c","https://www.ncbi.nlm.nih.gov/pubmed/9663178","with Perpetrator (Verapamil)","Buspirone","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",3.4,NA,NA,NA,3.4,NA,NA,NA,"0","inf","30","inf","h",NA,NA,"80",NA,"mg","PO","0-5-12-24-29","h",NA,"SD",NA,"Verapamil tablet Orion",NA,150,NA,"Fasted","2","3","wrt. administration of buspirone"
333,"Lamberg 1998c","https://www.ncbi.nlm.nih.gov/pubmed/9663178","with Perpetrator (Diltiazem)","Buspirone","Diltiazem","PO","PO","Mechanism_based_Inactivation","Plasma",5.5,NA,NA,NA,4.1,NA,NA,NA,"0","inf","30","inf","h",NA,NA,"60",NA,"mg","PO","0-5-12-24-29","h",NA,"SD",NA,"Diltiazem tablet Orion",NA,150,NA,"Fasted","2","3","wrt. administration of buspirone"
337,"Larsen 2007","https://www.ncbi.nlm.nih.gov/pubmed/17365992","with Perpetrator (Rifampicin)","Digoxin","Rifampicin","PO","PO","Induction","Serum",0.81734693877551,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","24","144","168","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA
338,"Larsen 2007","https://www.ncbi.nlm.nih.gov/pubmed/17365992","with Perpetrator (Ketoconazole)","Digoxin","Ketoconazole","PO","PO","Reversible_Inhibition","Serum",1.09183673469388,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","24","96","120","h",1,NA,"200",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA
2036,"Kim 2018","https://www.ncbi.nlm.nih.gov/pubmed/28877336","Midazolam + Rifampicin Male","Midazolam","Rifampicin","IV","PO","Induction","Plasma",1.15,"geom. Mean (GMR)","1.025 - 1.275","90% CI",NA,NA,NA,NA,"0","inf","216","inf","h",2.5,"Cave! Different dose treatment vs control. Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control).","600",NA,"mg","PO","S0-T24-R10","h","MD OD (10 days)","MD, q.d. for 10 days","rifampicin","oral formulation",NA,NA,NA,NA,NA,NA,NA
2039,"Kim 2018","https://www.ncbi.nlm.nih.gov/pubmed/28877336","Midazolam + Rifampicin Female","Midazolam","Rifampicin","IV","PO","Induction","Plasma",1.225,"geom. Mean (GMR)","1.15 - 1.325","90% CI",NA,NA,NA,NA,"0","inf","216","inf","h",2.5,"Cave! Different dose treatment vs control. Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control).","600",NA,"mg","PO","S0-T24-R10","h","MD OD (10 days)","MD, q.d. for 10 days","rifampicin","oral formulation",NA,NA,NA,NA,NA,NA,NA
354,"Markert 2013","https://www.ncbi.nlm.nih.gov/pubmed/23748747","with Perpetrator (Clarithromycin)","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Plasma",5.55555555555556,"geo. Mean?","4.76190476190476-6.66666666666667",NA,NA,NA,NA,NA,"0","inf","72.25","inf","h",NA,"from metabolic clearance ratio","500",NA,"mg","PO","(S-0,T-12,R-8)","h","MD BID (4 days)","MD",NA,"Klacid Pro",NA,NA,NA,NA,NA,NA,NA
362,"Okudaira 2007","https://www.ncbi.nlm.nih.gov/pubmed/17585116","EM 2 with Perpetrator (Erythromycin)","Midazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",1.16,"arith. mean","0.45","arith. SD",0.909090909090909,"Approx. Avg",NA,NA,"0","25","25","73","h",NA,"Reported values in the paper are dose-normalized; the values given here refer to the absolute doses and are not dose-normalized","200",NA,"mg","PO","0-5-10.5-15-24-29-34.5-39","h","MD QID (2 days)","MD","erythromycin","Erythrocin Dainippon Pharmaceutical Co",NA,150,NA,"Fed",NA,NA,"standardized light breakfast at 07:20am"
363,"Okudaira 2007","https://www.ncbi.nlm.nih.gov/pubmed/17585116","EM 4 with Perpetrator (Erythromycin)","Midazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",1.69,"arith. mean","0.8","arith. SD",1.2,"Approx. Avg",NA,NA,"0","25","73","145","h",NA,"Reported values in the paper are dose-normalized; the values given here refer to the absolute doses and are not dose-normalized","200",NA,"mg","PO","0-5-10.5-15-24-29-34.5-39-48-53-58.5-63-72-77-82.5-87","h","MD QID (4 days)","MD","erythromycin","Erythrocin Dainippon Pharmaceutical Co",NA,150,NA,"Fed",NA,NA,"standardized light breakfast at 07:20am"
364,"Okudaira 2007","https://www.ncbi.nlm.nih.gov/pubmed/17585116","EM 7 with Perpetrator (Erythromycin)","Midazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",1.69,"arith. mean","0.7","arith. SD",1.17272727272727,"Approx. Avg",NA,NA,"0","25","145","inf","h",NA,"Reported values in the paper are dose-normalized; the values given here refer to the absolute doses and are not dose-normalized","200",NA,"mg","PO","0-5-10.5-15-24-29-34.5-39-48-53-58.5-63-72-77-82.5-87-96-101-106.5-111-120-125-130.5-135-144-149-154.5-159","h","MD QID (7 days)","MD","erythromycin","Erythrocin Dainippon Pharmaceutical Co",NA,150,NA,"Fed",NA,NA,"standardized light breakfast at 07:20am"
366,"Olkkola 1993","https://www.ncbi.nlm.nih.gov/pubmed/8453848","po with Perpetrator (Erythromycin)","Midazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",4.067402,"geo. Mean","0.71-12.0","Range",2.7,"Approx. Avg",NA,NA,"0","inf","128","inf","h",NA,"Individual AUC ratios extracted from Fig. 5, the geometric mean value listed here as calculated based on the extracted values","500",NA,"mg","PO","(S0-T8-R16)-126-136-144-152-160","h","MD TID (7 days)","three times a day","erythromycin base","Etromycin, 500 mg enterotablet, Orion Pharmaceutical Company Ltd.",NA,200,NA,NA,NA,NA,NA
368,"Olkkola 1993","https://www.ncbi.nlm.nih.gov/pubmed/8453848","iv with Perpetrator (Erythromycin)","Midazolam","Erythromycin","IV","PO","Mechanism_based_Inactivation","Plasma",1.961934,"geo. Mean","1.30-2.48","Range",NA,NA,NA,NA,"0","inf","128","inf","h",NA,"Individual AUC ratios extracted from Fig. 5, the geometric mean value listed here as calculated based on the extracted values","500",NA,"mg","PO","(S0-T8-R16)-126-136-144-152-160","h","MD TID (7 days)","three times a day","erythromycin base","Etromycin, 500 mg enterotablet, Orion Pharmaceutical Company Ltd.",NA,200,NA,NA,NA,NA,NA
370,"Olkkola 1994","https://www.ncbi.nlm.nih.gov/pubmed/8181191","po with Perpetrator (Itraconazole)","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",10.8,"arith. mean",NA,NA,3.4,"arith. Mean",NA,NA,"0","inf","73","inf","h",NA,NA,"200",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD","itraconazole","Sporanox, Orion",NA,NA,NA,"Fasted","2","5",NA
371,"Olkkola 1994","https://www.ncbi.nlm.nih.gov/pubmed/8181191","po with Perpetrator (Ketoconazole","Midazolam","Ketoconazole","PO","PO","Reversible_Inhibition","Plasma",15.9,"arith. mean",NA,NA,4.1,"arith. Mean",NA,NA,"0","inf","73","inf","h",NA,NA,"400",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD","ketoconazole","Nizoral, Orion",NA,NA,NA,"Fasted","2","5",NA
377,"Olkkola 1996","https://www.ncbi.nlm.nih.gov/pubmed/8623953","day 1 (po) with Perpetrator (Itraconazole)","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",3.4,"arith. mean",NA,NA,1.8,"arith. Mean",NA,NA,"0","inf","2","74","h",NA,NA,"200",NA,"mg","PO","0","h","SD","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA
378,"Olkkola 1996","https://www.ncbi.nlm.nih.gov/pubmed/8623953","day 4 (iv) with Perpetrator (Itraconazole)","Midazolam","Itraconazole","IV","PO","Reversible_Inhibition","Plasma",3.2258064516129,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","74","122","h",NA,NA,"200",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA
379,"Olkkola 1996","https://www.ncbi.nlm.nih.gov/pubmed/8623953","day 6 (po) with Perpetrator (Itraconazole)","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",6.6,"arith. mean",NA,NA,2.5,"arith. Mean",NA,NA,"0","inf","122","inf","h",NA,NA,"200",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA
380,"Olkkola 1996","https://www.ncbi.nlm.nih.gov/pubmed/8623953","day 1 (po) with Perpetrator (Fluconazole)","Midazolam","Fluconazole","PO","PO","Reversible_Inhibition","Plasma",2.5,"arith. mean",NA,NA,2.5,"arith. Mean",NA,NA,"0","inf","2","inf","h",NA,NA,"400",NA,"mg","PO","0","h","SD","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA
381,"Olkkola 1996","https://www.ncbi.nlm.nih.gov/pubmed/8623953","day 4 (iv) with Perpetrator (Fluconazole)","Midazolam","Fluconazole","IV","PO","Reversible_Inhibition","Plasma",2.04081632653061,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","74","inf","h",NA,NA,"400/200",NA,"mg","PO","400: 0, 200: 24-48-72","h","MD OD (4 days)","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA
382,"Olkkola 1996","https://www.ncbi.nlm.nih.gov/pubmed/8623953","day 6 (po) with Perpetrator (Fluconazole)","Midazolam","Fluconazole","PO","PO","Reversible_Inhibition","Plasma",3.6,"arith. mean",NA,NA,1.7,"arith. Mean",NA,NA,"0","inf","122","inf","h",NA,NA,"400/200",NA,"mg","PO","400: 0, 200: 24-48-72-96-120","h","MD OD (6 days)","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA
342,"Link 2008","https://www.ncbi.nlm.nih.gov/pubmed/18537963","iv with Perpetrator (Rifampicin)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.6550079491,"Approx. Median",NA,NA,1.1059602649,"Approx. Median",NA,NA,"0","inf","144","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampicin","Rimactan®, 600 mg coated tablet, Medika AG,",NA,NA,"in the morning",NA,NA,NA,NA
391,"Phimmasone 2001","https://www.ncbi.nlm.nih.gov/pubmed/11753266","with Perpetrator (Rifampicin)","Alfentanil","Rifampicin","IV","PO","Induction","Plasma",0.55,"arith. mean",NA,NA,NA,NA,NA,NA,"0","inf","107","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)","MD","rifampin",NA,NA,NA,"in the evening",NA,NA,NA,NA
344,"Link 2008","https://www.ncbi.nlm.nih.gov/pubmed/18537963","po with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.01554907677,"Approx. Median",NA,NA,0.034865293,"Approx. Median",NA,NA,"0","inf","144","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD","rifampicin","Rimactan®, 600 mg coated tablet, Medika AG,",NA,NA,"in the morning",NA,NA,NA,NA
389,"Phimmasone 2001","https://www.ncbi.nlm.nih.gov/pubmed/11753266","with Perpetrator (Rifampicin)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.51,"arith. mean",NA,NA,NA,NA,NA,NA,"0","inf","106","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)","MD","rifampin",NA,NA,NA,"in the evening",NA,NA,NA,NA
1098,"Prueksaritanont 2017","https://www.ncbi.nlm.nih.gov/pubmed/27943276","Midazolam in microdosecocktail + Rifampin","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.94,"Geom. mean","0.66 - 1.35","90% CI",1.3,"Geom. mean","1.16 - 1.46","90% CI","0","inf","0","inf","h",1,"Also available: ratio for AUC(0-last): geom. Mean (GMR) (90% CI) in pg*h/ml: 0.86 (0.62 - 1.20)","600",NA,"mg","PO","0","h","SD","SD","rifampin","USP 300 mg capsules",NA,NA,NA,NA,NA,NA,NA
396,"Reitman 2011","https://www.ncbi.nlm.nih.gov/pubmed/21191377","Week 0 after Perpetrator (Rifampicin)","Digoxin","Rifampicin","PO","PO","Induction","Plasma",1.462,"arith. mean",NA,NA,1.49,"arith. mean",NA,NA,"1321","inf","649","817","h",1,"Week 4 as Control","600",NA,"mg","PO","S0-T24-R28","h","MD OD (28 days)",NA,NA,"Rifadin (2x 300mg)",NA,NA,"Rifadin 2x 300 mg (Merrel)","Fasted",NA,NA,NA
397,"Reitman 2011","https://www.ncbi.nlm.nih.gov/pubmed/21191377","Week 1 after Perpetrator (Rifampicin)","Digoxin","Rifampicin","PO","PO","Induction","Plasma",0.683,"arith. mean",NA,NA,0.693,"arith. mean",NA,NA,"1321","inf","817","985","h",1,"Week 4 as Control","600",NA,"mg","PO","S0-T24-R28","h","MD OD (28 days)",NA,NA,"Rifadin (2x 300mg)",NA,NA,"Rifadin 2x 300 mg (Merrel)","Fasted",NA,NA,NA
398,"Reitman 2011","https://www.ncbi.nlm.nih.gov/pubmed/21191377","Week 2 after Perpetrator (Rifampicin)","Digoxin","Rifampicin","PO","PO","Induction","Plasma",0.977,"arith. mean",NA,NA,0.876,"arith. mean",NA,NA,"1321","inf","985","1321","h",1,"Week 4 as Control","600",NA,"mg","PO","S0-T24-R28","h","MD OD (28 days)",NA,NA,"Rifadin (2x 300mg)",NA,NA,"Rifadin 2x 300 mg (Merrel)","Fasted",NA,NA,NA
401,"Saari 2006","https://www.ncbi.nlm.nih.gov/pubmed/16580904","po with Perpetrator (Voriconazole)","Midazolam","Voriconazole","PO","PO",NA,"Plasma",9.85,"geo. Mean","8.23-11.79","90% CI",3.56,"geo. Mean","2.85-4.44","90% CI","0","inf","37","inf","h",NA,NA,"400/200",NA,"mg","PO","400mg: 0-12, 200mg: 24-36","h","MD BID (2 days), with first dose as loading dose","MD","voriconazole","Vfend tablet Pfizer",NA,150,"The last dose of voriconazole was given at 8 AM with 150 mL of water","Fasted","11","5",NA
404,"Saari 2006","https://www.ncbi.nlm.nih.gov/pubmed/16580904","iv with Perpetrator (Voriconazole)","Midazolam","Voriconazole","IV","PO",NA,"Plasma",3.61,"geo. Mean","3.20-4.08","90% CI",NA,NA,NA,NA,"0","inf","37","inf","h",NA,NA,"400/200",NA,"mg","PO","400mg: 0-12, 200mg: 24-36","h","MD BID (2 days), with first dose as loading dose","MD","voriconazole","Vfend tablet Pfizer",NA,150,"The last dose of voriconazole was given at 8 AM with 150 mL of water","Fasted","11","5",NA
420,"Swart 2002","https://www.ncbi.nlm.nih.gov/pubmed/11851636 ","day 10 Control with Perpetrator (Erythromycin)","Midazolam","Erythromycin","IV","PO","Mechanism_based_Inactivation","Plasma",1.597786,"geo. Mean","0.872-3.0","Range",NA,NA,NA,NA,"0","inf","96","inf","h",NA,"according to the methods section, AUC was calculated, but data are not given in text or tables.","500",NA,"mg","PO","(S0-T6-R20)","h","MD QID (5 days)","erythromycin was taken 4 times per day, but timing was not specified. A fixed dose interval oh tau=6h was assumed. Midazolam and lignocaine were co-administered with erythromycin.",NA,"Capsule",NA,200,"2x 100-mg itraconazole capsules with coated sugar spheres",NA,NA,NA,NA
392,"Reitman 2011","https://www.ncbi.nlm.nih.gov/pubmed/21191377","Week 0 after Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.123,"arith. mean",NA,NA,0.162,"arith. mean",NA,NA,"1320","inf","648","816","h",1,"Week 4 as Control","600",NA,"mg","PO","S0-T24-R28","h","MD OD (28 days)",NA,NA,"Rifadin (2x 300mg)",NA,NA,"Rifadin 2x 300 mg (Merrel)","Fasted",NA,NA,NA
424,"Templeton 2010","https://www.ncbi.nlm.nih.gov/pubmed/20739919","with Perpetrator (Itraconazole @ 50 mg)","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",2,"arith. Mean","0.6","arith. SD",NA,NA,NA,NA,"0","inf","4","inf","h",NA,NA,"50",NA,"mg","PO","0","h","SD","SD",NA,"Oral solution",NA,NA,NA,"Fasted",NA,"0.5","wrt. administration of midazolam"
425,"Templeton 2010","https://www.ncbi.nlm.nih.gov/pubmed/20739919","with Perpetrator (Itraconazole @ 200 mg)","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",4.7,"arith. Mean","1.4","arith. SD",NA,NA,NA,NA,"0","inf","4","inf","h",NA,NA,"200",NA,"mg","PO","0","h","SD","SD",NA,"Oral solution",NA,NA,NA,"Fasted",NA,"0.5","wrt. administration of midazolam"
426,"Templeton 2010","https://www.ncbi.nlm.nih.gov/pubmed/20739919","with Perpetrator (Itraconazole @ 400 mg)","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",5.4,"arith. Mean","1.5","arith. SD",NA,NA,NA,NA,"0","inf","4","inf","h",NA,NA,"400",NA,"mg","PO","0","h","SD","SD",NA,"Oral solution",NA,NA,NA,"Fasted",NA,"0.5","wrt. administration of midazolam"
428,"Tham 2006","https://www.ncbi.nlm.nih.gov/pubmed/16628140","with Perpetrator (Ketoconazole 50 mg)","Midazolam","Ketoconazole","IV","PO","Reversible_Inhibition","Plasma",1.58823529411765,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","47","inf","h",NA,NA,"200",NA,"mg","PO","0-12-24-36-48-60","h","MD BID (3 days)","MD","ketoconazole","Janssen Cilag",NA,NA,"at 8am and 8pm",NA,NA,NA,NA
469,"Yeates 1996","http://www.ncbi.nlm.nih.gov/pubmed/8880291","with Perpetrator (Clarithromycin)","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Plasma",3.57157209451857,"Approx. Avg",NA,NA,2.43997919105215,"Approx. CmaxR",NA,NA,"0","inf","97.5","inf","h",NA,NA,"250",NA,"mg","PO","(S-0,T-12-R-10)","h","MD BID (5 days)","MD BID",NA,"Klacid tabelts",NA,NA,"Kacid tablets from Abbot","Fasted",NA,"2",NA
471,"Zimmermann 1996","https://www.ncbi.nlm.nih.gov/pubmed/8720318","with Perpetrator (Erythromycin)","Midazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",3.81371928411118,"Approx. Avg",NA,NA,2.7114383459765,"Approx. CmaxR",NA,NA,"0","inf","97.5","inf","h",NA,NA,"500",NA,"mg","PO","(S-0,T-8-R-15)","h","MD TID (3 days)","MD TID",NA,"Zithromax",NA,100,"Zitrhromax Pfizer","Fasted","10","3.5",NA
571,"Iwamoto 2008","https://www.ncbi.nlm.nih.gov/pubmed/18513146","Study I, Period 2 (ATV treatment)","Raltegravir","Atazanavir","PO","PO","Reversible_Inhibition","Plasma",1.72,"geo. Mean","1.47-2.02","90% CI",1.53,"geo. Mean","1.11-2.12","90% CI","0","inf","144","inf","h",NA,NA,"400",NA,"mg","PO","0-24-48-72-96-120-144-168-192","h","MD OD (9 days)","MD QD",NA,NA,NA,NA,NA,"Fed",NA,NA,NA
573,"Neely 2010","https://www.ncbi.nlm.nih.gov/pubmed/20823282","Study arm B (Raltegravir 400mg OD + Atazanavir 400 mg OD)","Raltegravir","Atazanavir","PO","PO","Reversible_Inhibition","Plasma",1.72,"geo. Mean","0.79-3.75","90% CI",1.37,"geo. Mean","0.62-3.02","90% CI","168","180","168","192","h",NA,NA,"400",NA,"mg","PO","0-24-48-72-96-120-144-168","h","MD OD (8 days)","MD QD",NA,NA,NA,NA,"Capsule","Semifasted","1","2",NA
575,"Krishna 2016","https://www.ncbi.nlm.nih.gov/pubmed/27696440","Period 2, Day 7 (1200 mg raltegravir SD with OD doses of 400 mg ATV)","Raltegravir","Atazanavir","PO","PO","Reversible_Inhibition","Plasma",1.67,"geo. Mean","1.34-2.10","90% CI",1.16,"geo. Mean","1.01-1.33","90% CI","0","inf","144","inf","h",NA,NA,"400",NA,"mg","PO","0-24-48-72-96-120-144-168-192","h","MD OD (9 days)","MD QD",NA,NA,NA,NA,NA,"Fed",NA,NA,"standard moderate-fat breakfast"
579,"Zhu 2010","https://www.ncbi.nlm.nih.gov/pubmed/21149917","Raltegravir 400 mg twice daily plus atazanavir 300 mg twice daily","Raltegravir","Atazanavir","PO","PO","Reversible_Inhibition","Plasma",1.536,"geo. Mean","1.135-2.081","90% CI",1.394,"geo. Mean","0.990-1.964","90% CI","96","108","600","612","h",NA,NA,"400",NA,"mg","PO","288-300-312-324-336-348-360-372-384-396-408-420-432-444-456-468-480-492-504-516-528-540-552-564-576-588-600-612","h","MD BID (14 days)","MD BID","Atazanavir sulfate","Reyataz® Bristol-Myers Squibb",NA,NA,NA,"Fed",NA,NA,"light meal (277 kcal)"
642,"Kasichayanula 2013a","https://www.ncbi.nlm.nih.gov/pubmed/23061428","Study 2: with Perpetrator (Mefenamic Acid)","Dapagliflozin","Mefenamic Acid","PO","PO","Reversible_Inhibition","Plasma",1.51,"geo. Mean","1.44-1.58","90% CI",1.13,"geo. Mean","1.03-1.24","90% CI","0","inf","24","inf","h",NA,NA,"500 / 250",NA,"mg","PO","0-6-12-18-24-(S-30,T-6,R-11)","h","MD QID (4 days), with first dose ad loading dose","first dose 500, then 250 mg",NA,NA,NA,NA,NA,"Fed/Fasted",NA,NA,"24h hour dose fasted, other fed"
643,"Kasichayanula 2013a","https://www.ncbi.nlm.nih.gov/pubmed/23061428","Study 1: with Perpetrator (Rifampicin)","Dapagliflozin","Rifampicin","PO","PO","Induction","Plasma",0.78,"geo. Mean","0.73-0.83","90% CI",0.93,"geo. Mean","0.78-1.11","90% CI","0","inf","120","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96-120-144-168-192-216","h","MD OD (10 days)","OD",NA,NA,NA,NA,NA,NA,NA,NA,NA
757,"Phillips 1986","https://www.ncbi.nlm.nih.gov/pubmed/3771812","Triazolam after 3 days of erythromycin","Triazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",2.059701,"Approx. Avg",NA,NA,1.464286,"Approx. Avg",NA,NA,"0","inf","64","inf","h",NA,"Time of triazolam administration relative to erythromycin administration not reported, both drugs were assumed to be taken at the same time","333",NA,"mg","PO","0-8-16-24-32-40-48-56-64","h","MD TID (3 days)","MD TID",NA,"E-Mycin",NA,NA,NA,NA,NA,NA,NA
761,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil IV Grapefruit coadmin sequential","Alfentanil","Grapefruit juice","IV","PO",NA,"Plasma",1,"Geom. mean","0.9-1.0","90% CI",NA,NA,NA,NA,"0","inf","0","inf","h",NA,NA,"8",NA,"oz","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
762,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil IV Ketoconazole coadmin sequential","Alfentanil","Ketoconazole","IV","PO","Reversible_Inhibition","Plasma",2.4,"Geom. mean",NA,NA,NA,NA,NA,NA,"0","inf","60","inf","h",NA,"calculated as reported AUCR*Dose(under Keto coadmin)/Dose(control)","400",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
763,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil IV Rifampin coadmin sequential","Alfentanil","Rifampicin","IV","PO","Induction","Plasma",0.4,"Geom. mean","0.3-0.4","90% CI",NA,NA,NA,NA,"0","24","108","132","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
765,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil IV Grapefruit coadmin simultaneous","Alfentanil","Grapefruit juice","IV","PO",NA,"Plasma",1.2,"Geom. mean","1.1-1.2","90% CI",NA,NA,NA,NA,"0","inf","24","inf","h",NA,NA,"8",NA,"oz","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
766,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil IV Ketoconazole coadmin simultaneous","Alfentanil","Ketoconazole","IV","PO","Reversible_Inhibition","Plasma",2.5,"Geom. mean",NA,NA,NA,NA,NA,NA,"0","inf","84","inf","h",NA,"calculated as reported AUCR*Dose(under Keto coadmin)/Dose(control)","400",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
767,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil IV Rifampin coadmin simultaneous","Alfentanil","Rifampicin","IV","PO","Induction","Plasma",0.4,"Geom. mean","0.2-0.7","90% CI",NA,NA,NA,NA,"24","inf","132","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
769,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil PO Grapefruit coadmin sequential","Alfentanil","Grapefruit juice","PO","PO",NA,"Plasma",1.7,"Geom. mean","1.5-1.7","90% CI",NA,NA,NA,NA,"0","inf","0","inf","h",NA,NA,"8",NA,"oz","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
770,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil PO Ketoconazole coadmin sequential","Alfentanil","Ketoconazole","PO","PO","Reversible_Inhibition","Plasma",2.3,"Geom. mean",NA,NA,NA,NA,NA,NA,"0","inf","63","inf","h",NA,"calculated as reported AUCR*Dose(under Keto coadmin)/Dose(control)","400",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
771,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil PO Rifampin coadmin sequential","Alfentanil","Rifampicin","PO","PO","Induction","Plasma",0.06,"Geom. mean","0.05-0.07","90% CI",NA,NA,NA,NA,"0","21","111","132","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
773,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil PO Grapefruit coadmin simultaneous","Alfentanil","Grapefruit juice","PO","PO",NA,"Plasma",2.2,"Geom. mean","1.9-2.5","90% CI",NA,NA,NA,NA,"0","inf","21","inf","h",NA,NA,"8",NA,"oz","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
774,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil PO Ketoconazole coadmin simultaneous","Alfentanil","Ketoconazole","PO","PO","Reversible_Inhibition","Plasma",3,"Geom. mean",NA,NA,NA,NA,NA,NA,"0","inf","84","inf","h",NA,"calculated as reported AUCR*Dose(under Keto coadmin)/Dose(control)","400",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
775,"Kharasch 2011b","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584707/","Alfentanil PO Rifampin coadmin simultaneous","Alfentanil","Rifampicin","PO","PO","Induction","Plasma",0.06,"Geom. mean","0.01-0.22","90% CI",NA,NA,NA,NA,"21","inf","132","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96-120","h","MD OD (6 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
777,"Yasui 1996","https://www.ncbi.nlm.nih.gov/pubmed/8646822","Treatment with erythromycin","Alprazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",2.471616,"Approx. Avg",NA,NA,1.183333,"Approx. Avg",NA,NA,"0","inf","170","inf","h",NA,NA,"400",NA,"mg","PO","0-8-16-24-32-40-48-56-64-72-80-88-96-104-112-120-128-136-144-152-160-168-176-184-192-200-208-216-224-232","h","MD TID (10 days)","MD TID",NA,"Ilotysin",NA,NA,NA,"Fasted","overnight",NA,NA
779,"Bartkowski 1989","https://www.ncbi.nlm.nih.gov/pubmed/2501060","Treatment Day 1","Alfentanil","Erythromycin","IV","PO","Mechanism_based_Inactivation","Serum",1.026178,"Geom. mean","1.204995","Geom. SD",NA,NA,NA,NA,"0","inf","1.5","inf","h",NA,"Individual AUCinf calculated as Dose/CL. Individual CL values are given in Tab. 1. Individual values subsequently used to calculate Geom. Mean and geom. SD.","500",NA,"mg","PO","0","h","SD","SD",NA,"E-Mycin",NA,NA,NA,"Fasted","overnight",NA,NA
780,"Bartkowski 1989","https://www.ncbi.nlm.nih.gov/pubmed/2501060","Treatment Day 7","Alfentanil","Erythromycin","IV","PO","Mechanism_based_Inactivation","Serum",1.461094,"Geom. mean","1.312773","Geom. SD",NA,NA,NA,NA,"0","inf","145.5","inf","h",NA,"Individual AUCinf calculated as Dose/CL. Individual CL values are given in Tab. 1. Individual values subsequently used to calculate Geom. Mean and geom. SD.","500",NA,"mg","PO","0-12-24-36-48-60-72-84-96-108-120-132-144","h","MD BID (6 days)","MD BID",NA,"E-Mycin",NA,NA,NA,"Fasted","overnight",NA,NA
781,"Greenblatt 1998a","https://www.ncbi.nlm.nih.gov/pubmed/9757151","Triazolam + Erythromycin (Trial D)","Triazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",3.65,"Arith. Mean","0.42","Arith. SEM",1.768,"Approx. Avg",NA,NA,"0","inf","25","inf","h",NA,NA,"500",NA,"mg","PO","0-8-24-33","h","MD OD (2 days)","MD, day1: 8 am., 4 pm., day2: 8 am., 5 pm.",NA,"capsules",NA,NA,"double blind design, medication were packaged identically in opaque capsules","Fed",NA,"4","Light breakfast"
801,"Kharasch 2012","https://www.ncbi.nlm.nih.gov/pubmed/22398970","Alfentanil PO + efavirenz","Alfentanil","Efavirenz","PO","PO","Induction","Plasma",0.22,"Geom. mean","0.16-0.30","90% CI",0.4285714,"Approx. Avg",NA,NA,"0","inf","336.5","inf","h",NA,"Administration time of alfenatil relative to efavirenz administration was not reported, here, it was assumed that alfentanil was dosed 30 min after efavirenz administration","600",NA,"mg","PO","0-24-48-72-96-120-144-168-192-216-240-264-288-312-336-360-384-408-432-456","h","MD OD (19 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
803,"Kharasch 2012","https://www.ncbi.nlm.nih.gov/pubmed/22398970","Alfentanil IV + efavirenz","Alfentanil","Efavirenz","IV","PO","Induction","Plasma",0.54,"Geom. mean","0.47-0.62","90% CI",1.097826,"Approx. Avg",NA,NA,"0","inf","360.5","inf","h",NA,"Administration time of alfenatil relative to efavirenz administration was not reported, here, it was assumed that alfentanil was dosed 30 min after efavirenz administration","600",NA,"mg","PO","0-24-48-72-96-120-144-168-192-216-240-264-288-312-336-360-384-408-432-456","h","MD OD (19 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
828,"Carls 2014","https://www.ncbi.nlm.nih.gov/pubmed/25139487","Midazolam + 250 mg erythromycin ","Midazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",1.71781305114638,"Approx. Avg",NA,NA,NA,NA,NA,NA,"2","4","3","5","h",NA,NA,"250",NA,"mg","PO","0","h","SD","SD",NA,"Erythromycin-ratiopharm® 500 mg filmtablets containing 694 mg erythromycinstearate",NA,NA,NA,NA,NA,NA,NA
829,"Carls 2014","https://www.ncbi.nlm.nih.gov/pubmed/25139487","Midazolam + 1000 mg erythromycin ","Midazolam","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",4.99118165784832,"Approx. Avg",NA,NA,NA,NA,NA,NA,"2","4","3","5","h",NA,NA,"1000",NA,"mg","PO","0","h","SD","SD",NA,"Erythromycin-ratiopharm® 500 mg filmtablets containing 694 mg erythromycinstearate",NA,NA,NA,NA,NA,NA,NA
1001,"Schmider 1999","https://www.ncbi.nlm.nih.gov/pubmed/10634135","Alprazolam + Rifampin","Alprazolam","Rifampicin","PO","PO","Induction","Plasma",0.117258464079273,"Approx. Avg",NA,NA,0.638157894736842,"Approx. CmaxR",NA,NA,"0","inf","96","inf","h",1,"Administration time of alprazolam relative to rifampin administration was not reported, here, it was assumed that alprazolam was administered 24h after the last rifampin administration","450",NA,"mg",NA,"S0-T24-R4","h","MD OD (4 days)","MD QD",NA,NA,NA,NA,NA,NA,NA,NA,NA
1002,"Schmider 1999","https://www.ncbi.nlm.nih.gov/pubmed/10634135","Alprazolam + Ketoconazole","Alprazolam","Ketoconazole","PO","PO","Reversible_Inhibition","Plasma",1.75970272502064,"Approx. Avg",NA,NA,1.07894736842105,"Approx. CmaxR",NA,NA,"0","inf","48","inf","h",NA,"Administration time of alprazolam relative to ketoconazole administration was not reported, here, it was assumed that alprazolam was administered 12h after the last ketoconazole administration","200",NA,"mg",NA,"S0-T12-R4","h","MD BID (2 days)","MD BID",NA,NA,NA,NA,NA,NA,NA,NA,NA
1004,"Villikka 1997","https://www.ncbi.nlm.nih.gov/pubmed/9024169","Treatment arm (pretreatment with rifampin, 600 mg, 5 days)","Triazolam","Rifampicin","PO","PO","Induction","Plasma",0.051,"Arith. Mean","0.032-0.071","95%CI",0.124137931034483,"Approx. CmaxR",NA,NA,"0","inf","113","inf","h",1,"AUC ratio from Tab. 1","600",NA,"mg","PO","S0-T24-R5","h","MD OD (5 days)","MD, QD (at 8 pm)",NA,"two 300 mg Rimapen capsules, Orion Pharmaceutical Company Ltd., Espoo, Finland",NA,NA,NA,NA,NA,NA,NA
1026,"Yasui 1998","https://www.ncbi.nlm.nih.gov/pubmed/9784084","Alprazolam with itraconazole","Alprazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",2.66269841269841,"Approx. Avg",NA,NA,1.28682170542636,"Approx. CmaxR",NA,NA,"0","inf","73","inf","h",NA,NA,"200",NA,"mg","PO","(S0-T24-R6)","h","MD OD (6 days)","MD, QD (at 8 am)",NA,"capsule formulation (Itrizole, Janssen-Kyowa Co. Ltd, Tokyo, Japan)",NA,NA,NA,NA,NA,NA,NA
1028,"Varhe 1994","https://www.ncbi.nlm.nih.gov/pubmed/7995001","Triazolam with ketoconazole","Triazolam","Ketoconazole","PO","PO","Reversible_Inhibition","Plasma",20.0638618873603,"Geom. Mean","5.00-71.1","Range",3.10748712639809,"Geom. Mean","1.46-5.1","Range","0","inf","73","inf","h",NA,"AUC and Cmax ratios calculated based on individual data listed in Tab. 2","400",NA,"mg",NA,"S0-T24-R4","h","MD OD (4 days)","MD, QD",NA,"Nizoral, Orion, Helsinki, Finland",NA,NA,NA,NA,NA,NA,"The use of alcohol, coffee, tea, and cola was not allowed during the testdays"
1029,"Varhe 1994","https://www.ncbi.nlm.nih.gov/pubmed/7995001","Triazolam with Itraconazole","Triazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",19.0287455476447,"Geom. Mean","7.24-181","Range",2.68544783283575,"Geom. Mean","1.17-10.4","Range","0","inf","73","inf","h",NA,"AUC and Cmax ratios calculated based on individual data listed in Tab. 2","200",NA,"mg",NA,"S0-T24-R4","h","MD OD (4 days)","MD, QD",NA,"Sporanox, Orion",NA,NA,NA,NA,NA,NA,"The use of alcohol, coffee, tea, and cola was not allowed during the testdays"
1078,"Neuvonen 1996","https://www.ncbi.nlm.nih.gov/pubmed/8841155","Treatment phase (triazolam + ITZ simultaneously)","Triazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",3.11,"Arith. mean",NA,NA,1.41,"arith. Mean",NA,NA,"0","inf","0","inf","h",NA,"AUC and Cmax ratio taken from percentage change listed in Tab. 1","200",NA,"mg","PO","0","h","SD","SD",NA,"Sporanox, Janssen Pharma, Beerse, Belgium",NA,150,NA,"fasted","3","4","itraconazole dose was taken 3 h after lunch, the use of alcohol, tea, coffee, and cola was not allowed during the test days"
1079,"Neuvonen 1996","https://www.ncbi.nlm.nih.gov/pubmed/8841155","Treatment phase (triazolam + ITZ 3 hr before)","Triazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",4.79,"Arith. mean",NA,NA,1.76,"arith. Mean",NA,NA,"0","inf","3","inf","h",NA,"AUC and Cmax ratio taken from percentage change listed in Tab. 1","200",NA,"mg","PO","0","h","SD","SD",NA,"Sporanox, Janssen Pharma, Beerse, Belgium",NA,150,NA,"Triazola, fasted, ITZ fed","3",NA,"itraconazole dose was taken after lunch, the use of alcohol, tea, coffee, and cola was not allowed during the test days"
1080,"Neuvonen 1996","https://www.ncbi.nlm.nih.gov/pubmed/8841155","Treatment phase (triazolam + ITZ 12 hr before)","Triazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",4.63,"Arith. mean",NA,NA,1.76,"arith. Mean",NA,NA,"0","inf","12","inf","h",NA,"AUC and Cmax ratio taken from percentage change listed in Tab. 1","200",NA,"mg","PO","0","h","SD","SD",NA,"Sporanox, Janssen Pharma, Beerse, Belgium",NA,150,NA,"Triazola, fasted, ITZ fed","3",NA,"itraconazole dose was taken with a snack, the use of alcohol, tea, coffee, and cola was not allowed during the test days"
1081,"Neuvonen 1996","https://www.ncbi.nlm.nih.gov/pubmed/8841155","Treatment phase (triazolam + ITZ 24 hr before)","Triazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",3.82,"Arith. mean",NA,NA,1.71,"arith. Mean",NA,NA,"0","inf","24","inf","h",NA,"AUC and Cmax ratio taken from percentage change listed in Tab. 1","200",NA,"mg","PO","0","h","SD","SD",NA,"Sporanox, Janssen Pharma, Beerse, Belgium",NA,150,NA,"Triazola, fasted, ITZ fed","3",NA,"i"
1087,"Lam 2003","https://www.ncbi.nlm.nih.gov/pubmed/14551182","Midazolam after Ketoconazole","Midazolam","Ketoconazole","PO","PO","Reversible_Inhibition","Plasma",8.72,"mean percent change","5.96","SD",3.68,"mean percent change","2.2200000000000002","SD","0","inf","265","inf","h",NA,NA,"200",NA,"mg",NA,"(S0-T24-R12)","h","MD OD (12 days)","MD, once daily","ketoconazole",NA,NA,NA,NA,NA,NA,NA,NA
1089,"Lam 2003","https://www.ncbi.nlm.nih.gov/pubmed/14551182","Midazolam after Fluvoxamine","Midazolam","Fluvoxamine","PO","PO","Reversible_Inhibition","Plasma",1.66,"mean percent change","0.8","SD",1.63,"mean percent change","1.07","SD","0","inf","265","inf","h",NA,NA,"50/100",NA,"mg",NA,"(S0-T12-R23)","h","MD OD (12 days), titrated from 50 mg BID to 100 mg BID administered for 6 days","MD, twice daily, titrated from 50 mg bid to 100 mg bid 100 mg bid administered for 6 days","fluvoxamine",NA,NA,NA,NA,NA,NA,NA,NA
1091,"Shin 2013","https://www.ncbi.nlm.nih.gov/pubmed/23784264","CYP3A4 inhibited phase (Midazolam + ketoconazole)","Midazolam","Ketoconazole","IV","PO","Reversible_Inhibition","Plasma",2.89,"geom. Mean (GMR)","2.57 - 3.25","90% CI",NA,NA,NA,NA,"0","inf","73","inf","h",1,"also available: Ratio of geom. Mean (90% CI) of CL in L/h: 0.35 (0.32 - 0.37)","400",NA,"mg","PO","(S0-T24-R4)","h","MD OD (4 days)","MD, q.d. for 4 days","ketoconazole (400-mg tablet)","Spike, Choong Wae Pharm, Seoul, Korea",NA,NA,NA,NA,NA,NA,NA
393,"Reitman 2011","https://www.ncbi.nlm.nih.gov/pubmed/21191377","Week 1 after Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.383,"arith. mean",NA,NA,0.403,"arith. mean",NA,NA,"1320","inf","816","984","h",1,"Week 4 as Control","600",NA,"mg","PO","S0-T24-R28","h","MD OD (28 days)",NA,NA,"Rifadin (2x 300mg)",NA,NA,"Rifadin 2x 300 mg (Merrel)","Fasted",NA,NA,NA
1094,"Shin 2016","https://www.ncbi.nlm.nih.gov/pubmed/27317471","Midazolam + ketoconazole","Midazolam","Ketoconazole","IV","PO","Reversible_Inhibition","Plasma",4.77,"geom. Mean (GMR)","4.52 - 5.03","90% CI",1.45,"geom. Mean (GMR)","1.38 - 1.53","90% CI","0","inf","73","inf","h",1,NA,"400",NA,"mg",NA,"(S0-T24-R4)","h","MD OD (4 days)","MD, q.d. for 4 days","ketoconazole","Spike, Choongwae Pharma Co., Seoul, Korea",NA,NA,NA,NA,NA,NA,NA
394,"Reitman 2011","https://www.ncbi.nlm.nih.gov/pubmed/21191377","Week 2 after Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.815,"arith. mean",NA,NA,0.731,"arith. mean",NA,NA,"1320","inf","984","1320","h",1,"Week 4 as Control","600",NA,"mg","PO","S0-T24-R28","h","MD OD (28 days)",NA,NA,"Rifadin (2x 300mg)",NA,NA,"Rifadin 2x 300 mg (Merrel)","Fasted",NA,NA,NA
1097,"Prueksaritanont 2017","https://www.ncbi.nlm.nih.gov/pubmed/27943276","Midazolam in microdosecocktail + Itraconazole","Midazolam","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",7.04,"Geom. mean","4.58 - 10.81","90% CI",3.71,"Geom. mean","3.38 - 4.09","90% CI","0","inf","72","inf","h",NA,"Also available: ratio for AUC(0-last): geom. Mean (GMR) (90% CI) in pg*h/ml: 6.80 (4.52 - 10.23)","200",NA,"mg","PO","(S0-T24-R5)","h","MD OD (5 days)","MD, q.d. for 5 days","itraconazole","10 mg/mL oral solution",NA,NA,NA,NA,NA,NA,NA
1092,"Shin 2013","https://www.ncbi.nlm.nih.gov/pubmed/23784264","CYP3A4 induced phase (Midazolam + rifampicin)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",1.15,"geom. Mean (GMR)","1.025 - 1.275","90% CI",NA,NA,NA,NA,"0","inf","216","inf","h",2.5,"Cave! Cave! Different dose treatment vs control. Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control). Also avaiable: Ratio of geom. Mean (90% CI) of CL in L/h: 2.19 (1.99 - 2.40)","600",NA,"mg","PO","S0-T24-R10","h","MD OD (10 days)","MD, q.d. for 10 days","rifampicin (600-mg tablet)","Rifodex, Chong Kun Dang Pharmaceutical, Seoul, Korea",NA,NA,NA,NA,NA,NA,NA
1099,"Prueksaritanont 2017","https://www.ncbi.nlm.nih.gov/pubmed/27943276","Midazolam in microdosecocktail + Clarithromycin","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Plasma",4.84,"Geom. mean","3.21 - 7.29","90% CI",2.69,"Geom. mean","2.47 - 2.93 ","90% CI","0","inf","72","inf","h",NA,"Also available: ratio for AUC(0-last): geom. Mean (GMR) (90% CI) in pg*h/ml: 4.71 (3.20 - 6.96)","500",NA,"mg","PO","(S0-T12-R10)","h","MD BID (5 days)","MD, b.i.d. (approx. every 12 h) for 5 days","clarithromycin","USP 500 mg tablets",NA,NA,NA,NA,NA,NA,NA
1102,"Greenblatt 1998a","https://www.ncbi.nlm.nih.gov/pubmed/9757151","Triazolam + Clarithromycin (Trial E)","Triazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Plasma",5.06,"arithm. Mean","0.44","Arith. SEM",1.968,"Approx. Avg",NA,NA,"0","inf","25","inf","h",NA,NA,"500",NA,"mg","PO","0-8-24-33","h","MD OD (2 days)","MD, day1: 8 am., 4 pm., day2: 8 am., 5 pm.",NA,"capsules",NA,NA,"double blind design, medication were packaged identically in opaque capsules","fed",NA,"4","Light breakfast"
1104,"Fleishaker 1994","https://www.ncbi.nlm.nih.gov/pubmed/8005185","Alprazolam + fluvoxamine","Alprazolam","Fluvoxamine","PO","PO","Reversible_Inhibition","Plasma",1.25514403292181,"Approx. Avg",NA,NA,1.17692307692308,"Approx. CmaxR",NA,NA,"0","5","144","149","h",NA,"Measurement documented with day 1,  actually is day 7 of study period","50/100",NA,"mg","PO","S0-T24-R7","h","MD OD (10 days), 50 mg day 1-3, then 100 mg","MD, 50 mg qd days 1-3, 100 mg qd days 4 -7","fluvoxamine maleate","oral capsules",NA,NA,"for days 4-7: subjects took two 50 mg fluvoxamine maleate capsules","fed",NA,NA,"The subjects ate standard meals at 07.00, 12.00, 18.00, and 22.00 h on all study days."
1106,"Fleishaker 1994","https://www.ncbi.nlm.nih.gov/pubmed/8005185","Fluvoxamine + alprazolam","Fluvoxamine","Alprazolam","PO","PO",NA,"Plasma",0.920731707317073,"Approx. Avg",NA,NA,0.962790697674419,"Approx. CmaxR",NA,NA,"0","inf","0","inf","h",NA,"Measurement on day 1","1",NA,"mg","PO","144-149-154-159-168-173-178-183-192-197-202-207-216-221-226-231","h","MD QID (4 days)","MD, 4 times daily for 4 days (days 7-10 of the study period)","alprazolam","oral tablet",NA,NA,NA,"fed",NA,NA,"The subjects ate standard meals at 07.00, 12.00, 18.00, and 22.00 h on all study days."
1108,"Backman 1994","https://www.ncbi.nlm.nih.gov/pubmed/8198928","Midazolam with verapamil","Midazolam","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",2.91666666666667,"Arith. mean",NA,NA,1.96923076923077,"Arith. mean",NA,NA,"0","inf","25","inf","h",NA,NA,"80",NA,"mg","PO","S0-T8-R5","h","MD TID (2 days)","MD, day1: 14:30, 22:30, day2: 6:30, 14:30, 22:30","verpamil","Verpamil 40 mg tabl., Orion Pharmaceutical Company Ltd",NA,NA,NA,NA,NA,NA,NA
1111,"Wang 2005","https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2004.11.014","Midazolam after VER treatment","Midazolam","Verapamil","IV","PO","Mechanism_based_Inactivation","Plasma",1.45238095238095,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","24","168","192","h",NA,"AUCR was calculated with CLiv values","240",NA,"mg",NA,"S0-T24-R7","h","MD OD (7 days)","MD","verapamil","verapamil (SR, 240 mg qd.)",NA,NA,NA,NA,NA,NA,NA
1113,"Fleishaker 1994","https://www.ncbi.nlm.nih.gov/pubmed/8005185","Alprazolam + fluvoxamine (day 10)","Alprazolam","Fluvoxamine","PO","PO","Reversible_Inhibition","Plasma",1.96313799621928,"Approx. Avg",NA,NA,1.86194046594315,"Approx. CmaxR",NA,NA,"72","96","216","240","h",NA,"AUCratio and Cmax ratio also available for Day1","50/100",NA,"mg","PO","S0-T24-R10","h","MD OD (10 days), 50 mg day 1-3, then 100 mg","MD, QD","fluvoxamin maleate",NA,NA,NA,NA,"fed",NA,NA,"The subjects ate standard meals at 07.00, 12.00, 18.00, and 22.00 h on all study days."
1114,"Fleishaker 1994","https://www.ncbi.nlm.nih.gov/pubmed/8005185","Fluvoxamine + alprazolam (day 10)","Fluvoxamine","Alprazolam","PO","PO",NA,"Plasma",0.761066969353008,"Approx. Avg",NA,NA,0.787512588116818,"Approx. CmaxR",NA,NA,"0","216","0","216","h",NA,"Measurement on day 10","1",NA,"mg","PO","144-149-154-159-168-173-178-183-192-197-202-207-216-221-226-231","h","MD QID (4 days)","MD, 4 times daily for 4 days (days 7-10 of the study period)","alprazolam","oral tablet",NA,NA,NA,"fed",NA,NA,"The subjects ate standard meals at 07.00, 12.00, 18.00, and 22.00 h on all study days."
1116,"Wang 2005","https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2004.11.014","Midazolam after VER treatment","Midazolam","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",3.50561797752809,"Arith. mean",NA,NA,NA,NA,NA,NA,"24","inf","192","inf","h",NA,"AUCR was calculated with CLpo values","240",NA,"mg",NA,"S0-T24-R7","h","MD OD (7 days)","MD","verapamil","verapamil (SR, 240 mg qd.)",NA,NA,NA,NA,NA,NA,NA
1095,"Shin 2016","https://www.ncbi.nlm.nih.gov/pubmed/27317471","Midazolam + rifampicin","Midazolam","Rifampicin","IV","PO","Induction","Plasma",1.225,"geom. Mean (GMR)","1.15 - 1.325","90% CI",1.775,"geom. Mean (GMR)","1.7 - 1.9","90% CI","0","inf","216","inf","h",2.5,"Cave! Different dose treatment vs control. Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control).","600",NA,"mg","PO","S0-T24-R10","h","MD OD (10 days)","MD, q.d. for 10 days","rifampicin","Rifodex, Chong Kun Dang Pharmaceutical, Seoul, Korea",NA,NA,NA,NA,NA,NA,NA
422,"Szalat 2007","https://www.ncbi.nlm.nih.gov/pubmed/17553741","with Perpetrator (Rifampicin)","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.579467113843861,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","132","inf","h",1,NA,"600",NA,"mg","PO","0-24-48-72-96-120-144","h","MD OD (7 days)","MD","rifampicin","rifampicin (Sandoz GmbH)",NA,NA,NA,NA,NA,NA,NA
2004,"van Dyk 2018","https://www.ncbi.nlm.nih.gov/pubmed/29572563","Midazolam in Caucasian following 3d of Clarithromycin (between day 12 and 14)","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Plasma",1.9,"geom. Mean","1.5, 2.3","95% CI",1.75,"Approx. CmaxR",NA,NA,"0","6","324","330","h",NA,"Adjusted AUCratios (adjustment of different genotypes) are also available: AUC0-6 GMR with (95% CI)in µg/L/min: 2.0 (1.5, 2.4); Time adjusted to Time after first rifampicin dose","250",NA,"mg",NA,"S252-T12-R6","h","MD BID (3 days)","MD, bd for a 3-day course","clarithromycin","Klacid Abbott Laboratories, NSW, Australia",NA,NA,NA,NA,NA,NA,NA
2005,"van Dyk 2018","https://www.ncbi.nlm.nih.gov/pubmed/29572563","Midazolam in South Asian following 3d of Clarithromycin (between day 12 and 14)","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Plasma",1.5,"geom. Mean","0.8, 2.2","95% CI",1.50909090909091,"Approx. CmaxR",NA,NA,"0","6","324","330","h",NA,"Adjusted AUCratios (adjustment of different genotypes) are also available: AUC0-6 GMR with (95% CI)in µg/L/min: 1.7 (1.0, 2.5); Time adjusted to Time after first rifampicin dose","250",NA,"mg",NA,"S252-T12-R6","h","MD BID (3 days)","MD, bd for a 3-day course","clarithromycin","Klacid Abbott Laboratories, NSW, Australia",NA,NA,NA,NA,NA,NA,NA
2007,"Kashuba 1998","https://www.ncbi.nlm.nih.gov/pubmed/9757149","Midazolam after Fluvoxamine","Midazolam","Fluvoxamine","IV","PO","Reversible_Inhibition","Plasma",1.5,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","517","inf","h",NA,"AUCR was calculated with CLiv values, 517 h is the mean of the two assessments (2 weeks / 4 weeks)","50/100",NA,"mg","PO","0-24-48-58-72-82-96-106-120-130-144-154-168-178-192-202-216-226-240-250-264-274-288-298-312-322-336-346-360-370-384-394-408-418-432-442-456-466-480-490-504-514-528-538-552-562-576-586-600-610-624-634-648","h","MD BID (4 weeks), dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, then 50 mg in the morning and 100 mg in the evening","MD, twice a day for 4 weeks, dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, 50 mg in the morning and 100 mg in the evening for the remainder of the study.","fluvoxamine","50 mg fluvoxamine capsules (Luvox, lot number 87145, Solvay, Marietta, Ga.)",NA,NA,NA,NA,NA,NA,NA
2009,"Gashaw 2003","https://www.ncbi.nlm.nih.gov/pubmed/?term=14586385","Alprazolam 10h concentration after Rifampin treatment (5 day rifampin treatment, day 7)","Alprazolam","Rifampicin","PO","PO","Induction","Plasma",0.1793478,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","100","436","h",1,"AUCR was calculated with estimated CLoral values estimated from 1 plasma sample","450",NA,"mg","PO","0-14-38-62-86","h","MD OD (5 days)","MD, q.d. for 5 days",NA,"Eremfat Fatol, Schiffweiler, Germany",NA,NA,NA,NA,NA,NA,NA
2010,"Gashaw 2003","https://www.ncbi.nlm.nih.gov/pubmed/?term=14586385","Alprazolam 10h concentration after wash out (day 22)","Alprazolam","Rifampicin","PO","PO","Induction","Plasma",0.9166667,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","436","inf","h",1,"AUCR was calculated with estimated CLoral values estimated from 1 plasma sample","450",NA,"mg","PO","0-14-38-62-86","h","MD OD (5 days)","MD, q.d. for 5 days",NA,"Eremfat Fatol, Schiffweiler, Germany",NA,NA,NA,NA,NA,NA,NA
2012,"Chen 2006","https://www.ncbi.nlm.nih.gov/pubmed/16842393","Midazolam post treatment with fluvoxamine (28 days of fluvoxamine) overall","Midazolam","Fluvoxamine","IV","PO","Reversible_Inhibition","Plasma",1.49056603773585,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","inf","336","inf","h",NA,"AUCR was calculated with CLiv values","50/100",NA,"mg","PO","0-24-48-58-72-82-96-106-120-130-144-154-168-178-192-202-216-226-240-250-264-274-288-298-312-322-336-346-360-370-384-394-408-418-432-442-456-466-480-490-504-514-528-538-552-562-576-586-600-610-624-634-648","h","MD BID (4 weeks), dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, then 50 mg in the morning and 100 mg in the evening","MD, twice a day for 4 weeks, dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, 50 mg in the morning and 100 mg in the evening for the remainder of the study.","fluvoxamine","50 mg fluvoxamine capsules (Luvox, lot number 87145, Solvay, Marietta, Ga.)",NA,NA,NA,NA,NA,NA,NA
2014,"Chen 2006","https://www.ncbi.nlm.nih.gov/pubmed/16842393","Midazolam post treatment with fluvoxamine (28 days of fluvoxamine) Male","Midazolam","Fluvoxamine","IV","PO","Reversible_Inhibition","Plasma",1.61702127659574,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","inf","336","inf","h",NA,"AUCR was calculated with CLiv values","50/100",NA,"mg","PO","0-24-48-58-72-82-96-106-120-130-144-154-168-178-192-202-216-226-240-250-264-274-288-298-312-322-336-346-360-370-384-394-408-418-432-442-456-466-480-490-504-514-528-538-552-562-576-586-600-610-624-634-648","h","MD BID (4 weeks), dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, then 50 mg in the morning and 100 mg in the evening","MD, twice a day for 4 weeks, dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, 50 mg in the morning and 100 mg in the evening for the remainder of the study.","fluvoxamine","50 mg fluvoxamine capsules (Luvox, lot number 87145, Solvay, Marietta, Ga.)",NA,NA,NA,NA,NA,NA,NA
2016,"Chen 2006","https://www.ncbi.nlm.nih.gov/pubmed/16842393","Midazolam post treatment with fluvoxamine (28 days of fluvoxamine) female","Midazolam","Fluvoxamine","IV","PO","Reversible_Inhibition","Plasma",1.3728813559322,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","inf","336","inf","h",NA,"AUCR was calculated with CLiv values","50/100",NA,"mg","PO","0-24-48-58-72-82-96-106-120-130-144-154-168-178-192-202-216-226-240-250-264-274-288-298-312-322-336-346-360-370-384-394-408-418-432-442-456-466-480-490-504-514-528-538-552-562-576-586-600-610-624-634-648","h","MD BID (4 weeks), dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, then 50 mg in the morning and 100 mg in the evening","MD, twice a day for 4 weeks, dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, 50 mg in the morning and 100 mg in the evening for the remainder of the study.","fluvoxamine","50 mg fluvoxamine capsules (Luvox, lot number 87145, Solvay, Marietta, Ga.)",NA,NA,NA,NA,NA,NA,NA
2018,"Suzuki 2003","https://www.ncbi.nlm.nih.gov/pubmed/12698310","Alprazolam with fluvoxamine (Japanese)","Alprazolam","Fluvoxamine","PO","PO","Reversible_Inhibition","Plasma",NA,NA,NA,NA,NA,NA,NA,NA,"316 (N=13) / 324 (N=10)","inf","316 (N=13) / 324 (N=10)","inf","h",NA,NA,"25 (N=19) / 50 (N=2) / 100 (N=2)",NA,"mg","PO","S0-T24-R14","h","MD OD (14 days)","MD, The doses of FLV were 25 mg in 19 subjects, 50 mg in 2, and 100 mg in 2. FLV taken at 21:00 by all subjects.","fluvoxamine","oral formulation",NA,NA,NA,NA,NA,NA,NA
2025,"Quinney 2008","https://www.ncbi.nlm.nih.gov/pubmed/17635500","iv Midazolam Female after clarithromycin","Midazolam","Clarithromycin","IV","PO","Mechanism_based_Inactivation","Whole Blood",3.6,"GMR","2.8, 4.4","95% CI",1.20689655172414,"Approx. CmaxR",NA,NA,"0","inf","146","inf","h",NA,NA,"500",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD, bid for 7 days","clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA
2026,"Quinney 2008","https://www.ncbi.nlm.nih.gov/pubmed/17635500","iv Midazolam Male after clarithromycin","Midazolam","Clarithromycin","IV","PO","Mechanism_based_Inactivation","Whole Blood",2.9,"GMR","2.0, 3.7","95% CI",1.11864406779661,"Approx. CmaxR",NA,NA,"0","inf","146","inf","h",NA,NA,"500",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD, bid for 7 days","clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA
2027,"Quinney 2008","https://www.ncbi.nlm.nih.gov/pubmed/17635500","iv Midazolam All after clarithromycin","Midazolam","Clarithromycin","IV","PO","Mechanism_based_Inactivation","Whole Blood",3.2,"GMR","2.7, 3.8","95% CI",1.17241379310345,"Approx. CmaxR",NA,NA,"0","inf","146","inf","h",NA,NA,"500",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD, bid for 7 days","clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA
2028,"Quinney 2008","https://www.ncbi.nlm.nih.gov/pubmed/17635500","po Midazolam Female after clarithromycin","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Whole Blood",8.2,"GMR","4.8, 11.6","95% CI",2.83333333333333,"Approx. CmaxR",NA,NA,"0","inf","146","inf","h",NA,NA,"500",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD, bid for 7 days","clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA
2029,"Quinney 2008","https://www.ncbi.nlm.nih.gov/pubmed/17635500","po Midazolam Male after clarithromycin","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Whole Blood",7.7,"GMR","4.5, 11","95% CI",2.58333333333333,"Approx. CmaxR",NA,NA,"0","inf","146","inf","h",NA,NA,"500",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD, bid for 7 days","clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA
2030,"Quinney 2008","https://www.ncbi.nlm.nih.gov/pubmed/17635500","po Midazolam All after clarithromycin","Midazolam","Clarithromycin","PO","PO","Mechanism_based_Inactivation","Whole Blood",8,"GMR","5.7, 10.2","95% CI",2.75,"Approx. CmaxR",NA,NA,"0","inf","146","inf","h",NA,NA,"500",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD, bid for 7 days","clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA
2035,"Kim 2018","https://www.ncbi.nlm.nih.gov/pubmed/28877336","Midazolam + Ketoconazole Male","Midazolam","Ketoconazole","IV","PO","Reversible_Inhibition","Plasma",2.89,"geom. Mean (GMR)","2.57 - 3.25","90% CI",NA,NA,NA,NA,"0","inf","72","inf","h",1,NA,"400",NA,"mg","PO","S0-T24-R4","h","MD OD (4 days)","MD, q.d. for 4 days","ketoconazole","oral formulation",NA,NA,NA,NA,NA,NA,NA
2002,"van Dyk 2018","https://www.ncbi.nlm.nih.gov/pubmed/29572563","Midazolam in Caucasian following 7d of Rifampicin (between day 1 and 8)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.256410256410256,"geom. Mean","0.208333333333333-0.333333333333333","95% CI",0.375,"Approx. CmaxR",NA,NA,"0","6","156","162","h",1,"Adjusted AUCratios (adjustment of different genotypes) are also available: AUC0-6 GMR with (95% CI)in µg/L/min: 4.2 (3.2, 5.2)","300",NA,"mg","PO","S0-T24-R7","h","MD OD (7 days)","MD, qd for a 7-day course each evening","rifampicin","Rifadin Sanofi, NSW, Australia",NA,NA,NA,NA,NA,NA,NA
2038,"Kim 2018","https://www.ncbi.nlm.nih.gov/pubmed/28877336","Midazolam + Ketoconazole Female","Midazolam","Ketoconazole","IV","PO","Reversible_Inhibition","Plasma",4.77,"geom. Mean (GMR)","4.52 - 5.03","90% CI",NA,NA,NA,NA,"0","inf","72","inf","h",1,NA,"400",NA,"mg","PO","S0-T24-R4","h","MD OD (4 days)","MD, q.d. for 4 days","ketoconazole","oral formulation",NA,NA,NA,NA,NA,NA,NA
2003,"van Dyk 2018","https://www.ncbi.nlm.nih.gov/pubmed/29572563","Midazolam in South Asian following 7d of Rifampicin (between day 1 and 8)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.188679245283019,"geom. Mean","0.15625-0.263157894736842","95% CI",0.218181818181818,"Approx. CmaxR",NA,NA,"0","6","156","162","h",1,"Adjusted AUCratios (adjustment of different genotypes) are also available: AUC0-6 GMR with (95% CI)in µg/L/min: 5.4 (3.8, 7.0)","300",NA,"mg","PO","S0-T24-R7","h","MD OD (7 days)","MD, qd for a 7-day course each evening","rifampicin","Rifadin Sanofi, NSW, Australia",NA,NA,NA,NA,NA,NA,NA
2044,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam PO day 1","Midazolam","Efavirenz","PO","PO","Induction","Plasma",0.5905511,"Geom. mean",NA,NA,NA,NA,NA,NA,"0","6","12","18","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2045,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam IV day 1","Midazolam","Efavirenz","IV","PO","Induction","Plasma",0.78537735,"Geom. mean",NA,NA,NA,NA,NA,NA,"6","14","18","26","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2047,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam PO day 6","Midazolam","Efavirenz","PO","PO","Induction","Plasma",0.6141732,"Geom. mean",NA,NA,NA,NA,NA,NA,"0","6","132","138","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2048,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam IV day 6","Midazolam","Efavirenz","IV","PO","Induction","Plasma",0.7771226,"Geom. mean",NA,NA,NA,NA,NA,NA,"6","14","138","146","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2049,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam PO day 11","Midazolam","Efavirenz","PO","PO","Induction","Plasma",0.769685,"Geom. mean",NA,NA,NA,NA,NA,NA,"0","6","252","258","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2050,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam IV day 11","Midazolam","Efavirenz","IV","PO","Induction","Plasma",0.9375,"Geom. mean",NA,NA,NA,NA,NA,NA,"6","14","258","266","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2051,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam PO day 16","Midazolam","Efavirenz","PO","PO","Induction","Plasma",0.7480314,"Geom. mean",NA,NA,NA,NA,NA,NA,"0","6","372","378","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2052,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam IV day 16","Midazolam","Efavirenz","IV","PO","Induction","Plasma",0.8537735,"Geom. mean",NA,NA,NA,NA,NA,NA,"6","14","378","386","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2053,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam PO  day 22","Midazolam","Efavirenz","PO","PO","Induction","Plasma",0.8366141,"Geom. mean",NA,NA,NA,NA,NA,NA,"0","6","516","522","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2054,"Mikus 2017","https://www.ncbi.nlm.nih.gov/pubmed/28194792","Efavirenz + Midazolam IV  day 22","Midazolam","Efavirenz","IV","PO","Induction","Plasma",0.9221698,"Geom. mean",NA,NA,NA,NA,NA,NA,"6","14","522","530","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
197,"Yu 2004","https://www.ncbi.nlm.nih.gov/pubmed/15289787","Treatment Itraconazole CYP3A5*1/*1","Midazolam","Itraconazole","IV","PO","Reversible_Inhibition","Plasma",2.27272727272727,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","9999","72","9999","h",1,"AUCR was calculated with CLiv values","200",NA,"mg","PO","S0-T24-R4","h","MD OD (4 days)","MD, q.d. for 4 days",NA,"Sporanox capsules",NA,NA,NA,"fasted","overnight",NA,NA
198,"Yu 2004","https://www.ncbi.nlm.nih.gov/pubmed/15289787","Treatment Itraconazole CYP3A5*1/*3","Midazolam","Itraconazole","IV","PO","Reversible_Inhibition","Plasma",2.7027027027027,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","9999","72","9999","h",1,"AUCR was calculated with CLiv values","200",NA,"mg","PO","S0-T24-R4","h","MD OD (4 days)","MD, q.d. for 4 days",NA,"Sporanox capsules",NA,NA,NA,"fasted","overnight",NA,NA
199,"Yu 2004","https://www.ncbi.nlm.nih.gov/pubmed/15289787","Treatment Itraconazole CYP3A5*3/*3","Midazolam","Itraconazole","IV","PO","Reversible_Inhibition","Plasma",3.33333333333333,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","9999","72","9999","h",1,"AUCR was calculated with CLiv values","200",NA,"mg","PO","S0-T24-R4","h","MD OD (4 days)","MD, q.d. for 4 days",NA,"Sporanox capsules",NA,NA,NA,"fasted","overnight",NA,NA
204,"Wiesinger 2020","https://www.ncbi.nlm.nih.gov/pubmed/32275771","Weak-induction phase (RIF 10 mg)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.539,"GMR","0.491-0.592","90% CI",0.63265306122449,"Approx. Avg",NA,NA,"0","9999","180","444","h",1,NA,"10",NA,"mg","PO","S0-T24-R22","h","MD OD (22 days)","MD, q.d. for 22 days",NA,"Eremfat Sirup Suspension",NA,NA,NA,NA,NA,NA,NA
205,"Wiesinger 2020","https://www.ncbi.nlm.nih.gov/pubmed/32275771","Strong-induction phase (RIF 600 mg)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.137,"GMR","0.124-0.150","90% CI",0.187551020408163,"Approx. Avg",NA,NA,"0","9999","444","9999","h",1,NA,"600",NA,"mg","PO","S0-T24-R22","h","MD OD (22 days)","MD, q.d. for 22 days",NA,"Eremfat Tablet",NA,NA,NA,NA,NA,NA,NA
200,"Yu 2004","https://www.ncbi.nlm.nih.gov/pubmed/15289787","Treatment Rifampicin CYP3A5*1/*1","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.985221674876847,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","9999","240","9999","h",2,"Cave! Different dose treatment vs control. Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control). AUCR was calculated with CLiv values.","600",NA,"mg","PO","S0-T24-R10","h","MD OD (10 days)","MD, q.d. for 10 days",NA,"Rifodex",NA,NA,NA,"fasted","overnight",NA,NA
2041,"Katzenmaier 2010","https://www.ncbi.nlm.nih.gov/pubmed/20680253","Midazolam + Efavirenz","Midazolam","Efavirenz","PO","PO","Induction","Plasma",0.1027,"Approx. Avg",NA,NA,0.1806,"Approx. Avg",NA,NA,"0","12","336","340","h",NA,"not mentioned in the paper, calculated from scanned aggregated data","400",NA,"mg","PO","S0-T24-R14","h","MD OD (14 days)","MD, q.d. for 14 days","Efavirenz","Sustiva",NA,NA,NA,NA,NA,NA,NA
201,"Yu 2004","https://www.ncbi.nlm.nih.gov/pubmed/15289787","Treatment Rifampicin CYP3A5*1/*3","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.819672131147541,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","9999","240","9999","h",2,"Cave! Different dose treatment vs control. Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control). AUCR was calculated with CLiv values.","600",NA,"mg","PO","S0-T24-R10","h","MD OD (10 days)","MD, q.d. for 10 days",NA,"Rifodex",NA,NA,NA,"fasted","overnight",NA,NA
202,"Yu 2004","https://www.ncbi.nlm.nih.gov/pubmed/15289787","Treatment Rifampicin CYP3A5*3/*3","Midazolam","Rifampicin","IV","PO","Induction","Plasma",0.833333333333333,"Arith. mean",NA,NA,NA,NA,NA,NA,"0","9999","240","9999","h",2,"Cave! Different dose treatment vs control. Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control). AUCR was calculated with CLiv values.","600",NA,"mg","PO","S0-T24-R10","h","MD OD (10 days)","MD, q.d. for 10 days",NA,"Rifodex",NA,NA,NA,"fasted","overnight",NA,NA
2056,"Barbarash 1988","https://www.ncbi.nlm.nih.gov/pubmed/3180898","Verapamil IV after 2 weeks of Rifampicin therapy","Verapamil","Rifampicin","IV","PO","Induction","Serum",0.818652849740933,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","300","inf","h",1,NA,"600",NA,"mg","PO","S0-T24-R13","h","MD OD (13 days)","1 oral dose every night","rifampin","oral formulation",NA,NA,NA,NA,NA,NA,NA
2058,"Barbarash 1988","https://www.ncbi.nlm.nih.gov/pubmed/3180898","Verapamil PO after 2 weeks of Rifampicin therapy","Verapamil","Rifampicin","PO","PO","Induction","Serum",0.0651100987091875,"Approx. Avg",NA,NA,0.0369609856262834,"Approx. Avg",NA,NA,"0","inf","348","inf","h",1,NA,"600",NA,"mg","PO","S0-T24-R15","h","MD OD (15 days)","1 oral dose every night","rifampin","oral formulation",NA,NA,NA,NA,NA,NA,NA
1319,"Greenblatt 1986","https://pubmed.ncbi.nlm.nih.gov/2935051/","300 mg QD Cimetidine, 5 mg Midazolam IV","Midazolam","Cimetidine","IV","PO","Reversible_Inhibition","Plasma",0.892561983471075,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","24","inf","h",NA,"calculated from CL values","300",NA,"mg",NA,"S0-T6-R8","h","MD QID (2 days)","MD: QID (Day 1-2)",NA,NA,NA,NA,NA,NA,NA,NA,"Fasted on Day 2 (Subjects fasted 8h before and for 3h after MDZ dosing)"
1321,"Greenblatt 1986","https://pubmed.ncbi.nlm.nih.gov/2935051/","300 mg QD Cimetidine, 15 mg Midazolam PO","Midazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.13286713286713,"Approx. Avg",NA,NA,1.05555555555556,"Approx. Avg",NA,NA,"0","inf","24","inf","h",NA,"calculated from CL values","300",NA,"mg",NA,"S0-T6-R8","h","MD QID (2 days)","MD: QID (Day 1-2)",NA,NA,NA,NA,NA,NA,NA,NA,"Fasted on Day 2 (Subjects fasted 8h before and for 3h after MDZ dosing)"
1322,"Martinez 1999","https://pubmed.ncbi.nlm.nih.gov/10223772/","800 mg Cimetidine, 7.5 mg Midazolam PO","Midazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.49733333333333,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","0","inf","h",NA,NA,"800",NA,"mg",NA,"0","h","SD","SD",NA,"Sigma Chemical Co (Barcelona, Spain)",NA,NA,NA,NA,NA,NA,NA
1324,"Fee 1987","https://pubmed.ncbi.nlm.nih.gov/3802710/","400 mg BID Cimetidine, 15 mg Midazolam","Midazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.34563758389262,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","25","inf","h",NA,NA,"400",NA,"mg",NA,"0-12-24,5","h","MD: BID (1 day), OD (1 day)","MD: BID (Day 1), OD (Day 2)",NA,NA,NA,NA,NA,"Fasted","overnight",NA,NA
1326,"Salonen 1986","https://pubmed.ncbi.nlm.nih.gov/2939688/","400 mg Cimetidine, 15 mg Midazolam","Midazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.36487758945386,"Approx. Avg",NA,NA,1.37321196358908,"Approx. Avg",NA,NA,"0","5","2","7","h",NA,NA,"400",NA,"mg","PO","0","h","SD","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA
1328,"Smith 1984","https://pubmed.ncbi.nlm.nih.gov/6478741/","IV 10 mg Verapamil + Cimetidine","Verapamil","Cimetidine","IV","PO","Reversible_Inhibition","Plasma",0.707692307692308,"Approx. Avg",NA,NA,0.959239130434783,"Approx. Avg",NA,NA,"0","inf","168","inf","h",NA,NA,"300",NA,"mg","PO","S0-T6-R36","h","MD QID (9 days)","MD QID (Day 1-9)",NA,NA,NA,NA,NA,NA,NA,NA,NA
1330,"Smith 1984","https://pubmed.ncbi.nlm.nih.gov/6478741/","PO 120 mg Verapamil + Cimetidine","Verapamil","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.36968085106383,"Approx. Avg",NA,NA,1.13333333333333,"Approx. Avg",NA,NA,"0","inf","168","inf","h",NA,NA,"300",NA,"mg","PO","S0-T6-R36","h","MD QID (9 days)","MD QID (Day 1-9)",NA,NA,NA,NA,NA,NA,NA,NA,NA
1332,"Abernethy 1983","https://pubmed.ncbi.nlm.nih.gov/6137021/","Alprazolam + Cimetidine","Alprazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.58095238095238,"Approx. Avg",NA,NA,1.03225806451613,"Approx. Avg",NA,NA,"0","inf","12","inf","h",NA,"calculated from CL values","300",NA,"mg","PO","S0-T6-R4","h","MD QID (1 day)","MD QID (Day 1)",NA,NA,NA,NA,NA,"Fasted",NA,NA,NA
1334,"Abernethy 1983","https://pubmed.ncbi.nlm.nih.gov/6137021/","Triazolam + Cimetidine","Triazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.54285714285714,"Approx. Avg",NA,NA,1.20408163265306,"Approx. Avg",NA,NA,"0","inf","12","inf","h",NA,NA,"300",NA,"mg","PO","S0-T6-R4","h","MD QID (1 day)","MD QID (Day 1)",NA,NA,NA,NA,NA,"Fasted",NA,NA,NA
1336,"Friedman 1988","https://pubmed.ncbi.nlm.nih.gov/3360971/","Triazolam + Cimetidine","Triazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.32298136645963,"Approx. Avg",NA,NA,1.39018087855297,"Approx. Avg",NA,NA,"0","inf","24","inf","h",NA,NA,"300",NA,"mg","PO","S0-T6-R8","h","MD QID (2 days)","MD QID (Day 1-2)",NA,NA,NA,NA,NA,NA,NA,NA,"Subjects fasted overnight before triazolam administration"
1338,"Cox 1986","https://pubmed.ncbi.nlm.nih.gov/3828486/","triazolam + cimetidine","Triazolam","Cimetidine","intraduodenal","PO","Reversible_Inhibition","Serum",1.54545454545455,"Approx. Avg",NA,NA,1.35087719298246,"Approx. Avg",NA,NA,"0","inf","13","inf","h",NA,NA,"300",NA,"mg","PO","S0-T6-R4","h","MD QID (1 day)","MD QID (Day 1)",NA,"oral liquid",NA,NA,NA,NA,NA,NA,"Subjects were fasted for 12h prior to each triazolam treatment and for 4h after each treatment"
1340,"Pourbaix 1985","https://pubmed.ncbi.nlm.nih.gov/2864320/","Alprazolam + Cimetidine","Alprazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.72789115646258,"Approx. Avg",NA,NA,1.81868131868132,"Approx. Avg",NA,NA,"168","240","336","408","h",NA,NA,"200/400",NA,"mg",NA,"(200mg): (S0-T5-R3)-(S24-T5-R3)-(S48-T5-R3)-(S72-T5-R3)-(S96-T5-R3)-(S120-T5-R3)-(S144-T5-R3)-(S168-T5-R3)-(S192-T5-R3)-(S216-T5-R3)-(S240-T5-R3)-(S264-T5-R3)-(S288-T5-R3)-(S312-T5-R3)-(S336-T5-R3)-(S360-T5-R3)-(S384-T5-R3); (400mg): S15-T24-R17","h","(200mg): MD TID (17 days); (400mg): OD (17 days)","(200mg): MD TID (Day 15-31); (400mg): OD (Day 15-31); 1 g/d",NA,NA,NA,NA,NA,NA,NA,NA,NA
1342,"Pourbaix 1985","https://pubmed.ncbi.nlm.nih.gov/2864320/","Triazolam + Cimetidine","Triazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",2.20127795527157,"Approx. Avg",NA,NA,1.51088348271447,"Approx. Avg",NA,NA,"144","168","327","351","h",NA,NA,"200/400",NA,"mg",NA,"(200mg): (S0-T5-R3)-(S24-T5-R3)-(S48-T5-R3)-(S72-T5-R3)-(S96-T5-R3)-(S120-T5-R3)-(S144-T5-R3)-(S168-T5-R3)-(S192-T5-R3)-(S216-T5-R3)-(S240-T5-R3)-(S264-T5-R3)-(S288-T5-R3)-(S312-T5-R3)-(S336-T5-R3)-(S360-T5-R3)-(S384-T5-R3); (400mg): S15-T24-R17","h","(200mg): MD TID (17 days); (400mg): OD (17 days)","(200mg): MD TID (Day 15-31); (400mg): OD (Day 15-31); 1 g/d",NA,NA,NA,NA,NA,NA,NA,NA,NA
1344,"Kienlen 1993","https://link.springer.com/article/10.1007/BF03259596","Alfentanil + Cimetidine","Alfentanil","Cimetidine","IV","IV","Reversible_Inhibition","Serum",2.80314960629921,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","48","inf","h",NA,NA,"1200",NA,"mg","IV","0-24","h","MD OD (2 days)","MD OD (Day 1-2)",NA,NA,NA,NA,"15 to 20 mg/kg",NA,NA,NA,NA
1346,"Elliott 1984","https://pubmed.ncbi.nlm.nih.gov/6152615/","Midazolam/cimetidine","Midazolam","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",2.01604278074866,"Approx. Avg",NA,NA,2.38333333333333,"Approx. Avg",NA,NA,"0","inf","26.5","inf","h",NA,NA,"200/400",NA,"mg",NA,"(200mg): 0-6-12-24; (400mg): 18","h","(200mg): MD TID (1 day), OD (1 day); (400mg): OD (1 day)","(200mg): MD TID (Day 1), OD (Day 2); (400mg): OD (Day 2)",NA,NA,NA,NA,NA,NA,NA,NA,NA
211,"Jacobson 2004","https://pubmed.ncbi.nlm.nih.gov/15518608/","Pravastatin with Itraconazole","Pravastatin","Itraconazole","PO","PO",NA,"Plasma",1.11702127659574,"Approx. Avg","11","% Change",1.140625,"Approx. Avg","14","% Change","0","inf","696","inf","h",NA,NA,"200",NA,"mg",NA,"S24-T24-R29","h","MD OD (29 days)","MD OD (Day 2-30)",NA,NA,NA,NA,NA,NA,NA,NA,NA
1124,"Neuvonen 1998","https://pubmed.ncbi.nlm.nih.gov/9542477/","Pravastatin with Itraconazole","Pravastatin","Itraconazole","PO","PO",NA,"Plasma",1.7,"Arith. Mean",NA,NA,2.5,"arith. Mean",NA,NA,"0","inf","74","inf","h",NA,NA,"200",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD",NA,"Sporanox, Janssen Pharma, Beerse, Belgium",NA,NA,"Dosing at 7:30 am for 4 days",NA,NA,NA,NA
1126,"Kantola 2000","https://pubmed.ncbi.nlm.nih.gov/10952477/","Pravastatin with Fluconazole","Pravastatin","Fluconazole","PO","PO",NA,"Plasma",1.4,"Arith. Mean","0,5-2,7","Relative to control (range)",1.3,"arith. Mean","0,3-2,8","Relative to control (range)","0","inf","73","inf","h",NA,NA,"400 / 200",NA,"mg","PO","0-24-48-72","h","MD OD (4 days)","MD, Day1: 400mg, Day 2-4: 200mg",NA,"Diflucan, Pfizer Inc., N.Y.",NA,NA,NA,NA,NA,NA,NA
1129,"Maeda 2011","https://pubmed.ncbi.nlm.nih.gov/21832990/","Pravastatin with Itraconazole","Pravastatin","Itraconazole","PO","PO",NA,"Plasma",1.47236180904523,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","8","1","9","h",NA,"AUCR was calculated by using these values: AUC(0-t)/dose, area under the plasma concentration-time curve from time 0 to t hours normalized by dose in each phase.","200",NA,"mg","IV","0","h","SD",NA,NA,"Itrizole 1% solution",60,NA,"1h before oral solution",NA,NA,NA,NA
1130,"Maeda 2011","https://pubmed.ncbi.nlm.nih.gov/21832990/","Pravastatin with Rifampicin","Pravastatin","Rifampicin","PO","PO",NA,"Plasma",4.63986599664992,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","8","0","8","h",1,"AUCR was calculated by using these values: AUC(0-t)/dose, area under the plasma concentration-time curve from time 0 to t hours normalized by dose in each phase.","600",NA,"mg","PO","0","h","SD",NA,NA,"four 150mg Rifadin capsules",NA,NA,"at the same time of oral solution",NA,NA,NA,NA
1146,"Azie 1998","https://pubmed.ncbi.nlm.nih.gov/9797793/","with Diltiazem","Pravastatin","Diltiazem","PO","PO",NA,"Plasma",1.02702702702703,"Approx. Avg",NA,NA,1.3030303030303,"Approx. Avg",NA,NA,"0","inf","325","inf","h",NA,NA,"120",NA,"mg",NA,"S0-T12-R42","h","MD: BID for 2 weeks","2 weeks of 120 mg diltiazem twice a day",NA,"Cardizem SR",NA,NA,NA,NA,NA,NA,NA
1149,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Cohort 2, 2 mg Rifampicin","Pravastatin","Rifampicin","PO","PO",NA,"Plasma",0.833,"geom mean","(0,716; 0,970)","90%CI",0.856,"geom mean","(0,690; 1,063)","90%CI","0","inf","276","708","h",1,NA,"2",NA,"mg","PO","S0-T24-R18","h","MD OD (18 days)","Acc. to Table 2: RIF was given q.d. from DAY 9 to DAY 26 (RIF 10mg and 2mg) and DAY 27 to DAY 44 (RIF 75mg and 600mg)",NA,NA,NA,NA,NA,NA,NA,NA,NA
1150,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Cohort 1, 10 mg Rifampicin","Pravastatin","Rifampicin","PO","PO",NA,"Plasma",0.813,"geom mean","(0,713; 0,926)","90%CI",0.788,"geom mean","(0,660; 0,939)","90%CI","0","inf","276","708","h",1,NA,"10",NA,"mg","PO","S0-T24-R18","h","MD OD (18 days)","Acc. to Table 2: RIF was given q.d. from DAY 9 to DAY 26 (RIF 10mg and 2mg) and DAY 27 to DAY 44 (RIF 75mg and 600mg)",NA,NA,NA,NA,NA,NA,NA,NA,NA
1151,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Cohort 1, 75 mg Rifampicin","Pravastatin","Rifampicin","PO","PO",NA,"Plasma",0.421,"geom mean","(0,350; 0,505)","90%CI",0.407,"geom mean","(0,325; 0,511)","90%CI","0","inf","708","inf","h",1,NA,"10, 75",NA,"mg","PO","S0-T24-R18 (10 mg), S432-T24-R18 (75 mg)","h","MD OD (18 day 10 mg, 18 days 75 mg)","Acc. to Table 2: RIF was given q.d. from DAY 9 to DAY 26 (RIF 10mg and 2mg) and DAY 27 to DAY 44 (RIF 75mg and 600mg)",NA,NA,NA,NA,NA,NA,NA,NA,NA
1152,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Cohort 2, 600 mg Rifampicin","Pravastatin","Rifampicin","PO","PO",NA,"Plasma",0.416,"geom mean","(0,333; 0,521)","90%CI",0.473,"geom mean","(0,361; 0,621)","90%CI","0","inf","708","inf","h",1,NA,"2, 600",NA,"mg","PO","S0-T24-R18 (2 mg), S432-T24-R18 (600 mg)","h","MD OD (18 day 2 mg, 18 days 600 mg)","Acc. to Table 2: RIF was given q.d. from DAY 9 to DAY 26 (RIF 10mg and 2mg) and DAY 27 to DAY 44 (RIF 75mg and 600mg)",NA,NA,NA,NA,NA,NA,NA,NA,NA
1169,"Jacobson 2004","https://pubmed.ncbi.nlm.nih.gov/15518608/","Pravastatin with Verapamil","Pravastatin","Verapamil","PO","PO",NA,"Plasma",1.31578947368421,"Approx. Avg","+31","%Change",1.40625,"Approx. Avg","+42","%Change","0","24","72","96","h",NA,"AUCRVar and CmaxR Var taken from %Change (Table 1)","120 IR / 480 ER",NA,"mg",NA,"0-12-36-60","h","MD: Day 1: 120mg IR in the morning, Day 2-4: 480mg ER in the evening","120mg immediate-released (IR), 480mg extended-released (ER)",NA,NA,NA,NA,NA,NA,NA,NA,NA
1172,"Jacobson 2004","https://pubmed.ncbi.nlm.nih.gov/15518608/","Pravastatin with Clarithromycin","Pravastatin","Clarithromycin","PO","PO",NA,"Plasma",2.11111111111111,"Approx. Avg","+110","%Change",2.27777777777778,"Approx. Avg","+128","%Change","144","154","168","181.5","h",NA,"AUCRVar and CmaxR Var taken from %Change (Table 4)","500",NA,"mg",NA,"S0-T12-R18","h","MD BID (9 days)","MD: bid for 9 days",NA,NA,NA,NA,NA,NA,NA,NA,NA
1174,"Yee 2019","https://pubmed.ncbi.nlm.nih.gov/30982223/","Pravastatin with Cyclosporin","Pravastatin","Cyclosporin","PO","PO",NA,"Plasma",3.41975308641975,"Approx. Avg",NA,NA,3.19811320754717,"Approx. Avg",NA,NA,"0","12","11","23","h",NA,"AUCR & CmaxR: (PRA + CsA) / (PRA + Placebo)","100",NA,"mg",NA,"0-10","h","MD OD (2 days)","MD: Day 1 evening: 100mg, Day 2 morning: 100mg",NA,NA,NA,NA,NA,NA,NA,NA,"fasted at least for 10h for dosing at Day 2"
1183,"Becquemont 2007","https://pubmed.ncbi.nlm.nih.gov/17301736/","with Amiodarone","Pravastatin","Amiodarone","PO","PO",NA,"Plasma",0.899854862119013,"Approx. Avg","86% (63-118%)","90% CI",0.767511177347243,"Approx. Avg","72% (47-109%)","90% CI","0","24","72","96","h",NA,"AUCRVar and CmaxR Var taken from Point Estimates (Table 1)","400",NA,"mg","PO","S0-T24-R4","h","MD: OD (4 days)","MD, q.d. for 4 days",NA,"amiodarone (Cordarone(R), 200 mg tablets, Sanofi-Aventis, France)",NA,NA,NA,"fasted","overnight fast",NA,NA
1185,"Mazzu 2000","https://pubmed.ncbi.nlm.nih.gov/11061579/","Pravastatin + Itraconazole","Pravastatin","Itraconazole","PO","PO",NA,"Plasma",1.51,"Geom LS means","1,10 -2,06","90% CI",1.24,"Geom LS means","0,86 - 1,79","90% CI","0","inf","100","inf","h",NA,"AUC(0-tn): AUCR: 1,56 (Geom LS means); AUCR Var: 1,18-2,06 (90% CI)","200",NA,"mg","PO","S0-T24-R5","h","MD OD (5 days)","MD: OD Day 6-10",NA,NA,NA,NA,"Dosing of ITZ at 6PM  ± 30 min",NA,NA,NA,NA
1198,"Kyrklund 2003","https://pubmed.ncbi.nlm.nih.gov/12811363/","with Gemfibrozil","Pravastatin","Gemfibrozil","PO","PO",NA,"Plasma",2.01870503597122,"Approx Avg",NA,NA,1.80995475113122,"Approx. Avg",NA,NA,"0","inf","49","inf","h",NA,"Cmax(mg/L) of Gemfibrozil: 32+/- 8.5; AUC(1-25)(mg*h/L): 209+/- 97 [arith mean+/- SD]; Difference between phases: AUC(0-inf): 141.6 (12.6 to 270.6) [mean and 95%CI]; AUC(0-24): 141,1 (12,4 to 269,9) [mean and 95%CI]; Cmax: 53.7 (–12.1 to 119.6) [mean and 95%CI]","600",NA,"mg","PO","S0-T12-R6","h","MD BID (3 days)","MD: BID Day1-3",NA,"one 600-mg tablet of Lopid; Parke-Davis, Freiburg, Germany",NA,NA,"Dosing of Gemfibrozil at 8 AM and 8 PM",NA,NA,NA,"overnight fast on Day 3. At 8AM: gemfibrozil was given; at 9AM: pravastatin was given; 3h after pravastatin administration standard meal was given."
1200,"Kyrklund 2004","https://pubmed.ncbi.nlm.nih.gov/14748817/","with Rifampicin (MD 600 mg)","Pravastatin","Rifampicin","PO","PO",NA,"Plasma",0.690845070422535,"Approx Avg",NA,NA,0.788018433179724,"Approx. Avg",NA,NA,"0","inf","113","inf","h",1,"Difference between phases: AUC(0-inf): -51.9–-0.4 [95%CI]; AUC(0-12): (-51,7 to -0,4) [95%CI]; Cmax: -24.9–5.1 [95%CI]","600",NA,"mg","PO","S0-T24-R5","h","MD OD (5 days)","MD: OD Day 1-5",NA,"Rifarm, Pharmacal, Helsinki, Finland",NA,NA,"Dosing at 4 PM daily for 5 days",NA,NA,NA,NA
1350,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Cohort 2, 2 mg Rifampicin","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.769,"GMR","0.730-0.810","90%CI",0.79,"GMR","0.738-0.846","90%CI","0","inf","228","660","h",1,NA,"2",NA,"mg","PO","S0-T24-R18","h","MD OD (18 days)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1351,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Cohort 1, 10 mg Rifampicin","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.398,"GMR","0.359-0.441","90%CI",0.516,"GMR","0.460-0.579","90%CI","0","inf","228","660","h",1,NA,"10",NA,"mg","PO","S0-T24-R18","h","MD OD (18 days)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1352,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Cohort 1, 75 mg Rifampicin","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.0916,"GMR","0.0795-0.1055","90%CI",0.149,"GMR","0.130-0.171","90%CI","0","inf","660","inf","h",1,NA,"first 10, then 75",NA,"mg","PO","S0-T24-R18 (10 mg), S432-T24-R18 (75 mg)","h","MD OD (18 days 10 mg, then 18 days 75 mg)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1353,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Cohort 2, 600 mg Rifampicin","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.0859,"GMR","0.0695-0.1061","90%CI",0.139,"GMR","0.112-0.172","90%CI","0","inf","660","inf","h",1,NA,"first 2, then 600",NA,"mg","PO","S0-T24-R18 (2 mg), S432-T24-R18 (600 mg)","h","MD OD (18 days 2 mg, then 18 days 600 mg)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1355,"Björkhem-Bergman 2013","https://pubmed.ncbi.nlm.nih.gov/23674608/","with Rifampicin 10 mg","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.5,"GMR",NA,NA,NA,NA,NA,NA,"0","10","336","346","h",1,"AUCR inverted from CL ratio","10",NA,"mg","PO","S0-T24-R14","h","MD OD (14 days)",NA,NA,"Rifadin oral suspension",NA,NA,NA,NA,NA,NA,NA
1356,"Björkhem-Bergman 2013","https://pubmed.ncbi.nlm.nih.gov/23674608/","with Rifampicin 20 mg","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.384615384615385,"GMR",NA,NA,NA,NA,NA,NA,"0","10","336","346","h",1,"AUCR inverted from CL ratio","20",NA,"mg","PO","S0-T24-R14","h","MD OD (14 days)",NA,NA,"Rifadin oral suspension",NA,NA,NA,NA,NA,NA,NA
1357,"Björkhem-Bergman 2013","https://pubmed.ncbi.nlm.nih.gov/23674608/","with Rifampicin 100 mg","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.25,"GMR",NA,NA,NA,NA,NA,NA,"0","10","336","346","h",1,"AUCR inverted from CL ratio","100",NA,"mg","PO","S0-T24-R14","h","MD OD (14 days)",NA,NA,"Rifadin oral suspension",NA,NA,NA,NA,NA,NA,NA
1362,"Chattopadhyay 2018","https://pubmed.ncbi.nlm.nih.gov/30171692/","with Perpetrator (Rifampicin)","Midazolam","Rifampicin","PO","PO","Induction","Plasma",0.141,"GMR","28.8","geom. CV%",0.138,"GMR","20.8","geom. CV%","0","inf","168","inf","h",1,"Subjects received a single dose of vilaprisan 4 mg simultaneously with midazolam.","600",NA,"mg","PO","0-24-48-72-96-120-144-180-192-216-240","h","MD OD (11 days)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1392,"Ahonen 1997","https://pubmed.ncbi.nlm.nih.gov/9049584/","Midazolam with perpetrator fluconazole i.v","Midazolam","Fluconazole","PO","IV","Reversible_Inhibition","Plasma",3.08,"Approx. Avg",NA,NA,1.786,"Approx. Avg",NA,NA,"1","18","1","18","h",NA,NA,"400",NA,"mg","IV","0","h","SD",NA,NA,NA,60,NA,NA,"Fasted",NA,NA,NA
1393,"Ahonen 1997","https://pubmed.ncbi.nlm.nih.gov/9049584/","Midazolam with perpetrator fluconazole oral","Midazolam","Fluconazole","PO","PO","Reversible_Inhibition","Plasma",3.41,"Approx. Avg",NA,NA,2.296,"Approx. Avg",NA,NA,"1","18","1","18","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,"Diflucan ",NA,150,NA,"Fasted",NA,NA,NA
1394,"Varhe 1996c","https://pubmed.ncbi.nlm.nih.gov/8904618/","Triazolam with perpetrator fluconazole 50mg ","Triazolam","Fluconazole","PO","PO","Reversible_Inhibition","Plasma",1.587,"Approx. Avg",NA,NA,1.467,"Approx. Avg",NA,NA,"73","92","73","92","h",NA,NA,"50",NA,"mg","PO","0-24-48-72","h","MD for 4 days","victim administered 1 h after last dose",NA,"Diflucan ",NA,150,NA,"Fasted",NA,NA,NA
1395,"Varhe 1996c","https://pubmed.ncbi.nlm.nih.gov/8904618/","Triazolam with perpetrator fluconazole 100mg ","Triazolam","Fluconazole","PO","PO","Reversible_Inhibition","Plasma",1.99,"Approx. Avg",NA,NA,1.4,"Approx. Avg",NA,NA,"73","92","73","92","h",NA,NA,"100",NA,"mg","PO","0-24-48-73","h","MD for 4 days","victim administered 1 h after last dose",NA,"Diflucan ",NA,150,NA,"Fasted",NA,NA,NA
1396,"Varhe 1996c","https://pubmed.ncbi.nlm.nih.gov/8904618/","Triazolam with perpetrator fluconazole 200mg ","Triazolam","Fluconazole","PO","PO","Reversible_Inhibition","Plasma",3.652,"Approx. Avg",NA,NA,2.33,"Approx. Avg",NA,NA,"73","92","73","92","h",NA,NA,"200",NA,"mg","PO","0-24-48-74","h","MD for 4 days","victim administered 1 h after last dose",NA,"Diflucan ",NA,150,NA,"Fasted",NA,NA,NA
1398,"Palkama 1998","https://pubmed.ncbi.nlm.nih.gov/9661572/","Alfentanil with perpetrator fluconazole i.v.","Alfentanil","Fluconazole","IV","IV","Reversible_Inhibition","Plasma",2.07,"Approx. Avg",NA,NA,1.2,"Approx. Avg",NA,NA,"1","11","1","11","h",NA,NA,"400",NA,"mg","IV","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1399,"Palkama 1998","https://pubmed.ncbi.nlm.nih.gov/9661572/","Alfentanil with perpetrator fluconazole po","Alfentanil","Fluconazole","IV","PO","Reversible_Inhibition","Plasma",1.97,"Approx. Avg",NA,NA,1.04,"Approx. Avg",NA,NA,"1","11","1","11","h",NA,NA,"400",NA,"mg","PO","0","h","SD",NA,NA,"Diflucan",NA,NA,NA,"Fasted",NA,NA,NA
895,"Burstein 2000","https://pubmed.ncbi.nlm.nih.gov/11180020/","After St John’s Wort","Carbamazepine","St John's Wort","PO","PO","Induction","Plasma",0.9976024,"GMR","1.179883","Geom. SD",1.053142,"GMR","1.241582","Geom. SD","480","504","816","840","h",NA,NA,"300",NA,"mg","PO","S504-T8-R42","h","MD","The St John’s Wort preparation used in this study was standardized to 0.3% hypericin (confirmed in our laboratory with a United States Pharmacopeia/National Formulary method)",NA,NA,NA,NA,NA,"Fed",NA,NA,NA
900,"Dalton 1985a","https://pubmed.ncbi.nlm.nih.gov/3987645/","Treatment with cimetidine","Carbamazepine","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.254777,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","48","inf","h",NA,NA,"300",NA,"mg","PO","(S0-T24-R9)-(S4-T24-R9)-(S8-T24-R9)-(S16-T24-R9)","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
465,"Barzaghi 1987","https://pubmed.ncbi.nlm.nih.gov/3440106/","With erythromycin","Carbamazepine","Erythromycin","PO","PO","Mechanism_based_Inactivation","Serum",1.319647,"Approx. Avg",NA,NA,0.9615385,"Approx. Avg",NA,NA,"0","inf","144","inf","h",1,NA,"500",NA,"mg","PO","S0-T8-R30","h","MD","Time of carbamazepine administration relative to erythromycin administration not reported","Erythromycin stearate",NA,NA,NA,NA,NA,NA,NA,NA
959,"Ji 2008","https://pubmed.ncbi.nlm.nih.gov/18519918/","Efavirenz + Carbamazepine, treatment (Arm 1)","Efavirenz","Carbamazepine","PO","PO","Induction","Plasma",0.64,"GMR","0.60-0.68","90%CI",0.79,"GMR","0.74-0.85","90%CI","312","336","816","840","h",1,NA,"200/400",NA,"mg","PO","Days15-17: S336-T24-R3; Days18-20: S408-T12-R6; Days21-35: S480-T24-R15","h","MD",NA,"tablets of 200-mg strength (Novartis Pharmaceuticals Co, East Hanover, New Jersey)",NA,NA,NA,NA,"Fasted","2","2","No food for at least 2h before and after dosing"
961,"Ji 2008","https://pubmed.ncbi.nlm.nih.gov/18519918/","Carbamazepine + Efavirenz, treatment (Arm 2)","Carbamazepine","Efavirenz","PO","PO","Induction","Plasma",0.73,"GMR","0.67-0.80","90%CI",0.8,"GMR","0.76-0.85","90%CI","480","504","816","840","h",1,NA,"600",NA,"mg","PO","S504-T24-R14","h","MD",NA,"tablets of 600-mg strength (Bristol-Myers Squibb Co, Princeton, New Jersey)",NA,NA,NA,NA,"Fasted","2","2","No food for at least 2h before and after dosing"
1157,"Miles 1989","https://pubmed.ncbi.nlm.nih.gov/2911854/","300 mg CBZ during ERY","Carbamazepine","Erythromycin","PO","PO","Mechanism_based_Inactivation","Serum",1.272997,"GMR",NA,NA,1.0927027,"GMR",NA,NA,"312","336","384","408","h",1,"GMR calculated from reported individual values","250",NA,"mg","PO","S336-T6-R12","h","MD QID (3 days)","MD QID (Day 15-17)",NA,"ERY base (ERYC, lot no. CL102037; Warner-Lambert, Ann Arbor, MI, USA)",NA,NA,NA,"fasted","12","4","Fasting of 12h only for morning of Day 14 + 17. During the control and treament admissions standardized caffeine-free, low fat diets were provided beginning 4h after the CBZ dose."
1158,"Miles 1989","https://pubmed.ncbi.nlm.nih.gov/2911854/","400 mg CBZ during ERY","Carbamazepine","Erythromycin","PO","PO","Mechanism_based_Inactivation","Serum",1.423285,"GMR",NA,NA,0.9979275,"GMR",NA,NA,"312","336","384","408","h",1,"GMR calculated from reported individual values","250",NA,"mg","PO","S336-T6-R12","h","MD QID (3 days)","MD QID (Day 15-17)",NA,"ERY base (ERYC, lot no. CL102037; Warner-Lambert, Ann Arbor, MI, USA)",NA,NA,NA,"fasted","12","4","Fasting of 12h only for morning of Day 14 + 17. During the control and treament admissions standardized caffeine-free, low fat diets were provided beginning 4h after the CBZ dose."
1154,"Wong 1983","https://pubmed.ncbi.nlm.nih.gov/6831824/","Treatment A (with erythromycin)","Carbamazepine","Erythromycin","PO","PO","Mechanism_based_Inactivation","Plasma",1.239669,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","120","inf","h",1,"AUCR calculated from reported model-dependent CL values; using the reported model-independent CL values yields an AUCR of 1.201","250",NA,"mg","PO","S0-T6-R32","h","MD","Time of carbamazepine administration relative to erythromycin administration not reported",NA,NA,NA,NA,NA,NA,NA,NA,NA
1457,"Furukori 1998","https://pubmed.ncbi.nlm.nih.gov/9536449/","treatment with carbamazepine","Alprazolam","Carbamazepine","PO","PO","Induction","Plasma",0.4225352,"Approx. Avg",NA,NA,1.111111,"Approx. Avg",NA,NA,"0","inf","170","inf","h",1,NA,"300",NA,"mg","PO","S0-T8-R30","h","MD",NA,NA,"Tegretol (Novartis Pharma, Tokyo, Japan)",NA,NA,NA,NA,NA,NA,NA
1460,"Lutz 2018b","https://pubmed.ncbi.nlm.nih.gov/29569712/","Cohort 1, 300 mg carbamazepine BID","Midazolam","Carbamazepine","PO","PO","Induction","Plasma",0.211,"GMR","0.183-0.244","90%CI",0.318,"GMR","0.281-0.361","90%CI","0","inf","404","inf","h",1,NA,"100, then escalated to 300",NA,"mg","PO","S0-T12-R52","h","MD","BID over 26 days; initiated at 100 mg BID and escalated to final 300 mg BID over 1 week",NA,NA,NA,NA,"For modeling, the following dosing regimen was assumed: Day 1 - 2: 100 mg BID; Day 3 - 4: 200 mg BID; thereafter: 300 mg BID",NA,NA,NA,NA
3003,"Verstuyft 2003","https://pubmed.ncbi.nlm.nih.gov/12545143/","0.5mg with dipyridamole","Digoxin","Dipyridamole","PO","PO",NA,"Plasma",1.07763061074319,"Approx. Avg",NA,NA,1.23333333333333,"Approx. Avg",NA,NA,"0","inf","48","inf","h",NA,NA,"75",NA,"mg","PO","75mg: 0-3-24-27; 150mg: 12-36-48","h","MD: BID 75mg (2 days); OD 150mg (3 days)","MD: BID 75mg Day 1-2; OD 150mg Day 1-3","tablet","dipyridamole (Persantine; Boehringer Ingelheim, Neuilly sur Seine, France)",NA,NA,NA,NA,NA,NA,"overnight fast on Day 3"
3014,"Ding 2004","https://pubmed.ncbi.nlm.nih.gov/15229466/","0.5mg iv with ritonavir","Digoxin","Ritonavir","IV","PO",NA,"Plasma",1.86363636363636,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","48.33","inf","h",NA,NA,"300",NA,"mg","PO","S0-T12-R22","h","MD BID (11 days)","MD BID (Day 1-11)",NA,"300 mg ritonavir (Norvir; Abbott Laboratories, Abbott Park, Ill)",NA,NA,NA,NA,NA,NA,NA
3022,"Lalonde 1985","https://pubmed.ncbi.nlm.nih.gov/3978996/","0.01mg/kg charcoal","Digoxin","Charcoal","IV","PO",NA,"Plasma",NA,NA,NA,NA,NA,NA,NA,NA,"0","inf","0","inf","h",NA,NA,"25",NA,"mg","PO","(S0-T4-R5)-22-28-34-40","h","MD","MD",NA,"activated charcoal slurry",NA,NA,NA,NA,NA,NA,NA
3025,"Rengelshausen 2003","https://pubmed.ncbi.nlm.nih.gov/12848773/","0.75mg/kg po with clarithromycin","Digoxin","Clarithromycin","PO","PO",NA,"Plasma",1.64285714285714,"Approx Avg","7,0; 12","95% CI (diff.)",1.83333333333333,"Approx. Avg","1,6; 3,9","95% CI (diff.)","0","inf","24.5","48.5","h",NA,NA,"250",NA,"mg","PO","S0-T12-R6","h","MD BID (3 days)","MD BID Day 1-3",NA,"Klacid® tablets, Abbott GmbH, Wiesbaden, Germany",NA,NA,"Klacid® tablets were encapsulated into hard gelatine capsules by the hospital pharmacy to match the corresponding placebo capsules filled with lactose.",NA,NA,NA,"Food or beverages containing alcohol or caffeine were not allowed from 12 h before clarithromycin administration until the last blood sample was drawn."
3028,"Tsutsumi 2002","https://pubmed.ncbi.nlm.nih.gov/12362931/","0.5mg iv with erythromycin","Digoxin","Erythromycin","IV","PO","Reversible_Inhibition","Plasma",0.955,"Approx Avg",NA,NA,0.989010989010989,"Approx. Avg",NA,NA,"0","inf","24","inf","h",1,NA,"200",NA,"mg","PO","S0-T6-R20","h","MD QID (5 days)","MD QID Day 1-5",NA,"Erythrocin®, Dainippon Pharmaceutical Co., Osaka, Japan",NA,NA,NA,NA,NA,NA,NA
3029,"Tsutsumi 2002","https://pubmed.ncbi.nlm.nih.gov/12362931/","0.5mg iv with clarithromycin","Digoxin","Clarithromycin","IV","PO","Reversible_Inhibition","Plasma",0.98,"Approx Avg",NA,NA,0.989010989010989,"Approx. Avg",NA,NA,"0","inf","24","inf","h",1,NA,"200",NA,"mg","PO","S0-T12-R10","h","MD BID (5 days)","MD BID Day 1-5",NA,"Klaricid®, Dainippon Pharmaceutical Co., Osaka, Japan",NA,NA,NA,NA,NA,NA,NA
3031,"Tsutsumi 2002","https://pubmed.ncbi.nlm.nih.gov/12362931/","0.5mg iv with erythromycin","Digoxin","Erythromycin","IV","PO","Reversible_Inhibition","Urine",0.716678805535324,"Approx Avg",NA,NA,NA,NA,NA,NA,"0","inf","24","inf","h",1,"1/CLR ratio","200",NA,"mg","PO","S0-T6-R20","h","MD QID (5 days)","MD QID Day 1-5",NA,"Erythrocin®, Dainippon Pharmaceutical Co., Osaka, Japan",NA,NA,NA,NA,NA,NA,NA
3032,"Tsutsumi 2002","https://pubmed.ncbi.nlm.nih.gov/12362931/","0.5mg iv with clarithromycin","Digoxin","Clarithromycin","IV","PO","Reversible_Inhibition","Urine",0.736526946107784,"Approx Avg",NA,NA,NA,NA,NA,NA,"0","inf","24","inf","h",1,"1/CLR ratio","200",NA,"mg","PO","S0-T12-R10","h","MD BID (5 days)","MD BID Day 1-5",NA,"Klaricid®, Dainippon Pharmaceutical Co., Osaka, Japan",NA,NA,NA,NA,NA,NA,NA
3034,"Becquemont 2001","https://pubmed.ncbi.nlm.nih.gov/11673746/","0.5mg po with grapefruit juice","Digoxin","Grapefruit Juice","PO","PO",NA,"Plasma",1.08577094695092,"Approx Avg",NA,NA,1.22727272727273,"Approx. Avg",NA,NA,"0.5","inf","0","12","h",NA,NA,"220 (0-4-8-12h); 50 (0,5h)",NA,"ml","PO","0-0,5-4-8-12","h","MD (1 day)","MD: 0-4-8-12h: 220ml, 0,5h: 50ml ",NA,"reconstituting frozen concentrated juice (Picard, France) from a single batch to regular strength. 200ml of concentrated juice was extemporaneously added to 600ml of water. Concentrated juice is made from Israeli white grapefruit by GAT Food Canneries (Israel) [brand name Jaffa Champion, distributed by Picard (France)] ",NA,NA,"220 mL of grapefruit 30 min before administration of digoxin and 3,5h, 7,5h and 11,5h after admin","Fasted","overnight","4","standard meal after 4 and 10 hours dosing"
3036,"Eckermann 2012","https://pubmed.ncbi.nlm.nih.gov/21257799/","0.25mg po with roflumilast","Digoxin","Roflumilast","PO","PO",NA,"Plasma",1.01,"geom. Mean","(0.92-1.11)","90%CI",1.15,"geom. Mean","(0.99-1.34)","90%CI","0","inf","312","inf","h",NA,NA,"500",NA,"µg","PO","S0-T24-R14","h","MD OD (14 days)","MD OD (Day 1-14)",NA,"roflumilast (500 μg, Nycomed, Germany; formerly Altana)",NA,240,NA,"fasted","10",NA,NA
3044,"Martin 1997","https://pubmed.ncbi.nlm.nih.gov/9205830/","0.6mg po with Eprosartan","Digoxin","Eprosartan","PO","PO",NA,"Plasma",1.01,"geom. Mean","[0,81; 1,26]","90% CI",1,"geom. Mean","[0,86; 1,17]","90% CI","0","inf","72","168","h",NA,NA,"200",NA,"mg","PO","S0-T12-R14","h","MD BID (7 days)","MD BID Day 1-7",NA,NA,NA,NA,NA,NA,NA,NA,NA
3046,"Oosterhuis 1991","https://pubmed.ncbi.nlm.nih.gov/1954072/","1mg po with omeprazole","Digoxin","Omeprazole","PO","PO",NA,"Plasma",1.13247172859451,"Approx Avg","98-128","90% CI",1.05527638190955,"Approx. Avg","85-126","90% CI","0","inf","170","inf","h",NA,"AUC(0,96): 90%CI: 103-119","20",NA,"mg","PO","S0-T24-R11","h","MD OD (11 days)","MD OD Day 1-11","capsule","capsule containing 20mg omeprazole as enteric coated granules (batch no. HC8582)",NA,200,NA,"Fasted",NA,NA,"Each capsule was swallowed at 08.00 h with 200 ml of water before breakfast"
3048,"Ragueneau 1999","https://pubmed.ncbi.nlm.nih.gov/10510161/","0.5mg po with macrogol 4000","Digoxin","Macrogol 4000","PO","PO",NA,"Plasma",0.703180212014134,"Approx Avg","70,3 [62 to 79]","90% CI",0.56,"Approx. Avg","58,6 [49 to 70]","90% CI","0","inf","96","inf","h",NA,"AUC(0,t): 90% CI: 70.0 [61 to 80]","20",NA,"g",NA,"S0-T24-R8","h","MD OD (8 days)","MD OD Day 1-8",NA,"Macrogol 4000 (Forlax® - laxative polymer)",NA,NA,NA,NA,NA,NA,NA
3050,"Tayrouz 2003","https://pubmed.ncbi.nlm.nih.gov/12732840/","0.5mg po with Cremophor RH40","Digoxin","Cremophor Rh40","PO","PO",NA,"Plasma",1.1447619047619,"Approx Avg",NA,NA,1.14,"Approx. Avg",NA,NA,"0","inf","24","33","h",NA,NA,"600",NA,"mg","PO","0-4-8-(S24-T8-25)","h","MD TID (9 days), SD (1 day)","MD TID (Day 1-9), SD (Day 10)","capsule","Cremophor RH40, BASF, Burgbernheim, Germany",NA,220,"capsules prepared by Hospital Pharmacy by putting together one Lanicor tablet with the appropriate amount of Cremophor RH40 or placebo into a hard gelatin capsule.",NA,NA,NA,"overnight fast before DIG administration"
3052,"Westphal 2000","https://pubmed.ncbi.nlm.nih.gov/10945310/","0.5mg po with talinolol p.o.","Digoxin","Talinolol","PO","PO",NA,"Plasma",1.17826086956522,"Approx. Avg",NA,NA,1.44559585492228,"Approx. Avg",NA,NA,"0","inf","0","inf","h",NA,NA,"100",NA,"mg","PO","0","h","SD","SD",NA,NA,NA,100,"The tablets were given with 100 mL tap water (room temperature). The subjects had to fast and to remain in the supine position with a raised upper body (30 degrees) for 5 hours.","fasted","overnight","5","Subjects were advised to consume a standard diet on the pharmacokinetic study days, and smoking was not allowed."
3053,"Westphal 2000","https://pubmed.ncbi.nlm.nih.gov/10945310/","0.5mg po with talinolol i.v.","Digoxin","Talinolol","PO","PO",NA,"Plasma",1.04782608695652,"Approx. Avg",NA,NA,1.09844559585492,"Approx. Avg",NA,NA,"0","inf","0","inf","h",NA,NA,"30",NA,"mg","IV","0","h","SD","SD","30mg talinolol in 250ml saline solution infused","talinolol (Cordanum, Arzneimittelwerk Dresden GmbH, Germany)",120,NA,NA,"fasted","overnight","5","Subjects were advised to consume a standard diet on the pharmacokinetic study days, and smoking was not allowed."
3056,"Friedrich 2011","https://pubmed.ncbi.nlm.nih.gov/21340661/","0.25mg po md with linagliptin","Digoxin","Linagliptin","PO","PO",NA,"Plasma",101.51,"geom mean","96,89-106,36","two-sided 90% CI",94.21,"geom mean","86,62-102,46","two-sided 90% CI","0","240","120","240","h",NA,"Intra-individual gCV (%): AUC: 8,5; Cmax 15,4","5",NA,"mg","PO","S120-T24-R6","h","MD OD (6 days)","MD OD Day 6-11",NA,"Boehringer Ingelheim Pharma GmbH; 5 mg tablet",NA,240,"administered between 0700 and 0800 h","Fasted","overnight","2","Water was allowed ad libitum except for 1 h before and after drug administration. Standardized meals were served at 2, 4.25, 10.5 and 13 h following drug administration on in-house days."
3060,"Kirch 1986","https://pubmed.ncbi.nlm.nih.gov/3943268/","2x0.25mg po md with nifedipine","Digoxin","Nifedipine","PO","PO",NA,"Plasma",1.17913385826772,"Approx Avg",NA,NA,1.08252427184466,"Approx Avg",NA,NA,"0","1020","672","832","h",NA,NA,"20",NA,"mg",NA,"S672-T8-R21","h","MD TID (7 days)","MD TID (Day 29-35)",NA,NA,NA,NA,NA,NA,NA,NA,NA
3063,"Rodin 1988","https://pubmed.ncbi.nlm.nih.gov/2967742/","2x0.25mg po md with verapamil","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",1.5031847133758,"Approx Avg",NA,NA,1.44,"Approx Avg",NA,NA,"312","324","312","324","h",1,NA,"80","74.06","mg","PO","S0-T12-R8, S96-T8-R30","h","MD: 80mg BID (4 days), 80mg TID (10 days)","MD: 80mg BID (Day 14-17), 80mg TID (Day 18-27)",NA,NA,NA,NA,NA,NA,NA,NA,"On Day 14 fasted"
3065,"Rodin 1988","https://pubmed.ncbi.nlm.nih.gov/2967742/","2x0.25mg po md with isradipine","Digoxin","Isradipine","PO","PO",NA,"Plasma",1.10691823899371,"Approx Avg",NA,NA,1.26086956521739,"Approx Avg",NA,NA,"312","324","312","324","h",1,NA,"2,5 / 5",NA,"mg","PO","2,5mg: S0-T12-R4; 5mg: (S48-T12-R4)-(S96-T8-R30)","h","MD: 2,5mg BID (2 days), 5mg BID (2 days), 5mg TID (10 days)","MD: 2,5mg BID (Day 14-15), 5mg BID (Day 16-17), 5mg TID (Day 18-27)",NA,NA,NA,NA,NA,NA,NA,NA,"On Day 14 fasted"
3067,"Vaidyanathan 2008","https://pubmed.ncbi.nlm.nih.gov/18784280/","0.25mg po pd with aliskiren","Digoxin","Aliskiren","PO","PO",NA,"Plasma",1.02,"Geom. Mean Ratio","(0.93, 1.13)","90% CI",0.98,"Geom. Mean Ratio","(0.8, 1.19)","90% CI","0","192","216","360","h",NA,NA,"300",NA,"mg","PO","S216-T24-R7","h","MD OD (7 days)","MD OD Day 27-33",NA,NA,NA,240,NA,"Fasted","10",NA,NA
3077,"Sanofi-Aventis 2009","https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P2.pdf","0.25mg md QD with dronedarone 400mg bid","Digoxin","dronedarone","PO","PO",NA,"Plasma",2.57,"geom. Mean Ratio","[2,21; 2,98]","90% CI",1.75,"geom. Mean Ratio","[1,58; 1,93]","90% CI","0","216","0","216","h",NA,"geometric mean ratio: digoxin + dronedarone/digoxin alone","400",NA,"mg","PO","S0-T12-R20","h","MD: BID (10 days)","MD: BID (Day 1-10)",NA,"400 mg tablet (2E3), batch number CL-04530",NA,NA,NA,NA,NA,NA,NA
3078,"Qiu 2010","https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1038/clpt.2009.277","0.125mg md QD with dimebon 20mg TID","Digoxin","dimebon","PO","PO",NA,"Plasma",99.1,"adjusted geom. Mean Ratio","93,51; 105.05","90% CI",0.955592105263158,"Approx. Avg",NA,NA,"0","312","0","312","h",NA,NA,"10; 20",NA,"mg","PO","10mg: S0-T8-21; 20mg: S168-T8-R21","h","MD: 10mg TID (7 days), 20mg TID (7 days)","MD: 10mg TID (Day 1-7), 20mg TID (Day 8-14)",NA,"Dimebon (latrepirdine)",NA,NA,NA,NA,NA,NA,NA
6110,"Balogh 1995","https://pubmed.ncbi.nlm.nih.gov/7589032/","Caffeine + Ethinylestradiol","Caffeine","Ethinylestradiol","PO","PO",NA,"Plasma",2.13,NA,NA,NA,1.15,NA,NA,NA,"480","inf","480","inf","h",NA,NA,"0.03",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
10027,"Yu 2001","https://pubmed.ncbi.nlm.nih.gov/11309556/","EM Moclobemide + Omeprazole","Moclobemide ","Omeprazole","PO","PO",NA,"Plasma",1.31,NA,NA,NA,1.11,NA,NA,NA,"0","inf","0","inf","h",NA,NA,"40",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
11048,"Cho 2002","https://pubmed.ncbi.nlm.nih.gov/11966672/","EM + moclobemide","Omeprazole","Moclobemide","PO","PO",NA,"Plasma",2.05,NA,NA,NA,1.67,NA,NA,NA,"0","inf","0","inf","h",NA,"EM","300",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
11049,"Cho 2002","https://pubmed.ncbi.nlm.nih.gov/11966672/","PM + moclobemide","Omeprazole","Moclobemide","PO","PO",NA,"Plasma",1.16,NA,NA,NA,0.97,NA,NA,NA,"0","inf","0","inf","h",NA,"PM","300",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
11050,"Yasui-Furukori 2004","https://pubmed.ncbi.nlm.nih.gov/15025747/","Omeprazole + Fluvoxamine (EM)","Omeprazole","Fluvoxamine","PO","PO",NA,"Plasma",5.34,NA,NA,NA,3.48,NA,NA,NA,"120","inf","120","inf","h",NA,"EM","50",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
11052,"Yasui-Furukori 2004","https://pubmed.ncbi.nlm.nih.gov/15025747/","Omeprazole + Fluvoxamine (PM)","Omeprazole","Fluvoxamine","PO","PO",NA,"Plasma",1.21,NA,NA,NA,1.12,NA,NA,NA,"120","inf","120","inf","h",NA,"PM","50",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
13017,"Granfors 2004","https://pubmed.ncbi.nlm.nih.gov/14998432/","Tizanidine + Fluvoxamine","Tizanidine","Fluvoxamine","PO","PO",NA,"Plasma",33,NA,NA,NA,12.1,NA,NA,NA,"73","inf","73","inf","h",NA,NA,"100",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
13018,"Momo 2010","https://pubmed.ncbi.nlm.nih.gov/19789372/","Tizanidine + Mexiletine","Tizanidine","Mexiletine","PO","PO",NA,"Plasma",3.42,NA,NA,NA,3.22,NA,NA,NA,NA,"inf",NA,"inf","h",NA,NA,"50",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
14002,"Granfors 2005","https://pubmed.ncbi.nlm.nih.gov/16198659/","Tizanidine + Ethinylestradiol","Tizanidine","Ethinylestradiol","PO","PO",NA,"Plasma",3.92,NA,NA,NA,3.02,NA,NA,NA,"480","inf","480","inf","h",NA,NA,"20",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
14004,"Jeppesen 1996","https://pubmed.ncbi.nlm.nih.gov/8807660/","Caffeine + Fluvoxamine","Caffeine","Fluvoxamine","PO","PO",NA,"Plasma",7.16,NA,NA,NA,1.09,NA,NA,NA,"168","inf","169","inf","h",NA,NA,"100",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
14006,"Culm-Merdek 2005","https://pubmed.ncbi.nlm.nih.gov/16236038/","Caffeine + Fluvoxamine","Caffeine","Fluvoxamine","PO","PO",NA,"Plasma",13.71,NA,NA,NA,1.4,NA,NA,NA,"25","inf","25","inf","h",NA,NA,"100",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
14008,"Joeres 1987","https://pubmed.ncbi.nlm.nih.gov/3628469/","Caffeine + Mexiletine","Caffeine","Mexiletine","PO","PO",NA,"Plasma",2.83,NA,NA,NA,1.89,NA,NA,NA,"0","inf","0","inf","h",NA,NA,"200",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
14010,"Kusumoto 2001","https://pubmed.ncbi.nlm.nih.gov/11240973/","Mexiletine + Fluvoxamine","Mexiletine","Fluvoxamine","PO","PO",NA,"Plasma",1.55,NA,NA,NA,1.16,NA,NA,NA,"168","inf","168","inf","h",NA,NA,"50",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
15001,"Yao 2003","https://pubmed.ncbi.nlm.nih.gov/12695344/","With 37.5mg Fluvoxamine","S-Mephenytoin","Fluvoxamine","PO","PO",NA,"Plasma",4.64,NA,NA,NA,2.12,NA,NA,NA,"176","inf","176","inf","h",NA,NA,"27.5",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
15002,"Yao 2003","https://pubmed.ncbi.nlm.nih.gov/12695344/","With 62.5mg Fluvoxamine","S-Mephenytoin","Fluvoxamine","PO","PO",NA,"Plasma",6.7,NA,NA,NA,2.4,NA,NA,NA,"176","inf","176","inf","h",NA,NA,"45.8",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
15003,"Yao 2003","https://pubmed.ncbi.nlm.nih.gov/12695344/","With 87.5mg Fluvoxamine","S-Mephenytoin","Fluvoxamine","PO","PO",NA,"Plasma",9.89,NA,NA,NA,2.42,NA,NA,NA,"176","inf","176","inf","h",NA,NA,"64.099999999999994",NA,"mg","PO",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16062,"Bailey 1996","https://pubmed.ncbi.nlm.nih.gov/8689808/","Erythromycin DDI, treatment group","Felodipine","Erythromycin","PO","PO",NA,"Plasma",2.59298633055426,"Geom. mean","1.2569993278062586","Geom. SD",2.28886420212023,"Geom. mean","1.174586180637271","Geom. SD","0","24","24","48","h",NA,NA,"250",NA,"mg","PO","(S0-T6-R8)","h","four times a day for 2 days",NA,NA,"Tablet",NA,NA,NA,"Fasted","10","4",NA
16063,"Jalava 1997","https://pubmed.ncbi.nlm.nih.gov/9129558/","Itraconazole DDI, treatment group","Felodipine","Itraconazole","PO","PO",NA,"Plasma",6.33584905660377,"Approx. avg",NA,NA,7.75,"Approx. avg",NA,NA,"0","inf","73","inf","h",NA,NA,"200",NA,"mg","PO","(S0-T24-R4)","h",NA,NA,NA,"Sporanox® ",NA,NA,NA,NA,NA,NA,NA
16065,"Lee 2021","https://pubmed.ncbi.nlm.nih.gov/33348240/","Clarithromycin DDI, treatment group","Sildenafil","Clarithromycin","PO","PO",NA,"Plasma",2.27664277369036,"Approx. avg",NA,NA,1.71571881128375,"Approx. avg",NA,NA,"0","inf","96","inf","h",NA,NA,"250",NA,"mg","PO","48 + 72 + 84 + 96","h","SD on D3, BID on D4, SD on D5",NA,NA,"Tablet",NA,NA,NA,NA,NA,NA,NA
16066,"Lee 2021","https://pubmed.ncbi.nlm.nih.gov/33348240/","Itraconazole DDI, treatment group","Sildenafil","Itraconazole","PO","PO",NA,"Plasma",2.49942041585163,"Approx. avg",NA,NA,1.43334034644786,"Approx. avg",NA,NA,"0","inf","96","inf","h",NA,NA,"100",NA,"mg","PO","48 + 72 + 84 + 96","h","SD on D3, BID on D4, SD on D5",NA,NA,"Capsule",NA,NA,NA,NA,NA,NA,NA
16067,"Hedaya 2006","https://pubmed.ncbi.nlm.nih.gov/16372380/","Clarithromycin DDI, treatment group","Sildenafil","Clarithromycin","PO","PO",NA,"Plasma",2.28073916133618,"Approx. avg",NA,NA,2.41811846689895,"Approx. avg",NA,NA,"0","inf","2","inf","h",NA,NA,"500",NA,"mg","PO","0","h","SD",NA,NA,"Tablet",NA,NA,NA,"Fasted","8","3",NA
16069,"Hesse 2005","https://pubmed.ncbi.nlm.nih.gov/16282844/","Fluvoxamine DDI, treatment group","Sildenafil","Fluvoxamine","PO","PO",NA,"Plasma",1.40394088669951,"Approx. avg",NA,NA,1.30331753554502,"Approx. avg",NA,NA,"0","inf","240","inf","h",NA,NA,"50, 100",NA,"mg","PO","50mg: S0-T24-R3, 100mg: S72-T24-R7","h","OD",NA,NA,"Coated tablet (Fevarin®)",NA,NA,NA,NA,NA,NA,NA
16073,"Muirhead 2002a","https://pubmed.ncbi.nlm.nih.gov/11879258/","Erythromycin DDI, treatment group, D6","Sildenafil","Erythromycin","PO","PO",NA,"Plasma",2.57930672268908,"Approx. avg",NA,NA,2.08892617449664,"Approx. avg",NA,NA,"0","inf","121","inf","h",NA,NA,"500",NA,"mg","PO","24, 36, 48, 60, 72, 84, 96, 108, 120","h",NA,NA,NA,"Unknown",NA,NA,NA,"Fed",NA,NA,"light breakfast"
16149,"Abernethy et al. 1985","https://pubmed.ncbi.nlm.nih.gov/4028631/","10mg Verapamil + cimetidine, IV","Verapamil","Cimetidine","IV","PO","Reversible_Inhibition","Plasma",1.04,"Approx. Avg",NA,NA,NA,NA,NA,NA,"12","inf","12","inf","h",NA,NA,"300",NA,"mg","PO","S0-T6-R7","h","MD QID","MD QID (12h before and 24h after Verapamil)",NA,NA,NA,NA,NA,NA,NA,NA,NA
16150,"Abernethy et al. 1985","https://pubmed.ncbi.nlm.nih.gov/4028631/","120mg Verapamil + cimetidine, PO","Verapamil","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",0.864957264957265,"Approx. Avg",NA,NA,1.0281690140845,"Approx. Avg",NA,NA,"12","inf","12","inf","h",NA,NA,"300",NA,"mg","PO","S0-T6-R7","h","MD QID","MD QID (12h before and 24h after Verapamil)",NA,NA,NA,NA,NA,NA,NA,NA,NA
16151,"Mikus et al. 1990","https://pubmed.ncbi.nlm.nih.gov/2359015/","160mg verapamil + cimetidine, PO","R-Verapamil","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.2574,"Approx. Avg",NA,NA,1.3309,"Approx. Avg",NA,NA,"144.5","inf","144.5","inf","h",NA,NA,"400",NA,"mg","PO","S0-T12-R14","h","MD BID (6 days)","R-verapamil (80 mg) and dideuterated S-verapamil (80 mg) were given in the same manner after a 6-day p.o. pretreatment with cimetidine (400 mg b.i.d.). The second dose of verapamil was taken 30 mm after the morning dose of cimetidine.",NA,NA,NA,NA,NA,NA,NA,NA,NA
16152,"Mikus et al. 1990","https://pubmed.ncbi.nlm.nih.gov/2359015/","160mg verapamil + cimetidine, PO","S-Verapamil","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.411,"Approx. Avg",NA,NA,1.8291,"Approx. Avg",NA,NA,"144.5","inf","144.5","inf","h",NA,NA,"400",NA,"mg","PO","S0-T12-R14","h","MD BID (6 days)","R-verapamil (80 mg) and dideuterated S-verapamil (80 mg) were given in the same manner after a 6-day p.o. pretreatment with cimetidine (400 mg b.i.d.). The second dose of verapamil was taken 30 mm after the morning dose of cimetidine.",NA,NA,NA,NA,NA,NA,NA,NA,NA
16153,"Mikus et al. 1990","https://pubmed.ncbi.nlm.nih.gov/2359015/","160mg verapamil + cimetidine, PO","R-Norverapamil","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.3424,"Approx. Avg",NA,NA,NA,NA,NA,NA,"144.5","inf","144.5","inf","h",NA,NA,"400",NA,"mg","PO","S0-T12-R14","h","MD BID (6 days)","R-verapamil (80 mg) and dideuterated S-verapamil (80 mg) were given in the same manner after a 6-day p.o. pretreatment with cimetidine (400 mg b.i.d.). The second dose of verapamil was taken 30 mm after the morning dose of cimetidine.",NA,NA,NA,NA,NA,NA,NA,NA,NA
16154,"Mikus et al. 1990","https://pubmed.ncbi.nlm.nih.gov/2359015/","160mg verapamil + cimetidine, PO","S-Norverapamil","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.4235,"Approx. Avg",NA,NA,NA,NA,NA,NA,"144.5","inf","144.5","inf","h",NA,NA,"400",NA,"mg","PO","S0-T12-R14","h","MD BID (6 days)","R-verapamil (80 mg) and dideuterated S-verapamil (80 mg) were given in the same manner after a 6-day p.o. pretreatment with cimetidine (400 mg b.i.d.). The second dose of verapamil was taken 30 mm after the morning dose of cimetidine.",NA,NA,NA,NA,NA,NA,NA,NA,NA
16155,"Wing et al. 1985","https://pubmed.ncbi.nlm.nih.gov/3986090/","10mg Verapamil + cimetidine, IV","Verapamil","Cimetidine","IV","PO","Reversible_Inhibition","Plasma",1.0714,"Approx. Avg",NA,NA,NA,NA,NA,NA,"168","inf","168","inf","h",NA,NA,"400/200",NA,"mg","PO","400: S18-T24-R9; 200mg: 0-6-12-24-30-36--48-54-60-72-78-84-96-102-108-120-126-132-144-150-156-168-174-180-192-198-204","h","MD QID (3times 200mg, fourth time 400mg)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16156,"Wing et al. 1985","https://pubmed.ncbi.nlm.nih.gov/3986090/","80mg Verapamil + cimetidine, PO","Verapamil","Cimetidine","PO","PO","Reversible_Inhibition","Plasma",1.0702,"Approx. Avg",NA,NA,NA,NA,NA,NA,"168","inf","168","inf","h",NA,NA,"400/200",NA,"mg","PO","400: S18-T24-R9; 200mg: 0-6-12-24-30-36--48-54-60-72-78-84-96-102-108-120-126-132-144-150-156-168-174-180-192-198-204","h","MD QID (3times 200mg, fourth time 400mg)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16159,"Johnson et al. 1987","https://pubmed.ncbi.nlm.nih.gov/2954736/","Digoxin IV + Verapamil","Digoxin","Verapamil","IV","PO","Mechanism_based_Inactivation","Serum",1.2419,"Approx. Avg",NA,NA,NA,NA,NA,NA,"288","inf","288","nf","h",NA,NA,"80","74.06138","mg","PO","(S0-T12-R8)-(S96-T8-R33)","h","MD BID 4days, TID 10days",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16162,"Pedersen et al. 1983","https://pubmed.ncbi.nlm.nih.gov/6628501/","Digoxin IV + Verapamil","Digoxin","Verapamil","IV","PO","Mechanism_based_Inactivation","Plasma",1.41748126952411,"Arith. mean","0.1326292","Arith. SD",NA,NA,NA,NA,"168","inf","168","inf","h",1,NA,"120","111.0921","mg","PO","S0-(S0-T6-R3)-T24-R12","h","TID, 7 days pre-treatment","Information retrieved from published model from Hanke et al. 2020 assuming they had more information (Original paper only says 3 times daily and does not comment on the time interval inbetween)","verapamil chloride (Isoptin ®, Knoll)","verapamil chloride (Isoptin ®, Knoll)",NA,NA,NA,NA,NA,NA,NA
16163,"Pedersen et al. 1982","https://pubmed.ncbi.nlm.nih.gov/7094982/","Digoxin and Verapamil in MD setting","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,"80/120","74.061376/111.0921","mg","PO","80:S360-(S0-T6-R3)-T24-R63; 120:S1896-(S0-T6-R3)-T24-R42","h",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16165,"Belz et al. 1983","https://pubmed.ncbi.nlm.nih.gov/6831819/","Digoxin + 80mg Verapamil","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",NA,NA,NA,NA,NA,NA,NA,NA,"0","336","0","336","h",NA,"Multiple Dose study for both victim and perpetrator; Only ctrough values available","80","74.061375999999996","mg","PO","S0-(S0-T6-R3)-T24-R14","h","TID",NA,"oral","oral",NA,NA,NA,NA,NA,NA,NA
16167,"Belz et al. 1983","https://pubmed.ncbi.nlm.nih.gov/6831819/","Digoxin + 120mg Verapamil","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",NA,NA,NA,NA,NA,NA,NA,NA,"0","336","0","336","h",NA,"Multiple Dose study for both victim and perpetrator; Only ctrough values available","120","111.09206399999999","mg","PO","S0-(S0-T6-R3)-T24-R14","h","TID",NA,"oral","oral",NA,NA,NA,NA,NA,NA,NA
16169,"Doering et al. 1983","https://pubmed.ncbi.nlm.nih.gov/6653647/","Digoxin+ 80mg Verapamil","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Serum",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"Multiple Dose study for both victim and perpetrator; Only ctrough values available","80","74.061375999999996","mg","PO","S0-(S0-T6-R3)-T24-R14","h","TID",NA,"Isoptin 80","oral",NA,NA,NA,"fasted",NA,NA,NA
16172,"Wiebe 2020","https://pubmed.ncbi.nlm.nih.gov/32504272/","DDI digoxin + verapamil - plasma","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",1.007,"Geom. mean","0.8884, 1.11415","90% confidence interval",1.2164,"Geom. mean","1.0043, 1.4733","90% confidence interval","1","25","1","25","h",1,NA,"120","111.0921","mg","PO","0","h","SD","PK data on verapamil also available (see IDs 6160 to 6163)","Verapamil, Isoptin film-coated tablet","oral tablet",NA,NA,NA,"fasted","9",NA,NA
16174,"Klein et al. 1982","https://pubmed.ncbi.nlm.nih.gov/7074765/","Digoxin and Verapamil in MD setting","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Serum",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"Multiple Dose study for both victim and perpetrator; Only ctrough values available","80","74.061375999999996","mg","PO","S350-T8-R42","h","TID","morning dose 1h before digoxin dose","oral","oral",NA,NA,NA,NA,NA,NA,NA
16175,"Schwartz et al. 1982","https://pubmed.ncbi.nlm.nih.gov/7074776/","Digoxin and Verapamil in MD setting","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Serum",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"Multiple Dose study for both victim and perpetrator; Only ctrough values available","80","74.061375999999996","mg","PO","S345-T6-R280","h","QID",NA,"oral tablet","oral tablet",NA,NA,NA,NA,NA,NA,NA
16244,"Prueksaritanont 2017","https://pubmed.ncbi.nlm.nih.gov/27943276/","Dabigatran in microdosecocktail + Rifampicin","Dabigatran","Rifampicin","PO","PO","Induction","Plasma",2.32,"GMR",NA,NA,1.78,"GMR",NA,NA,"0","inf","0","inf","h",1,NA,"600",NA,"mg","PO","1","h","SD","SD",NA,"Sporanox",NA,NA,"Sporanox Janssen","fasted",NA,NA,NA
16245,"Prueksaritanont 2017","https://pubmed.ncbi.nlm.nih.gov/27943276/","Dabigatran in microdosecocktail + Itraconazole","Dabigatran","Itraconazole","PO","PO","reversible Inhibition","Plasma",6.92,"GMR",NA,NA,6.42,"GMR",NA,NA,"0","inf","72","inf","h",1,NA,"200",NA,"mg","PO","(S-0,T-24,R-5)","h","OD (5 days)","OD",NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16246,"Prueksaritanont 2017","https://pubmed.ncbi.nlm.nih.gov/27943276/","Dabigatran in microdosecocktail + Clarithromycin","Dabigatran","Clarithromycin","PO","PO","mechanism-based inactivation","Plasma",4.02,"GMR",NA,NA,4.57,"GMR",NA,NA,"0","inf","72","inf","h",1,NA,"500",NA,"mg","PO","(S-0,T-12,R-10)","h","BID (5 days)","BID",NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16247,"Gouin-Thibault 2016","https://pubmed.ncbi.nlm.nih.gov/27893182/","Dabigatran + Clarithromycin","Dabigatran","Clarithromycin","PO","PO","mechanism-based inactivation","Plasma",2,NA,NA,NA,1.8,NA,NA,NA,"0","inf","96","inf","h",1,NA,"500",NA,"mg","PO","(S-0,T-12,R-10)","h","BID (5 days)","BID",NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16249,"Härtter 2012 RIF","https://pubmed.ncbi.nlm.nih.gov/22348256/","Dabigatran + Rifampicin Day 9","Dabigatran","Rifampicin","PO","PO","Induction","Plasma",0.33,"GMR",NA,NA,0.345,"GMR",NA,NA,"0","inf","156","324","h",1,NA,"600",NA,"mg","PO","(S-0,T-24,R-7)","h","OD (7 days)","OD",NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16250,"Härtter 2012 RIF","https://pubmed.ncbi.nlm.nih.gov/22348256/","Dabigatran + Rifampicin Day 16","Dabigatran","Rifampicin","PO","PO","Induction","Plasma",0.823,"GMR",NA,NA,0.814,"GMR",NA,NA,"0","inf","324","492","h",1,NA,"600",NA,"mg","PO","(S-0,T-24,R-7)","h","OD (7 days)","OD",NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16251,"Härtter 2012 RIF","https://pubmed.ncbi.nlm.nih.gov/22348256/","Dabigatran + Rifampicin Day 23","Dabigatran","Rifampicin","PO","PO","Induction","Plasma",0.857,"GMR",NA,NA,0.816,"GMR",NA,NA,"0","inf","492","526","h",1,NA,"600",NA,"mg","PO","(S-0,T-24,R-7)","h","OD (7 days)","OD",NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16253,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Dabigatran + 10 mg Rifampicin","Dabigatran total","Rifampicin","PO","PO","Induction","Plasma",0.594,"GMR","0.460-0.768","90% CI",0.568,"GMR","0.423-0.762","90% CI","0","inf","228","660","h",1,NA,"10",NA,"mg","PO","S0-T24-R18","h","OD",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16254,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Dabigatran + 75 mg Rifampicin","Dabigatran total","Rifampicin","PO","PO","Induction","Plasma",0.38,"GMR","0.304-0.475","90% CI",0.384,"GMR","0.308-0.479","90% CI","0","inf","660","inf","h",1,NA,"first 10, then 75",NA,"mg","PO","S0-T24-R18 (10 mg), S432-T24-R18 (75 mg)","h","OD",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16256,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Dabigatran + 2 mg Rifampicin","Dabigatran total","Rifampicin","PO","PO","Induction","Plasma",1.19,"GMR","0.93-1.53","90% CI",1.07,"GMR","0.82-1.40","90% CI","0","inf","228","660","h",1,NA,"2",NA,"mg","PO","S0-T24-R18","h","OD",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16257,"Lutz 2018a","https://pubmed.ncbi.nlm.nih.gov/29569723/","Dabigatran + 600 mg RIfampicin","Dabigatran total","Rifampicin","PO","PO","Induction","Plasma",0.334,"GMR","0.269-0.413","90% CI",0.305,"GMR","0.241-0.385","90% CI","0","inf","660","inf","h",1,NA,"first 2, then 600",NA,"mg","PO","S0-T24-R18 (2 mg), S432-T24-R18 (600 mg)","h","OD",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16259,"Rattanacheeworn 2021","https://pubmed.ncbi.nlm.nih.gov/34603040/","Dabigatran + 450 mg RIfampicin","Dabigatran","Rifampicin","PO","PO","Induction","Plasma",2.22,"GMR","1.74-2.83","95% CI",1.86,"GMR","1.43-2.43","95% CI","0","inf","0","inf","h",1,NA,"450",NA,"mg","PO","1","h","SD",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16261,"Tatosian 2020","https://pubmed.ncbi.nlm.nih.gov/32705692/","Dabigatran + 600 mg RIfampicin","Dabigatran","Rifampicin","PO","PO","Induction","Plasma",2.08,"GMR","1.66-2.60","95% CI",1.92,"GMR","1.47-2.43","95% CI","0","inf","0","inf","h",1,NA,"600",NA,"mg","PO","1","h","SD",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16263,"Härtter 2012 Vera","https://pubmed.ncbi.nlm.nih.gov/22348256/","Vera 120mg BID, Dabigatran 1h after (Treatment C)","Dabigatran total","Verapamil","PO","PO","mechanism-based inactivation","Plasma",1.54,"GMR","1.19-1.99","90% CI",1.63,"GMR","1.22-2.17","90% CI","0","inf","73","166","h",1,NA,"120",NA,"mg","PO","(S-0,T-12,R-14)","h","BID (7 days)",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16264,"Härtter 2012 Vera","https://pubmed.ncbi.nlm.nih.gov/22348256/","Vera 120mg BID, Dabigatran 2h before (Treatment D)","Dabigatran total","Verapamil","PO","PO","mechanism-based inactivation","Plasma",1.18,"GMR","0.91-1.52","90% CI",1.12,"GMR","0.84-1.49","90% CI","0","inf","166","265","h",1,NA,"120",NA,"mg","PO","(S-0,T-12,R-16)","h","BID (8 days)",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16265,"Härtter 2012 Vera","https://pubmed.ncbi.nlm.nih.gov/22348256/","Vera 120mg TID/QID, Dabigatran 1h after (Treatment E)","Dabigatran total","Verapamil","PO","PO","mechanism-based inactivation","Plasma",1.39,"GMR","1.07-1.81","90% CI",1.34,"GMR","1.00-1.80","90% CI","0","inf","265","336","h",1,NA,"120",NA,"mg","PO","(S-0,T-12,R-16), (S-192,T-8,R-3), (S-216,T-6,R-12)","h","BID (8 days), TID (1 day), QID (3 days)",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16228,"Delavenne 2013","https://pubmed.ncbi.nlm.nih.gov/23210726/","Subject 10 Clarithromycin treatment","Dabigatran","Clarihromycin","PO","PO","mechanism-based inactivation","Plasma",1.491,"GMR",NA,NA,1.602,"GMR",NA,NA,"0","inf","70.5","144","h",1,NA,"500",NA,"mg","PO","(S-0,T-12,R-6), 70.5","h","BID (3.5 days)",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16266,"Lutz 2018b","https://pubmed.ncbi.nlm.nih.gov/29569712/","Dabigatran control","Dabigatran total","Carbamazepine","PO","PO","Induction","Plasma",0.714,"GMR","0.593-0.859","90% CI",0.666,"GMR","0.521-0.852","90% CI","0","inf","404","480","h",1,NA,"300",NA,"mg","PO","(S-0,T-12,R-52)","h","BID (26 days)",NA,NA,NA,NA,NA,NA,"fasted",NA,NA,NA
16301,"Wiebe 2020","https://pubmed.ncbi.nlm.nih.gov/32504272/","Digoxin (Cocktail) + Rifampin","Digoxin","Rifampicin","PO","PO","induction","Plasma",1.31,"Geom. Mean","0.18","gCV",2.1826,"Geom. Mean","27.7","gCV","0","inf","312","inf","h",NA,NA,"600",NA,"mg","PO","S0-R1","h","SD",NA,"tablet","(Eremfat® 600 mg; Riemser Pharma GmbH, Greifswald–Insel Riems, Germany",NA,280,NA,"Fasted","overnight",NA,NA
16302,"Wiebe 2020","https://pubmed.ncbi.nlm.nih.gov/32504272/","Digoxin (Cocktail) + Rifampin","Digoxin","Rifampicin","PO","PO","induction","Urine",1.11,"Geom. Mean",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"h",NA,"1/CLR","600",NA,"mg","PO","S0-R1","h","SD",NA,"tablet","(Eremfat® 600 mg; Riemser Pharma GmbH, Greifswald–Insel Riems, Germany",NA,280,NA,"Fasted","overnight",NA,NA
16305,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","G/G2677C/C3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","serum",0.743,"Approx. Avg",NA,NA,1.025,"Approx. Avg",NA,NA,"0","inf","120","inf","h",0.5,NA,"400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16307,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","G/G2677C/C3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","IV","PO","Reversible_Inhibition","serum",0.574,"Approx. Avg",NA,NA,0.656,"Approx. Avg",NA,NA,"0","inf","120","inf","h",0.5,NA,"400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16309,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","T/T2677T/T3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","serum",0.641,"Approx. Avg",NA,NA,0.91,"Approx. Avg",NA,NA,"0","inf","120","inf","h",0.5,NA,"400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16311,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","T/T2677T/T3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","IV","PO","Reversible_Inhibition","serum",0.536,"Approx. Avg",NA,NA,0.662,"Approx. Avg",NA,NA,"0","inf","120","inf","h",0.5,NA,"400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16313,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","G/T2677C/T3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","serum",0.784,"Approx. Avg",NA,NA,0.916,"Approx. Avg",NA,NA,"0","inf","120","inf","h",0.5,NA,"400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16315,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","G/T2677C/T3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","IV","PO","Reversible_Inhibition","serum",0.555,"Approx. Avg",NA,NA,0.629,"Approx. Avg",NA,NA,"0","inf","120","inf","h",0.5,NA,"400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16319,"Drescher 2003","https://pubmed.ncbi.nlm.nih.gov/12621387/","day 15 plasma","Digoxin","Rifampicin","IV","PO","induction","Plasma",0.727,"Approx. Avg",NA,NA,0.806,"Approx. Avg",NA,NA,"0","inf","228","inf","h",NA,NA,"600",NA,"mg","PO","S0-T24-R14","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16320,"Drescher 2003","https://pubmed.ncbi.nlm.nih.gov/12621387/","day 15 urine","Digoxin","Rifampicin","IV","PO","induction","Urine",0.835,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","228","inf","h",NA,"1/CLR","600",NA,"mg","PO","S0-T24-R14","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16322,"Gurley 2006","https://pubmed.ncbi.nlm.nih.gov/16221754/","day 7 plasma + Rifampin","Digoxin","Rifampicin","PO","PO","induction","serum",0.844,"Approx. Avg",NA,NA,0.771,"Approx. Avg",NA,NA,"0","24","144","168","h",NA,NA,"300",NA,"mg","PO","S0-T12-R14","h","MD",NA,"Capsules","Rifadin®, Aventis Pharmaceuticals, Kansas City, MO",NA,NA,NA,NA,NA,NA,NA
16324,"Gurley 2006","https://pubmed.ncbi.nlm.nih.gov/16221754/","day 7 plasma + Clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","serum",1.351,"Approx. Avg",NA,NA,1.483,"Approx. Avg",NA,NA,"0","24","144","168","h",NA,NA,"500",NA,"mg","PO","S0-T12-R14","h","MD",NA,"Tablet","Biaxin; Abbott Diagnostics, Abbott Park, IL",NA,NA,NA,NA,NA,NA,NA
16326,"Gurley 2007","https://pubmed.ncbi.nlm.nih.gov/17079360/","Digoxin + Rifampicin","Digoxin","Rifampicin","PO","PO","induction","serum",0.84,"Approx. Avg",NA,NA,0.72,"Approx. Avg",NA,NA,"0","24","144","168","h",NA,NA,"300",NA,"mg","PO","S0-T12-R14","h","MD",NA,"Capsules","Rifadin",NA,NA,NA,NA,NA,NA,NA
16328,"Gurley 2007","https://pubmed.ncbi.nlm.nih.gov/17079360/","Digoxin + Clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","serum",1.567,"Approx. Avg",NA,NA,1.952,"Approx. Avg",NA,NA,"0","24","144","168","h",NA,NA,"500",NA,"mg","PO","S0-T12-R14","h","MD",NA,"Tablet","Biaxin",NA,NA,NA,NA,NA,NA,NA
16329,"Partanen 1996","https://pubmed.ncbi.nlm.nih.gov/8936563/","Digoxin + Itraconazol in Part 1","Digoxin","Itraconazole","PO","PO","Reversible_Inhibition","serum",NA,NA,NA,NA,1.634,"Approx. Avg",NA,NA,"456","480","216","240","h",NA,"concentration 12h after administration","200",NA,"mg","PO","S12-T24-R10","h","MD",NA,"Capsules",NA,NA,NA,NA,NA,NA,NA,NA
16330,"Partanen 1996","https://pubmed.ncbi.nlm.nih.gov/8936563/","Digoxin + Itraconazol in Part 2","Digoxin","Itraconazole","PO","PO","Reversible_Inhibition","serum",NA,NA,NA,NA,1.966,"Approx. Avg",NA,NA,"216","240","456","480","h",NA,"concentration 12h after administration","200",NA,"mg","PO","S252-T24-R10","h","MD",NA,"Capsules",NA,NA,NA,NA,NA,NA,NA,NA
16333,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","G/G2677C/C3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","Urine",1.192,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","120","inf","h",0.5,"1/CLR","400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16334,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","G/G2677C/C3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","IV","PO","Reversible_Inhibition","Urine",1.077,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","120","inf","h",0.5,"1/CLR","400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16335,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","T/T2677T/T3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","Urine",1,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","120","inf","h",0.5,"1/CLR","400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16336,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","T/T2677T/T3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","IV","PO","Reversible_Inhibition","Urine",0.95,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","120","inf","h",0.5,"1/CLR","400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16337,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","G/T2677C/T3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","Urine",1,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","120","inf","h",0.5,"1/CLR","400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16338,"Kurata 2002","https://pubmed.ncbi.nlm.nih.gov/12189368/","G/T2677C/T3435_Digoxin day 16 + Clarithromycin","Digoxin","Clarithromycin","IV","PO","Reversible_Inhibition","Urine",0.84,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","120","inf","h",0.5,"1/CLR","400",NA,"mg","PO","S0-T12-R16","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16401,"Greiner 1999","https://www.ncbi.nlm.nih.gov/pubmed/10411543","po with Perpetrator (Rifampicin)","Digoxin","Rifampicin","PO","PO","Induction","Urine",1,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","240","inf","h",1,"1/CLR ratio","600",NA,"mg","PO","S0-T24-R16","h","MD OD (16 days)","MD","rifampin","RIFA Grünenthal GmbH",NA,NA,NA,NA,NA,NA,NA
16403,"Greiner 1999","https://www.ncbi.nlm.nih.gov/pubmed/10411543","iv with Perpetrator (Rifampicin)","Digoxin","Rifampicin","IV","PO","Induction","Urine",1.02721088435374,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","inf","240","inf","h",1,"1/CLR ratio","600",NA,"mg","PO","S0-T24-R16","h","MD OD (16 days)","MD","rifampin","RIFA Grünenthal GmbH",NA,NA,NA,NA,NA,NA,NA
274,"Jalava 1997","https://www.ncbi.nlm.nih.gov/pubmed/9421099","po with Perpetrator (Itraconazole)","Digoxin","Itraconazole","PO","PO","Reversible_Inhibition","Urine",1.25,"arith. mean",NA,NA,NA,NA,NA,NA,"0","inf","49","inf","h",1,"1/CLR ratio","200",NA,"mg","PO","0-24-48-72-96","h","MD OD (5 days)",NA,NA,"Sporanox 100-mg caps, Janssen Pharmaceuticals, Beerse, Belgium",NA,120,NA,NA,NA,NA,NA
16409,"Rengelshausen 2003","https://pubmed.ncbi.nlm.nih.gov/12848773/","0.01mg/kg iv with clarithromycin","Digoxin","Clarithromycin","IV","PO","Reversible_Inhibition","Plasma",1.18518518518519,"Approx Avg",NA,NA,NA,NA,NA,NA,"0","24","26","50","h",1,NA,"250",NA,"mg","PO","S0-T12-R6","h","MD BID (3 days)","MD BID Day 1-3",NA,"Klacid® tablets, Abbott GmbH, Wiesbaden, Germany",NA,NA,"Klacid® tablets were encapsulated into hard gelatine capsules by the hospital pharmacy to match the corresponding placebo capsules filled with lactose.",NA,NA,NA,"Food or beverages containing alcohol or caffeine were not allowed from 12 h before clarithromycin administration until the last blood sample was drawn."
16411,"Rengelshausen 2003","https://pubmed.ncbi.nlm.nih.gov/12848773/","0.75mg/kg po with clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","Plasma",1.64285714285714,"Approx Avg",NA,NA,1.83333333333333,"Approx. Avg",NA,NA,"0","24","24.5","48.5","h",1,NA,"250",NA,"mg","PO","S0-T12-R6","h","MD BID (3 days)","MD BID Day 1-3",NA,"Klacid® tablets, Abbott GmbH, Wiesbaden, Germany",NA,NA,"Klacid® tablets were encapsulated into hard gelatine capsules by the hospital pharmacy to match the corresponding placebo capsules filled with lactose.",NA,NA,NA,"Food or beverages containing alcohol or caffeine were not allowed from 12 h before clarithromycin administration until the last blood sample was drawn."
16413,"Rengelshausen 2003","https://pubmed.ncbi.nlm.nih.gov/12848773/","0.75mg/kg po with clarithromycin","Digoxin","Clarithromycin","PO","PO","Reversible_Inhibition","Urine",1.2,"Approx Avg",NA,NA,NA,NA,NA,NA,"0","24","24.5","48.5","h",1,"1/CLR ratio","250",NA,"mg","PO","S0-T12-R6","h","MD BID (3 days)","MD BID Day 1-3",NA,"Klacid® tablets, Abbott GmbH, Wiesbaden, Germany",NA,NA,"Klacid® tablets were encapsulated into hard gelatine capsules by the hospital pharmacy to match the corresponding placebo capsules filled with lactose.",NA,NA,NA,"Food or beverages containing alcohol or caffeine were not allowed from 12 h before clarithromycin administration until the last blood sample was drawn."
16501,"Mueller 2009","https://pubmed.ncbi.nlm.nih.gov/18762932/","Midazolam after St. John's Wort","Midazolam","Hyperforin","PO","PO","Induction","Plasma",0.85,"Geom. mean","0.77, 0.95 ","90% confidence interval",0.93,"Geom. mean",NA,NA,"0","inf","312","inf","h",1,NA,"0.06",NA,"mg","PO","S0-T12-R28","h",NA,NA,"St John's Wort Extract	","capsules containing 500 mg Hyperici herba (Pharmacopoea Europaea) powder provided by Kneipp Werke, Würzburg, Germany.",NA,NA,NA,NA,NA,NA,NA
16512,"Hall 2003","https://pubmed.ncbi.nlm.nih.gov/14663455/","Midazolam with Hyperforin, IV dosing","Midazolam","Hyperforin","IV","PO","Induction","Plasma",0.96,"Geom. mean","0.86, 1.05","90% confidence interval",NA,NA,NA,NA,"1","inf","505","inf","h",1,NA,"8.9",NA,"mg","PO","S0-(S0-T6-R3)-T24-R28","h",NA,"300 mg 3 times a day with food from day 1 through day 28.; 8.9 +- 0.4 mg hyperforin per capsule","St John's Wort Extract	","Rexall-Sundown Pharmaceuticals, Boca Raton, Fla",NA,NA,NA,"fed",NA,NA,NA
16513,"Hall 2003","https://pubmed.ncbi.nlm.nih.gov/14663455/","Midazolam with Hyperforin, PO dosing","Midazolam","Hyperforin","PO","PO","Induction","Plasma",0.65,"Geom. mean","0.49, 0.81","90% confidence interval",0.84,"Geom. mean",NA,NA,"1","inf","529","inf","h",1,NA,"8.9",NA,"mg","PO","S0-(S0-T6-R3)-T24-R28","h",NA,"300 mg 3 times a day with food from day 1 through day 28.; 8.9 +- 0.4 mg hyperforin per capsule","St John's Wort Extract	","Rexall-Sundown Pharmaceuticals, Boca Raton, Fla",NA,NA,NA,"fed",NA,NA,NA
16515,"Gurley 2008b","https://pubmed.ncbi.nlm.nih.gov/18214850/","Digoxin with Hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Serum",0.769,"Approx. avg",NA,NA,0.643,"Approx. Avg",NA,NA,"0","24","312","336","h",1,NA,"8",NA,"mg","PO","S0-(S0-T6-R3)-T24-R14","h",NA,"Times of administration are an assumption; information given is ""three times daily""","St John's Wort Extract	","lot # 530812, standardized extract WS 5572 (3% Hyperforin) from Nature's Way Products, (Springville, UT)",NA,NA,NA,NA,NA,NA,NA
16517,"Mueller 2006","https://pubmed.ncbi.nlm.nih.gov/16341856/","Midazolam with hyperforin (group: LI 160)","Midazolam","Hyperforin","PO","PO","Induction","Plasma",0.2,"Geom. mean","0.09, 0.32","90% confidence interval",0.35,"Geom. mean","0.13, 0.57","90% confidence interval","0","12","312","324","h",1,NA,"13.75",NA,"mg","PO","S0-(S0-T6-R3)-T24-R15","h",NA,NA,"St John's Wort Extract	","Coated tablet: LI 160 (Jarsin 300, batch 02013320; Lichtwer Pharma, Berlin, Germany)",NA,NA,NA,"fed",NA,NA,"taken with breakfast, lunch and evening meal"
16519,"Mueller 2006","https://pubmed.ncbi.nlm.nih.gov/16341856/","Midazolam with hyperforin (group: Hypericum powder type B 2.7 g/day)","Midazolam","Hyperforin","PO","PO","Induction","Plasma",0.79,"Geom. mean","0.70, 0.87","90% confidence interval",1.01,"Geom. mean","0.56, 1.46","90% confidence interval","0","12","312","324","h",1,NA,"4.3333333333333335E-2",NA,"mg","PO","S0-(S0-T6-R3)-T24-R16","h",NA,NA,"St John's Wort Extract	","Coated tablet: Hypericum powder type B 2.7 g/day (Kneipp Werke, Würzburg, Germany)",NA,NA,"administered as 3 tablets","fed",NA,NA,"taken with breakfast, lunch and evening meal"
16521,"Mueller 2006","https://pubmed.ncbi.nlm.nih.gov/16341856/","Midazolam with hyperforin (group: Hypericum powder type A 2.7 g/day)","Midazolam","Hyperforin","PO","PO","Induction","Plasma",0.52,"Geom. mean","0.42, 0.62","90% confidence interval",0.61,"Geom. mean","0.30, 0.92","90% confidence interval","0","12","312","324","h",1,NA,"4.0200000000000005",NA,"mg","PO","S0-(S0-T6-R3)-T24-R17","h",NA,NA,"St John's Wort Extract	","Coated tablet: Hypericum powder type A 2.7 g/day (Kneipp Werke, Würzburg, Germany)",NA,NA,"administered as 3 tablets","fed",NA,NA,"taken with breakfast, lunch and evening meal"
16523,"Mueller 2006","https://pubmed.ncbi.nlm.nih.gov/16341856/","Midazolam with hyperforin (group: Hypericum powder type A 1.8 g/day)","Midazolam","Hyperforin","PO","PO","Induction","Plasma",0.62,"Geom. mean","0.47, 0.77","90% confidence interval",0.7,"Geom. mean","0.58, 0.82","90% confidence interval","0","12","312","324","h",1,NA,"2.6799999999999997",NA,"mg","PO","S0-(S0-T6-R3)-T24-R18","h",NA,NA,"St John's Wort Extract	","Coated tablet: Hypericum powder type A 1.8 g/day (Kneipp Werke, Würzburg, Germany)",NA,NA,"administered as 2 tablets","fed",NA,NA,"taken with breakfast, lunch and evening meal"
16525,"Mueller 2006","https://pubmed.ncbi.nlm.nih.gov/16341856/","Midazolam with hyperforin (group: Hypericum powder type A 1.2 g/day)","Midazolam","Hyperforin","PO","PO","Induction","Plasma",0.68,"Geom. mean","0.58, 0.78","90% confidence interval",0.66,"Geom. mean","0.39, 0.92","90% confidence interval","0","12","312","324","h",1,NA,"2.68",NA,"mg","PO","S0-T12-R28","h",NA,NA,"St John's Wort Extract	","Coated tablet: Hypericum powder type A 1.2 g/day (Kneipp Werke, Würzburg, Germany)",NA,NA,"administered as 2 tablets","fed",NA,NA,"taken with breakfast and evening meal"
16527,"Mueller 2006","https://pubmed.ncbi.nlm.nih.gov/16341856/","Midazolam with hyperforin (group: Hypericum powder type A 0.6 g/day)","Midazolam","Hyperforin","PO","PO","Induction","Plasma",0.78,"Geom. mean","0.63, 0.95","90% confidence interval",1.09,"Geom. mean","0.63, 1.55","90% confidence interval","0","12","312","324","h",1,NA,"1.34",NA,"mg","PO","S0-T12-R28","h",NA,NA,"St John's Wort Extract	","Coated tablet: Hypericum powder type A 0.6 g/day (Kneipp Werke, Würzburg, Germany)",NA,NA,NA,"fed",NA,NA,"taken with breakfast and evening meal"
16529,"Arold 2005","https://pubmed.ncbi.nlm.nih.gov/15856409/","Study A - Alprazolam with Hyperforin","Alprazolam","Hyperforin","PO","PO","Induction","Plasma",0.919,"Approx. avg",NA,NA,NA,NA,NA,NA,"0","24","216","240","h",1,NA,"1.76",NA,"mg","PO","S0-T12-R19","h",NA,"Administration as 2 capsules","St John's Wort Extract	","Esbericum® capsules",NA,NA,NA,"fed",NA,NA,"fasted for last dose"
16533,"Arold 2005","https://pubmed.ncbi.nlm.nih.gov/15856409/","Study B - Digoxin with Hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",NA,NA,NA,NA,NA,NA,NA,NA,"48","72","288","312","h",NA,NA,"1.76",NA,"mg","PO","S72-T12-R19","h",NA,"Administration as 2 capsules","St John's Wort Extract	","Esbericum® capsules",NA,NA,NA,"fed",NA,NA,"fasted for last dose"
16539,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","study part 1 - LI160 (~28.9mg/d hyperforin) - with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.752,"Arith. mean","0.717, 0.787","95% confidence interval",0.63,"Arith. mean","0.58, 0.68","95% confidence interval","144","168","480","504","h",1,NA,"9.6333333333333329",NA,"mg","PO","S168.5-T8-R42","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 1 capsule.","St John's Wort Extract	","coated tablet (Jarsin 300, Lichtwer Pharma)",NA,NA,NA,NA,NA,NA,NA
16541,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","study part 1 - Hypericum powder type A, 4 g/d (~21.1mg/d hyperforin) - with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.734,"Arith. mean","0.627, 0.841","95% confidence interval",0.62,"Arith. mean","0.52, 0.82","95% confidence interval","144","168","480","504","h",1,NA,"7.0333333333333341",NA,"mg","PO","S168.5-T8-R42","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 4 capsules.","St John's Wort Extract	","capsule with 333mg hypericum powder (encapsulated by Ursapharm, Buebingen,Germany, and provided by Kneipp-Werke, Wuerzburg, Germany)",NA,NA,NA,NA,NA,NA,NA
16543,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","study part 1 - Hypericum powder type A, 2 g/d (~10.6mg/d hyperforin) - with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.823,"Arith. mean","0.784, 0.863","95% confidence interval",0.79,"Arith. mean","0.6, 0.98","95% confidence interval","144","168","480","504","h",1,NA,"3.5333333333333332",NA,"mg","PO","S168.5-T8-R42","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 4 capsules.","St John's Wort Extract	","capsule with 166mg hypericum powder (encapsulated by Ursapharm, Buebingen,Germany, and provided by Kneipp-Werke, Wuerzburg, Germany)",NA,NA,NA,NA,NA,NA,NA
16547,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","Hypericum powder type A, 1 g/d (~5.3mg/d hyperforin) -  with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.982,"Arith. mean","0.878, 1.087","95% confidence interval",0.95,"Arith. mean","0.68, 1.22","95% confidence interval","144","168","480","504","h",1,NA,"1.7666666666666666",NA,"mg","PO","S168.5-T8-R42","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 1 capsule.","St John's Wort Extract	","capsule with 333mg hypericum powder (encapsulated by Ursapharm, Buebingen,Germany, and provided by Kneipp-Werke, Wuerzburg, Germany)",NA,NA,NA,NA,NA,NA,NA
16549,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","Hypericum powder type A, 0.5 g/d (~2.6mg/d hyperforin) - with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",1.015,"Arith. mean","0.878, 1.152","95% confidence interval",1.15,"Arith. mean","1.04, 1.26","95% confidence interval","144","168","480","504","h",1,NA,"0.8666666666666667",NA,"mg","PO","S168.5-T8-R42","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 1 capsule.","St John's Wort Extract	","capsule with 166mg hypericum powder (encapsulated by Ursapharm, Buebingen,Germany, and provided by Kneipp-Werke, Wuerzburg, Germany)",NA,NA,NA,NA,NA,NA,NA
16551,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","Hypericum oil extract (~0.13mg/d hyperforin) - with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.948,"Arith. mean","0.878, 1.019","95% confidence interval",0.96,"Arith. mean","0.8, 1.12","95% confidence interval","144","168","480","504","h",1,NA,"4.3333333333333335E-2",NA,"mg","PO","S168.5-T8-R42","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 2 capsules.","St John's Wort Extract	","soft gelatin capsule containing 200 mg Hypericum oil extract (drug extract ratio, 0.075:1) from Boerner GmbH, Berlin, Germany (Johanniskrautoel-Kapseln S, batch No. 281101401)",NA,NA,NA,NA,NA,NA,NA
16553,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","Tea (~0.04mg/d hyperforin) - with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.997,"Arith. mean","0.905, 1.09","95% confidence interval",1.04,"Arith. mean","0.85, 1.23","95% confidence interval","144","168","480","504","h",1,NA,"0.02",NA,"mg","PO","S168.5-T12-R28","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 1 cup.","St John's Wort Extract	","Sidroga Johanniskraut, batch No. 93716118; Sidroga, Bremen, Germany) prepared from 1 tea filter bag (1.75 g Herba hyperici) soaked in 150 mL of boiling water for 10min",NA,NA,NA,NA,NA,NA,NA
16557,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","Hypericum powder type B, 2 g/d (~0.3mg/d hyperforin) - with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.91,"Arith. mean","0.82, 1.001","95% confidence interval",0.86,"Arith. mean","0.76, 0.96","95% confidence interval","144","168","480","504","h",1,NA,"9.9999999999999992E-2",NA,"mg","PO","S168.5-T8-R42","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 2 capsules.","St John's Wort Extract	","capsule with 333mg hypericum powder (encapsulated by Ursapharm, Buebingen,Germany, and provided by Kneipp-Werke, Wuerzburg, Germany)",NA,NA,NA,NA,NA,NA,NA
16559,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","Fresh plant juice (~3.56mg/d hyperforin) - with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.927,"Arith. mean","0.866, 0.987","95% confidence interval",0.95,"Arith. mean","0.85, 1.05","95% confidence interval","144","168","480","504","h",1,NA,"1.78",NA,"mg","PO","S168.5-T12-R28","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 2 times 10mL.","St John's Wort Extract	","fresh plant juice (Kneipp Johanniskrautsaft, batch No. 915768/928379/933039) was provided by Kneipp-Werke",NA,NA,NA,NA,NA,NA,NA
16561,"Mueller 2004","https://pubmed.ncbi.nlm.nih.gov/15179409/","ZE 117 (~ca-0.38mg/d hyperforin) - with hyperforin","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.944,"Arith. mean","0.87, 1.017","95% confidence interval",0.96,"Arith. mean","0.85, 1.07","95% confidence interval","144","168","480","504","h",1,NA,"0.19",NA,"mg","PO","S168.5-T12-R28","h",NA,"Digoxin was given half an hour before St John’s wort or placebo. Administration as 1 tablet.","St John's Wort Extract	","coated tablet (Remotiv (Bayer Vital, batch GACER1; Bayer, Leverkusen, Germany))",NA,NA,NA,NA,NA,NA,NA
16566,"Tannergren 2004","https://pubmed.ncbi.nlm.nih.gov/15060508/","R-verapamil with hyperforin","R-Verapamil","Hyperforin","regional single-pass perfusion of the proximal jejunum","PO","Induction","Plasma",0.22,"Arith. mean","0.18","Arith. SD",0.24,"Arith. mean","0.19","Arith. SD","0","inf","336","inf","h",1,NA,"13.5",NA,"mg","PO","S0-T8-R42","h",NA,"St John’s wort extract contained 3% to 6% hyperforin","St John's Wort Extract	","tablets (300 mg, Movina, batch No. 90740603; Boehringer Ingelheim, Ingelheim, Germany)",NA,NA,NA,NA,NA,NA,NA
16567,"Tannergren 2004","https://pubmed.ncbi.nlm.nih.gov/15060508/","S-verapamil with hyperforin","S-Verapamil","Hyperforin","regional single-pass perfusion of the proximal jejunum","PO","Induction","Plasma",0.2,"Arith. mean","0.19","Arith. SD",0.22,"Arith. mean","0.18","Arith. SD","0","inf","336","inf","h",1,NA,"13.5",NA,"mg","PO","S0-T8-R42","h",NA,"St John’s wort extract contained 3% to 6% hyperforin","St John's Wort Extract	","tablets (300 mg, Movina, batch No. 90740603; Boehringer Ingelheim, Ingelheim, Germany)",NA,NA,NA,NA,NA,NA,NA
16568,"Tannergren 2004","https://pubmed.ncbi.nlm.nih.gov/15060508/","R-norverapamil with hyperforin","R-Norverapamil","Hyperforin","regional single-pass perfusion of the proximal jejunum","PO","Induction","Plasma",0.49,"Arith. mean","0.32","Arith. SD",0.68,"Arith. mean","0.52","Arith. SD","0","inf","336","inf","h",1,NA,"13.5",NA,"mg","PO","S0-T8-R42","h",NA,"St John’s wort extract contained 3% to 6% hyperforin","St John's Wort Extract	","tablets (300 mg, Movina, batch No. 90740603; Boehringer Ingelheim, Ingelheim, Germany)",NA,NA,NA,NA,NA,NA,NA
16569,"Tannergren 2004","https://pubmed.ncbi.nlm.nih.gov/15060508/","S-norverapamil with hyperforin","S-Norverapamil","Hyperforin","regional single-pass perfusion of the proximal jejunum","PO","Induction","Plasma",0.37,"Arith. mean","0.21","Arith. SD",0.72,"Arith. mean","0.73","Arith. SD","0","inf","336","inf","h",1,NA,"13.5",NA,"mg","PO","S0-T8-R42","h",NA,"St John’s wort extract contained 3% to 6% hyperforin","St John's Wort Extract	","tablets (300 mg, Movina, batch No. 90740603; Boehringer Ingelheim, Ingelheim, Germany)",NA,NA,NA,NA,NA,NA,NA
16571,"Wang 2001","https://pubmed.ncbi.nlm.nih.gov/11673747/","IV Midazolam after short-term hyperforin","Midazolam","Hyperforin","IV","PO","Induction","Serum",0.9303001,"Approx. avg",NA,NA,NA,NA,NA,NA,"1","inf","1","inf","h",1,NA,"33",NA,"mg","PO","0-24","h","1h before midazolam",NA,"St John's Wort Extract	","Sundown herbal products, 300mg",NA,NA,NA,"1h after breakfast",NA,NA,NA
16572,"Wang 2001","https://pubmed.ncbi.nlm.nih.gov/11673747/","IV Midazolam after long-term hyperforin","Midazolam","Hyperforin","IV","PO","Induction","Serum",0.78606,"Approx. avg",NA,NA,NA,NA,NA,NA,"1","inf","385","inf","h",1,NA,"33mg day 1 and2, later 11mg",NA,"mg","PO","33mg:0-24; 11mg: S48-(S0-T6-R3)-T24-R17","h","1h before midazolam","""14 to 15 additional days of St Johns Wort before part 3 started"", therefore R17; The volunteers continued St Johns Wort 3times a day with meals until the final blood sample was obtained.","St John's Wort Extract	","Sundown herbal products, 300mg",NA,NA,NA,"1h after breakfast",NA,NA,NA
16574,"Wang 2001","https://pubmed.ncbi.nlm.nih.gov/11673747/","PO Midazolam after short-term hyperforin","Midazolam","Hyperforin","PO","PO","Induction","Serum",0.7931873,"Approx. avg",NA,NA,0.6716418,"Approx. Avg",NA,NA,"1","inf","25","inf","h",1,NA,"33",NA,"mg","PO","0-24","h","1h before midazolam",NA,"St John's Wort Extract	","Sundown herbal products, 300mg",NA,NA,NA,"1h after breakfast",NA,NA,NA
16575,"Wang 2001","https://pubmed.ncbi.nlm.nih.gov/11673747/","PO Midazolam after long-term hyperforin","Midazolam","Hyperforin","PO","PO","Induction","Serum",0.4768856,"Approx. avg",NA,NA,0.5746269,"Approx. Avg",NA,NA,"1","inf","409","inf","h",1,NA,"33mg day 1 and2, later 11mg",NA,"mg","PO","33mg:0-24; 11mg: S48-(S0-T6-R3)-T24-R17","h","1h before midazolam","""14 to 15 additional days of St Johns Wort before part 3 started"", therefore R17; The volunteers continued St Johns Wort 3times a day with meals until the final blood sample was obtained.","St John's Wort Extract	","Sundown herbal products, 300mg",NA,NA,NA,"1h after breakfast",NA,NA,NA
16584,"Johne 1999","https://pubmed.ncbi.nlm.nih.gov/10546917/","Digoxin after SD St John's Wort","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.994,"Approx. avg",NA,NA,1.105,"Approx. Avg",NA,NA,"96","120","120","144","h",1,NA,"55.11",NA,"mg","PO","120","h",NA,NA,"St John's Wort Extract	","coated tablet (Jarsin 300, batch No. 97050277,Lichtwer Pharma AG, Berlin)",NA,NA,NA,NA,NA,NA,NA
16585,"Johne 1999","https://pubmed.ncbi.nlm.nih.gov/10546917/","Digoxin after MD St John's Wort","Digoxin","Hyperforin","PO","PO","Induction","Plasma",0.725,"Approx. avg",NA,NA,0.737,"Approx. Avg",NA,NA,"96","120","336","360","h",1,NA,"18.37 (days 7-9&11-15); 55.11 (day6&10)",NA,"mg","PO","55.11mg: 120-216; 18.37mg: S144-(S0-T5-R3)-T24-R3,  S240-(S0-T5-R3)-T24-R15","h","was taken three times a day at 8 AM, 1 PM, and 6 PM. On days 6 and 15, the daily dose (three coated tablets) of LI160 or placebo was administered in the morning",NA,"St John's Wort Extract	","coated tablet (Jarsin 300, batch No. 97050277,Lichtwer Pharma AG, Berlin)",NA,NA,NA,NA,NA,NA,NA
16589,"Rodin 1988","https://pubmed.ncbi.nlm.nih.gov/2967742/","2x0.25mg po md with verapamil","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Urine",0.9577,"Approx. avg",NA,NA,NA,NA,NA,NA,"312","336","312","336","h",1,"1/RenalClearanceRatio","80","74.06","mg","PO","S0-T12-R8, S96-T8-R30","h","MD: 80mg BID (4 days), 80mg TID (10 days)",NA,NA,NA,NA,NA,NA,NA,NA,NA,"On Day 14 fasted"
16591,"Rodin 1988","https://pubmed.ncbi.nlm.nih.gov/2967742/","2x0.25mg po md with isradipine","Digoxin","Isradipine","PO","PO",NA,"Urine",0.9577,"Approx. avg",NA,NA,NA,NA,NA,NA,"312","336","312","336","h",1,"1/RenalClearanceRatio","2,5 / 5",NA,"mg","PO","2,5mg: S0-T12-R4; 5mg: (S48-T12-R4)-(S96-T8-R30)","h","MD: 2,5mg BID (2 days), 5mg BID (2 days), 5mg TID (10 days)",NA,NA,NA,NA,NA,NA,NA,NA,NA,"On Day 14 fasted"
16593,"Pedersen et al. 1982","https://pubmed.ncbi.nlm.nih.gov/7094982/","Digoxin and Verapamil in MD setting","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Urine",1.575477,"Arith. mean","0.39310509999999999","Arith. SD",NA,NA,NA,NA,"unclear","unclear","unclear","unclear",NA,1,"Calculated as 1/ renal clearance ratio after 1 week; Verapamil caused an immediate 20%-30% reduction in renal digoxin clearance. After a few weeks, this change had completely disappeared, and in the remaining part of the study renal digoxin clearance did not differ from control values","80/120","74.061376/111.0922","mg","PO","80:S360-(S0-T6-R3)-T24-R63; 120:S1896-(S0-T6-R3)-T24-R42","h",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16595,"Klein et al. 1982","https://pubmed.ncbi.nlm.nih.gov/7074765/","Digoxin and Verapamil in MD setting","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Urine",1.695687,"Arith. mean","0.3341402","Arith. SD",NA,NA,NA,NA,"312","336","624","648","h",1,"1/RenalClearanceRatio","80","74.061375999999996","mg","PO","S350-T8-R42","h","TID","morning dose 1h before digoxin dose","oral","oral",NA,NA,NA,NA,NA,NA,NA
16160,"Johnson et al. 1987","https://pubmed.ncbi.nlm.nih.gov/2954736/","Digoxin IV + Verapamil","Digoxin","Verapamil","IV","PO","Mechanism_based_Inactivation","Urine",0.948787061994609,"Approx Avg",NA,NA,NA,NA,NA,NA,"0","48","288","336","h",1,"1/RenalClearanceRatio","80","74.06138","mg","PO","(S0-T12-R8)-(S96-T8-R33)","h","MD BID 4days, TID 10days",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16634,"Belz 1981","https://pubmed.ncbi.nlm.nih.gov/6111709/","Digoxin + Placebo","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"80","74.06138","mg","PO","S0-T8-R42","h","TID",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16635,"Belz 1981","https://pubmed.ncbi.nlm.nih.gov/6111709/","Digoxin + Verapamil","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Plasma",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"80","74.061375999999996","mg","PO","S0-T8-R42","h","TID",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16637,"Pedersen 1981","https://pubmed.ncbi.nlm.nih.gov/7273594/","Digoxin withVerapamil","Digoxin","Verapamil","IV","PO","Mechanism_based_Inactivation","Urine",1.319246,"Arith. mean","0.31093470000000001","Arith. SD",NA,NA,NA,NA,"0","96","216","312","h",0.75,"1/RenalClearanceRatio","80","74.06138","mg","PO","S0-T8-R30","h","TID","After 10 days of verapamil pretreatment, a second dose of digoxin was given","verapamil chloride","Isoptin",NA,NA,NA,NA,NA,NA,NA
16638,"Pedersen 1981","https://pubmed.ncbi.nlm.nih.gov/7273594/","Digoxin withVerapamil","Digoxin","Verapamil","IV","PO","Mechanism_based_Inactivation","Plasma",1.613336,"Arith. mean","0.33312700000000001","Arith. SD",NA,NA,NA,NA,"0.25","inf","216.25","inf","h",0.75,"1/total body clerance ratio","80","74.061375999999996","mg","PO","S0-T8-R30","h","TID","After 10 days of verapamil pretreatment, a second dose of digoxin was given","verapamil chloride","Isoptin",NA,NA,NA,NA,NA,NA,NA
16173,"Wiebe 2020","https://pubmed.ncbi.nlm.nih.gov/32504272/","DDI digoxin + verapamil - urine","Digoxin","Verapamil","PO","PO","Mechanism_based_Inactivation","Urine",1,"Geom. mean",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"1/RenalClearanceRatio; ""no significant impact on renal clearence""","120","111.0921","mg","PO","0","h","SD","PK data on verapamil also available (see IDs 6160 to 6163)","Verapamil, Isoptin film-coated tablet","oral tablet",NA,NA,NA,NA,NA,NA,NA
16640,"Scholz 2021","https://pubmed.ncbi.nlm.nih.gov/19564368/","Postinduction with St. Johns Wort","Midazolam","Hyperforin","PO","PO","induction","Plasma",0.58,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","275","276","inf","h",1,"Ratio Midazolam/1-hydroxy-midazolam","450","3.15","mg","PO","S0-T12-R28","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16642,"Scholz 2021","https://pubmed.ncbi.nlm.nih.gov/19564368/","Postinduction with St. Johns Wort","Midazolam","Hyperforin","PO","PO","induction","Urine",0.469,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","275","276","inf","h",1,"1/CLR ","450","3.15","mg","PO","S0-T12-R28","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16643,"Gurley 2002","https://pubmed.ncbi.nlm.nih.gov/12235448/","Postinduction with St. Johns Wort","Midazolam","Hyperforin","PO","PO","induction","Serum",1.98,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","1","648","649","h",1,"Ratio 1-hydroxy-midazolam/midazolam","300","0.9","mg","PO","S0-T8-R84","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16644,"Gurley 2005","https://pubmed.ncbi.nlm.nih.gov/15974642/","Postinduction with St. Johns Wort in Elderly","Midazolam","Hyperforin","PO","PO","induction","Serum",2.41,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","1","648","649","h",1,"Ratio 1-hydroxy-midazolam/midazolam","300","0.9","mg","PO","S0-T8-R84","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16646,"Markowitz 2003","https://pubmed.ncbi.nlm.nih.gov/13129991/","Alprazolam Postinduction with St. John´s Wort","Alprazolam","Hyperforin","PO","PO","induction","Plasma",0.463716814159292,"Approx. Avg",NA,NA,0.911764705882353,"Approx. Avg",NA,NA,"0","inf","312","inf","h",1,NA,"300","1.3979999999999999","mg","PO","S0-T8-R48","h","MD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16648,"Zahner 2020","https://pubmed.ncbi.nlm.nih.gov/30739325/","day 8","Midazolam","Hyperforin","PO","PO","induction","Plasma",0.975609756097561,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","72","168","240","h",1,"Metabolic ratio of metabolite AUC0–t over probe drug AUC0–t","0.96",NA,"mg","PO","S168-T24-R13","h","MD",NA,NA,NA,NA,240,NA,NA,NA,NA,NA
16649,"Zahner 2021","https://pubmed.ncbi.nlm.nih.gov/30739325/","day 17","Midazolam","Hyperforin","PO","PO","induction","Plasma",1,"Approx. Avg",NA,NA,NA,NA,NA,NA,"0","72","384","456","h",1,"Metabolic ratio of metabolite AUC0–t over probe drug AUC0–t","0.96",NA,"mg","PO","S168-T24-R13","h","MD",NA,NA,NA,NA,240,NA,NA,NA,NA,NA
16756,"Prueksaritanont 2014","https://pubmed.ncbi.nlm.nih.gov/24617605/","PO Rosuvastatin 5 mg | Rifampicin IV 600 mg SD ","Rosuvastatin","Rifampicin","PO","IV","Reversible_Inhibition","Plasma",3.3,"GMR",NA,NA,5.51,"GMR",NA,NA,"0","inf","0.5","inf","h",NA,"Single Dose study","600",NA,"mg","IV","0","h","SD",NA,NA,NA,30,NA,NA,NA,NA,NA,NA
16757,"Prueksaritanont 2014","https://pubmed.ncbi.nlm.nih.gov/24617605/","PO Rosuvastatin 5 mg | Rifampicin PO 600 mg SD ","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",4.37,"GMR",NA,NA,9.93,"GMR",NA,NA,"0","inf","0.5","inf","h",NA,"Single Dose study","600",NA,"mg","PO","0.5","h","SD",NA,"Solution",NA,NA,NA,NA,NA,NA,NA,NA
16758,"Prueksaritanont 2017","https://pubmed.ncbi.nlm.nih.gov/27943276/","PO Rosuvastatin 50 ug | Rifampicin PO 600 mg SD ","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",4.6,"GMR",NA,NA,11.52,"GMR",NA,NA,"0","inf","0","inf","h",NA,"Single Dose study","600",NA,"mg","PO","0","h","SD",NA,"Solution",NA,NA,NA,NA,NA,NA,NA,NA
16759,"Wiebe 2020","https://pubmed.ncbi.nlm.nih.gov/32504272/","PO Rosuvastatin 10 mg n = 11 | Rifampicin PO 600 mg SD","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",4.22,"GMR",NA,NA,4.08,"GMR",NA,NA,"0","inf","0","inf","h",NA,"Single Dose study","600",NA,"mg","PO","0","h","SD",NA,"Solution",NA,NA,NA,NA,NA,NA,NA,NA
16761,"Wu 2017","https://pubmed.ncbi.nlm.nih.gov/28385543/","PO Rosuvastatin 20 mg | Rifampicin IV 30 min 600 mg SD","Rosuvastatin","Rifampicin","PO","IV","Reversible_Inhibition","Plasma",3.37,"Approx. Avg",NA,NA,8.55,"Approx. Avg",NA,NA,"0","inf","0.5","inf","h",NA,"Single Dose study","600",NA,"mg","IV","0","h","SD",NA,NA,NA,30,NA,NA,NA,NA,NA,NA
16763,"Lutz 2018","https://pubmed.ncbi.nlm.nih.gov/29569723/","Rosuvastatin PO 10 mg SD | Rifampicin PO 2mg QD (Induction study) cohort 2","Rosuvastatin","Rifampicin","PO","PO","Induction","Plasma",0.882,NA,NA,NA,0.97,NA,NA,NA,"0","inf","224","inf","h",NA,"Multiple Dose study cohort 2 mg - 600 mg OD","2",NA,"mg","PO","0;24;48;72;96;120;144;168;192;216;240;264;288;312;336;360;384;408","h","MD",NA,NA,"oral",NA,NA,NA,NA,NA,NA,NA
16764,"Lutz 2018","https://pubmed.ncbi.nlm.nih.gov/29569723/","Rosuvastatin PO 10 mg SD | Rifampicin PO 10 mg QD (Induction study) cohort 1","Rosuvastatin","Rifampicin","PO","PO","Induction","Plasma",0.788,NA,NA,NA,0.846,NA,NA,NA,"0","inf","224","inf","h",NA,"Multiple Dose study cohort 10 mg - 75 mg OD","10",NA,"mg","PO","0;24;48;72;96;120;144;168;192;216;240;264;288;312;336;360;384;408","h","MD",NA,NA,"oral",NA,NA,NA,NA,NA,NA,NA
16765,"Lutz 2018","https://pubmed.ncbi.nlm.nih.gov/29569723/","Rosuvastatin PO 10 mg SD | Rifampicin PO 75 mg QD (Induction study) cohort 1","Rosuvastatin","Rifampicin","PO","PO","Induction","Plasma",0.462,NA,NA,NA,0.585,NA,NA,NA,"0","inf","680","inf","h",NA,"Multiple Dose study  cohort 10 mg - 75 mg OD","75;10",NA,"mg","PO","0;24;48;72;96;120;144;168;192;216;240;264;288;312;336;360;384;408;432;456;480;504;528;552;576;600;624;648;672;696;720;744;768;792;816;840",NA,NA,NA,NA,"oral",NA,NA,NA,NA,NA,NA,NA
16766,"Lutz 2018","https://pubmed.ncbi.nlm.nih.gov/29569723/","Rosuvastatin PO 10 mg SD | Rifampicin PO 600 mg QD (Induction study) cohort 2","Rosuvastatin","Rifampicin","PO","PO","Induction","Plasma",0.371,NA,NA,NA,0.702,NA,NA,NA,"0","inf","680","inf","h",NA,"Multiple Dose study cohort 2 mg - 600 mg OD","600;2",NA,"mg","PO","0;24;48;72;96;120;144;168;192;216;240;264;288;312;336;360;384;408;432;456;480;504;528;552;576;600;624;648;672;696;720;744;768;792;816;840",NA,NA,NA,NA,"oral",NA,NA,NA,NA,NA,NA,NA
16767,"Rattanacheeworn 2021","https://pubmed.ncbi.nlm.nih.gov/34603040/","Rosuvastatin PO 50 ug SD (Thai Population) | Rifampicin PO 450 mg SD","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",4.35,"GMR",NA,NA,7.21,"GMR",NA,NA,"0","12","0","12","h",NA,"Single Dose study","450",NA,"mg","PO","0","h","SD",NA,"Solution","oral",NA,NA,NA,NA,NA,NA,NA
16769,"Lai 2016","https://pubmed.ncbi.nlm.nih.gov/27317801/","Rosuvastatin PO 5 mg SD (Indian Population)  | Rifampicin PO 600 mg SD","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",5,"Approx. Avg",NA,NA,13.2,"Approx. Avg",NA,NA,"0","24","0","24","h",NA,"Single Dose study","600",NA,"mg","PO","0","h","SD",NA,"Capsule","oral",NA,NA,NA,NA,NA,NA,NA
16771,"Mori 2019","https://pubmed.ncbi.nlm.nih.gov/31628668/","Rosuvastatin PO 0.5 mg SD (Japanese Population)  | Rifampicin PO 150 mg SD","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",3.35,"GMR",NA,NA,7.73,"GMR",NA,NA,"0","24","0","24","h",NA,"Single Dose study","150",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16772,"Mori 2019","https://pubmed.ncbi.nlm.nih.gov/31628668/","Rosuvastatin PO 0.5 mg SD (Japanese Population)  | Rifampicin PO 300 mg SD","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",4.89,"GMR",NA,NA,11.7,"GMR",NA,NA,"0","24","0","24","h",NA,"Single Dose study","300",NA,"mg","PO","0","h","SD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16773,"Mori 2019","https://pubmed.ncbi.nlm.nih.gov/31628668/","Rosuvastatin PO 0.5 mg SD (Japanese Population)  | Rifampicin PO 600 mg SD","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",7.29,"GMR",NA,NA,13.3,"GMR",NA,NA,"0","24","0","24","h",NA,"Single Dose study","600",NA,"mg","PO","0","h","SD",NA,NA,"oral",NA,NA,NA,NA,NA,NA,NA
16775,"Takehara 2019","https://pubmed.ncbi.nlm.nih.gov/29748935/","Rosuvastatin PO 0.5 mg SD (Japanese Population)  | Rifampicin PO 300 mg SD","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",2.2,"Approx. Avg",NA,NA,5,"Approx. Avg",NA,NA,"0","24","0","24","h",NA,"Single Dose study","300",NA,"mg","PO","0","h","SD",NA,NA,"oral",NA,NA,NA,NA,NA,NA,NA
16776,"Takehara 2019","https://pubmed.ncbi.nlm.nih.gov/29748935/","Rosuvastatin PO 0.5 mg SD (Japanese Population)  | Rifampicin PO 600 mg SD","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",2.4,"Approx. Avg",NA,NA,6.7,"Approx. Avg",NA,NA,"0","24","0","24","h",NA,"Single Dose study","600",NA,"mg","PO","0","h","SD",NA,NA,"oral",NA,NA,NA,NA,NA,NA,NA
16779,"Wiebe 2020","https://pubmed.ncbi.nlm.nih.gov/32504272/","PO Rosuvastatin 10 mg n=13 |  Probenecid PO 1000 mg BID 2 days","Rosuvastatin","Probenecid","PO","PO","Reversible_Inhibition","Plasma",2.23,"Approx. Avg",NA,NA,4.28,"Approx. Avg",NA,NA,"0","24","13","24","h",NA,"Multiple Dose study","1000",NA,"mg","PO","0;12","h","BID",NA,"Tablet","oral",NA,NA,NA,NA,NA,NA,NA
16781,"Schneck 2004","https://pubmed.ncbi.nlm.nih.gov/15116058/","PO Rosuvastatin 80 mg | Gemfibrozil PO 600 mg BID 7 days","Rosuvastatin","Gemfibrozil","PO","PO","Reversible_Inhibition","Plasma",1.88,NA,NA,NA,2.21,NA,NA,NA,"0","30","72","102","h",NA,"Multiple Dose study","600",NA,"mg","PO","0;12;24;36;48;60;72;84;96;108;120;132;144;156","h","BID",NA,"Capsule","oral",NA,NA,NA,NA,NA,NA,NA
16782,"Cooper 2003b","https://pubmed.ncbi.nlm.nih.gov/12709722/","PO Rosuvastatin 10 mg | Itraconazole PO 200 mg OD 5 days - 1 hr","Rosuvastatin","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",1.389,"Ratio of geometric least squares",NA,NA,1.359,"Ratio of geometric least squares",NA,NA,"0","inf","73.5","inf","h",NA,"Multiple Dose study","200",NA,"mg","PO","0;24;48;72;96;","h","OD",NA,"Capsule","oral",NA,NA,NA,NA,NA,NA,NA
16783,"Cooper 2003b","https://pubmed.ncbi.nlm.nih.gov/12709722/","PO Rosuvastatin 80 mg | Itraconazole PO 200 mg OD 5 days - 1 hr","Rosuvastatin","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",1.28,"Ratio of geometric least squares",NA,NA,1.145,"Ratio of geometric least squares",NA,NA,"0","inf","73.5","inf","h",NA,"Multiple Dose study","200",NA,"mg","PO","0;24;48;72;96;","h","OD",NA,"Capsule","oral",NA,NA,NA,NA,NA,NA,NA
16777,"Prueksaritanont 2017","https://pubmed.ncbi.nlm.nih.gov/27943276/","PO Rosuvastatin 50 ug | Itraconazole PO 200 mg OD 5 days","Rosuvastatin","Itraconazole","PO","PO","Reversible_Inhibition","Plasma",1.78,"GMR",NA,NA,1.39,"GMR",NA,NA,"0","inf","72","inf","h",NA,"Multiple Dose study","200",NA,"mg","PO","0;24;48;72;96;","h","OD",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16778,"Prueksaritanont 2017","https://pubmed.ncbi.nlm.nih.gov/27943276/","PO Rosuvastatin 50 ug | Clarithromycin PO 500 mg BID 5 days","Rosuvastatin","Clarithromycin","PO","PO","Reversible_Inhibition","Plasma",1.56,"GMR",NA,NA,1.76,"GMR",NA,NA,"0","inf","72","inf","h",NA,"Multiple Dose study","500",NA,"mg","PO","0;12;24;36;48;60;72;84;96;108;120","h","BID",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16785,"Tatosian 2020","https://pubmed.ncbi.nlm.nih.gov/32705692/","PO Rosuvastatin 50 ug control","Rosuvastatin","Rifampicin","PO","PO","Reversible_Inhibition","Plasma",3.56,"GMR",NA,NA,10.94,"GMR",NA,NA,"0","inf","72","inf","h",NA,"Single Dose study",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16602,"Stangier 2009","https://pubmed.ncbi.nlm.nih.gov/19178132/","Dabigatran + Atorvastatin","Dabigatran total","Atorvastatin","PO","PO",NA,"Plasma",0.862,"Approx. Avg",NA,NA,0.847,"Approx. Avg",NA,NA,"72","inf","72","inf","h",NA,NA,"80",NA,"mg","PO","S0-T24-R4","h",NA,NA,"Tablet",NA,NA,NA,"Sortis ® ","fasted","overnight",NA,NA
943,"Kanefendt 2023","https://pubmed.ncbi.nlm.nih.gov/38105467/","Study 1, midazolam after pretreatment with carbamazepine","Midazolam","Carbamazepine","PO","PO","Induction","Plasma",0.282,"GMR","0.235, 0.340","95% confidence interval",0.44,"GMR","0.374, 0.518","95% confidence interval","0","inf","334","inf","h",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1133,"Kanefendt 2023","https://pubmed.ncbi.nlm.nih.gov/38105467/","Study 2, midazolam after pretreatment with carbamazepine","Midazolam","Carbamazepine","PO","PO","Induction","Plasma",0.323,"GMR","0.256, 0.407","95% confidence interval",0.455,"GMR","0.375, 0.552","95% confidence interval","0","inf","336","inf","h",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
16940,"Capon 1996","https://pubmed.ncbi.nlm.nih.gov/8841152/","QUI-DEX-DDI","Dextromethorphan","Quinidine","PO","PO",NA,"Plasma",6.84,NA,NA,NA,6.07,NA,NA,NA,"0","48","1","73","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","50","41.435000000000002","mg","PO","0","h","SD: 1h before DEX",NA,"quinidine sulfate",NA,NA,NA,NA,NA,NA,NA,NA
16942,"Capon 1996","https://pubmed.ncbi.nlm.nih.gov/8841152/","QUI-DTT-DDI","Total dextrorphan","Quinidine","PO","PO",NA,"Plasma",0.99,NA,NA,NA,0.24,NA,NA,NA,"0","24","1","97","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","50","41.435000000000002","mg","PO","0","h","SD: 1h before DEX",NA,"quinidine sulfate",NA,NA,NA,NA,NA,NA,NA,NA
16944,"Schadel 1995","https://pubmed.ncbi.nlm.nih.gov/7593709/","QUI-DXG-DDI","Dextrorphan-O-glucuronide","Quinidine","PO","PO",NA,"Plasma",0.61,NA,NA,NA,0.13,NA,NA,NA,"0","24","12","60","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","100","82.87","mg","PO","0","h","SD",NA,"quinidine sulfate",NA,NA,NA,NA,NA,NA,NA,NA
16946,"Steiness 1980","https://pubmed.ncbi.nlm.nih.gov/7379447/","QUI-DIG-DDI","Digoxin","Quinidine","IV","PO",NA,"Plasma",0.96,NA,NA,NA,NA,NA,NA,NA,"0","80","192","272","h",1,"AUCR derived from the digitized plasma profiles; CmaxR not evaluated due to bolus application","200","165.75","mg","PO","S0-T12-R24","h","BID",NA,"quinidine sulfate",NA,NA,NA,NA,NA,NA,NA,NA
16948,"Ochs 1981","https://pubmed.ncbi.nlm.nih.gov/7309901/","QUI-DIG-DDI","Digoxin","Quinidine","IV","PO",NA,"Plasma",2.05,NA,NA,NA,1.65,NA,NA,NA,"0","48","96","168","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","200","153.56","mg","PO","S0-T6-R28","h","QID",NA,"quinidine bisulfate",NA,NA,NA,NA,NA,NA,NA,NA
16950,"Abolfathi 1993","https://pubmed.ncbi.nlm.nih.gov/8371133/","QUI-MEX-DDI_PM","Mexiletine","Quinidine","PO","PO",NA,"Plasma",0.85,NA,NA,NA,0.79,NA,NA,NA,"0","48","48","96","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","50","41.435000000000002","mg","PO","S0-T6-R16","h","QID",NA,"quinidine sulfate",NA,NA,NA,NA,NA,NA,NA,NA
16952,"Abolfathi 1993","https://pubmed.ncbi.nlm.nih.gov/8371133/","QUI-MEX-DDI_NM","Mexiletine","Quinidine","PO","PO",NA,"Plasma",1.3,NA,NA,NA,1.27,NA,NA,NA,"0","48","48","96","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","50","41.435000000000002","mg","PO","S0-T6-R16","h","QID",NA,"quinidine sulfate",NA,NA,NA,NA,NA,NA,NA,NA
16954,"Schoedel 2012","https://pubmed.ncbi.nlm.nih.gov/22283559/","QUI-PAR-DDI","Paroxetine","Quinidine","PO","PO",NA,"Plasma",1.29,NA,NA,NA,1.14,NA,NA,NA,"0","288","0","480","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","30","24.861000000000001","mg","PO","S288-T12-R16","h","BID",NA,"quinidine sulfate",NA,NA,NA,NA,NA,NA,NA,NA
16956,"Andreasen 2007","https://pubmed.ncbi.nlm.nih.gov/17346248/","CBZ-QUI-DDI","Quinidine","Carbamazepine","PO","PO",NA,"Plasma",0.41,NA,NA,NA,0.5,NA,NA,NA,"0","24","384","408","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","200/400",NA,"mg","PO","S0-T12-R6/S72-T12-R28","h","BID",NA,"carbamazepine",NA,NA,NA,NA,NA,NA,NA,NA
16958,"Andreasen 2007","https://pubmed.ncbi.nlm.nih.gov/17346248/","CBZ-OHQ-DDI","3-Hydroxyquinidine","Carbamazepine","PO","PO",NA,"Plasma",0.9,NA,NA,NA,1.48,NA,NA,NA,"0","24","384","408","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","200/400",NA,"mg","PO","S0-T12-R6/S72-T12-R28","h","BID",NA,"carbamazepine",NA,NA,NA,NA,NA,NA,NA,NA
16960,"Kolb 1984","https://pubmed.ncbi.nlm.nih.gov/6506138/","CIM-QUI-DDI","Quinidine","Cimetidine","PO","PO",NA,"Plasma",1.13,NA,NA,NA,0.9,NA,NA,NA,"72","81","240","249","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","300",NA,"mg","PO","S168-T24-R7","h","QD","Split dose","cimetidine",NA,NA,NA,NA,NA,NA,NA,NA
16962,"Hardy 1983","https://pubmed.ncbi.nlm.nih.gov/3220613/","CIM-QUI-DDI","Quinidine","Cimetidine","PO","PO",NA,"Plasma",1.28,NA,NA,NA,1.26,NA,NA,NA,"0","12","168","180","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","300",NA,"mg","PO","S48-T6-R28","h","QID","Split dose","cimetidine",NA,NA,NA,NA,NA,NA,NA,NA
16964,"Damkier 1999a","https://link.springer.com/article/10.1007/s002280050655","FLV-QUI-DDI","Quinidine","Fluvoxamine","PO","PO",NA,"Plasma",1.66,NA,NA,NA,1.32,NA,NA,NA,"0","24","96","144","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","100","73.28","mg","PO","S0-T24-R6","h","QD",NA,"fluvoxamine maleate",NA,NA,NA,NA,NA,NA,NA,NA
16966,"Damkier 1999a","https://link.springer.com/article/10.1007/s002280050655","FLV-OHQ-DDI","3-Hydroxyquinidine","Fluvoxamine","PO","PO",NA,"Plasma",1.23,NA,NA,NA,0.96,NA,NA,NA,"0","24","96","144","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","100","73.28","mg","PO","S0-T24-R6","h","QD",NA,"fluvoxamine maleate",NA,NA,NA,NA,NA,NA,NA,NA
16968,"Ching 1991","https://pubmed.ncbi.nlm.nih.gov/1793783/","OME-QUI-DDI","Quinidine","Omeprazole","PO","PO",NA,"Plasma",1.15,NA,NA,NA,1.12,NA,NA,NA,"0","48","121","169","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","40",NA,"mg","PO","S0-T24-R7","h","QD",NA,"omeprazole",NA,NA,NA,NA,NA,NA,NA,NA
16970,"Ching 1991","https://pubmed.ncbi.nlm.nih.gov/1793783/","OME-OHQ-DDI","3-Hydroxyquinidine","Omeprazole","PO","PO",NA,"Plasma",0.9,NA,NA,NA,0.85,NA,NA,NA,"0","48","121","169","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","40",NA,"mg","PO","S0-T24-R7","h","QD",NA,"omeprazole",NA,NA,NA,NA,NA,NA,NA,NA
16972,"Damkier 1999","https://pubmed.ncbi.nlm.nih.gov/10628900/","RIF-QUI-DDI","Quinidine","Rifampicin","PO","PO",NA,"Plasma",0.12,NA,NA,NA,0.34,NA,NA,NA,"0","24","216","226","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","600",NA,"mg","PO","S0-T24-R11","h","QD",NA,"rifampicin",NA,NA,NA,NA,NA,NA,NA,NA
16974,"Damkier 1999","https://pubmed.ncbi.nlm.nih.gov/10628900/","RIF-OHQ-DDI","3-Hydroxyquinidine","Rifampicin","PO","PO",NA,"Plasma",0.78,NA,NA,NA,2.9,NA,NA,NA,"0","24","216","226","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","600",NA,"mg","PO","S0-T24-R11","h","QD",NA,"rifampicin",NA,NA,NA,NA,NA,NA,NA,NA
16976,"Edwards 1987","https://pubmed.ncbi.nlm.nih.gov/3802708/","VER-QUI-DDI_80mg","Quinidine","Verapamil","PO","PO",NA,"Plasma",1.21,NA,NA,NA,0.96,NA,NA,NA,"0","12","72.5","84.5","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","80","74.06","mg","PO","S0-T8-R12","h","TID",NA,"verapamil",NA,NA,NA,NA,NA,NA,NA,NA
16978,"Edwards 1987","https://pubmed.ncbi.nlm.nih.gov/3802708/","VER-QUI-DDI_120mg","Quinidine","Verapamil","PO","PO",NA,"Plasma",1.25,NA,NA,NA,0.96,NA,NA,NA,"0","12","72.5","84.5","h",1,"AUCR and CmaxR derived from the digitized plasma profiles","120","111.1","mg","PO","S0-T8-R12","h","TID",NA,"verapamil",NA,NA,NA,NA,NA,NA,NA,NA
16949,"Abolfathi 1993","https://pubmed.ncbi.nlm.nih.gov/8371133/","QUI-MEX-Control_PM","Mexiletine","Quinidine","PO","PO",NA,"Plasma",0.65,NA,NA,NA,0.63,NA,NA,NA,"0","48","48","96","h",1,"!! DDGI Ratios PM vs. NM !! DDGI AUCR and DDGI CmaxR derived from the digitized plasma profiles","50","41.435000000000002","mg","PO","S0-T6-R16","h","QID",NA,"quinidine sulfate",NA,NA,NA,NA,NA,NA,NA,NA
